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Abstract 
This thesis is concerned with the discovery of a novel heterocyclic compound – 
BRS-015,  its  synthesis  and  an  analysis  of  its  effects  on  excitatory  synaptic 
transmission at a major pathway in the brain. BRS-015 is related to the natural 
product  clausenamide,  which  has  been  shown  to  facilitate  synaptic 
transmission.  As  such,  clausenamide  and  related  analogues  may  possess 
therapeutic potential as memory enhancing drugs, which are in urgent need of 
development due to the increasing numbers of patients diagnosed with memory 
disorders  and  for  which  there  is  no  current  effective  therapy.  BRS-015  was 
synthesized  using  a  novel  approach  to  the  core  structure  of  clausenamide 
involving an intramolecular acylal cyclisation reaction, which has not previously 
been reported. 
The  first  section  of  the  thesis  opens  with  a  description  of  the  discovery, 
structure  and  biological  activity  of  clausenamide  and  discussion  of  previous 
synthetic strategies adopted by a number of research groups and attempts to 
classify  these  into  the  varying  approaches  towards  the  central  core  of 
clausenamide. The second section describes the structure of the rat brain and 
the  types  of  processes  involved  in  memory  formation,  as  well  as  the 
neurophysiological  assays  used  to  investigate  synaptic  transmission  and 
plasticity. 
The  second  group  of  chapters  describes  our  own  approach  to  the  core  of 
clausenamide and the synthesis of BRS-015, with a detailed discussion of the 
structural  analysis  and  investigation  of  the  intramolecular  acylal  cyclisation 
reaction used during the synthetic process. 
The  third  chapter  describes  the  neurophysiological  assays  used  in  our 
investigations  into  the  effects  of  BRS-015,  which  was  tested  against 
glutamatergic  synaptic  transmission  and  plasticity  in  acute  rat  hippocampal 
slices.  BRS-015  was  shown  to  reversibly  enhance  the  amplitude  of  AMPA 
receptor mediated EPSCs recorded from CA3 pyramidal neurones and evoked 
by  dentate  stimulation.  When  tested  in  the  presence  of  selective  glutamate 
receptor antagonists, BRS-015 did not have this powerful enhancing effect on 
kainate or NMDA receptor mediated EPSCs. In addition, BRS-015 increased 
the amplitude of glutamate-evoked currents in CA3 pyramidal neurones and did 
not alter short-term synaptic plasticity but facilitated the induction of mossy fibre 
LTP,  with  little  effect  at  associational/commissural  synapses.  BRS-015  has 
striking  enhancing  properties  on  AMPA  receptor  mediated  synaptic 
transmission at mossy fibre synapses either by directly interacting with AMPA 
receptors or via indirect modulation, the mechanisms of which could lead to 
synapse strengthening. Blanka Szulc                                          Discovery and mode of action of BRS-015  
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1.1.  General Introduction 
This thesis is concerned with the discovery of a novel heterocyclic compound – 
BRS-015 (1) (Figure 1), its synthesis and the analysis of its physiological effects 
on excitatory synaptic transmission in the brain. BRS-015 is structurally related 
to  the  natural  product  clausenamide  (2), which  has  been  shown  to  facilitate 
synaptic  transmission.  As  such,  clausenamide  and  related  analogues  may 
possess therapeutic potential as memory enhancing drugs. BRS-015 (1) was 
synthesized using a novel approach to the core structure of clausenamide (2). 
This  thesis  therefore  opens  with  a  description  of  clausenamide  (2)  and  the 
synthesis  of  compounds  related  to  BRS-015  (1),  to  place  our  research  into 
context for the exploration of its potential as a memory-enhancing compound.  
 
Figure 1: BRS-015 and (±)-clausenamide 
1.1.1.  Memory Deficit Disorders 
Memory deficit disorders are a broad spectrum of interrelated diseases that are 
characterised by a decline in cognitive function and a corresponding reduction 
in both memory formation and recall. Another facet of these disorders is that 
whilst they can occur at any time in a person’s lifetime, they are more strongly 
correlated  with  an  increase  in  age  (van  de  Glind  et  al.,  2013).  The  most 
prevalent amongst these disorders is dementia with around 800,000 people in 
the  UK  affected  by  this  condition.  There  are  approximately  one  hundred 
different types of dementia, with  Alzheimer's disease (AD) perhaps the most 
common  form,  affecting  62%  of  those  living  with  dementia.    Many  of  those 
affected have a mixed pattern of dementia, with the second most common type, 
vascular  dementia,  also  contributing  to  their  condition 
(http://www.alzheimers.org.uk.)  One  of  the  key  national  health  challenges 
associated with this disease, is the changing nature of the demographic profile Blanka Szulc                                                                                               Introduction 
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of industrialised nations. As the profile shifts towards a more elderly population, 
there is an associated increase in patients with memory related disorders. To 
highlight this, the Alzheimer's Society (UK) predicts that the number of people 
affected by dementia will increase to 1 million by 2021 and 1.7 million by 2051.  
Furthermore, these figures may be much higher, since many cases of dementia 
often go undiagnosed (especially in the early stages of dementia).  This rise in 
the number of dementia sufferers is attributed to increasing longevity, due to 
advances in public health and medical care.  For example, there is a sharp 
increase in the prevalence of dementia with age, while one in twenty-five people 
aged 70 to 79 has some form of dementia, this rises to one in six people over 
the age of 80 (http://www.alzheimers.org.uk.). 
At present, there are no medications that have been shown to prevent or cure 
dementia  with  one of  the main  obstacles  to  creating  effective  treatments for 
dementia,  being  that  the  disease  is  still  not  fully  understood.  The  condition 
appears  to  result  from  a  complex  interaction  of  genes,  lifestyle  factors,  and 
other  environmental  influences.  Without  knowing  the  exact  mechanisms  that 
cause  damage,  especially  in  AD,  it  is  difficult  to  target  the  disease  process 
effectively. A further obstacle is the difficulty of delivering medication across the 
blood-brain barrier (Marques et al., 2013).  
Current medication is used to treat the behavioural and cognitive symptoms of 
dementia, but has little effect on the underlying pathophysiology. By way of an 
example, many of the drugs used in clinical practice seek to improve memory 
deficits by targeting cholinergic neurotransmitter systems and the serotoninergic 
pathway, but less than 10% of patients respond to such treatment. 
1.1.2.  Nootropic drugs 
Nootropic drugs, also known as memory enhancers, smart drugs, and cognitive 
enhancers,  are  drugs  that  improve  cognitive  function,  memory,  and 
concentration.  Their  action  alters  the  availability  and  balance  of  brain 
neurotransmitters, hormones and enzymes, but the mechanisms by which they 
improve learning and memory are not fully understood (Froestl et al., 2012). 
One  plausible  mode  of  action  is  that  they  strengthen  inter-synaptic 
communication  between  neurones  and  brain  circuits  that  are  important  for Blanka Szulc                                                                                               Introduction 
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learning and memory. Consistent with this hypothesis, both in vitro studies and 
animal  behavior  experiments  suggest  that  nootropic  drugs  facilitate  the 
induction of long-term potentiation (LTP) in the hippocampus, a phenomenon 
leading to synapse reinforcement, which is thought to underlie memory storage 
and recall in this brain structure (Giurgea et al., 1983). Hippocampal LTP serves 
as  a  cellular  model  to  study  synaptic  plasticity  and  its  pharmacological 
enhancement can improve cognitive and memory associated deficts occuring in 
dementia patients (Bliss et al., 2014). Such an enhancement of LTP can be 
associated  with  a  lowering  of  the  threshold  of  its  induction,  or  with  its 
maintance,  which  is  mechanistically  relevant  to  chemically  induced  basal 
neurotransmission (Oh-Nishi et al., 2009). 
Thus,  one  candidate  mechanism  by  which  a  drug  could  prove  beneficial  in 
treating the progressive decline typical of these disorders would be by either 
facilitating basal neurotransmission, or secondly by lowering the threshold for 
LTP induction in the hippocampus, which will be discussed in detail in section 
1.7.2.2.  
In 2010 Malykh and Sadaie (Malykh and Sadaie, 2010) published a review of 
piracetam-like drugs, where they divided them into three families, according to 
their  medicinal  use:  cognitive  enhancers,  antiepileptic  drugs  and  drugs  with 
unknown  clinical  efficacy.  Piracetam  (3),  oxiracetam  (4),  aniracetam  (5), 
pramiracetam  (6)  and  phenylpiracetam  (7)  are  members  of  the  first  group 
known as cognitive enhancers (Figure 2).  
 
Figure 2: Piracetam-like cognitive enhancers 
Mechanistically,  most  have  been  shown  to  activate  ʱ-amino-3-hydroxy-5-
methyl-D-isoxazole-propionic acid (AMPA) but not kainate (KA) or N-methyl-D-Blanka Szulc                                                                                               Introduction 
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aspartate  (NMDA)  receptors  in  neuronal  cultures.  Their  effect  on  AMPA 
receptors is proposed to occur via an increase in the density of receptor binding 
sites and elevation of intracellular calcium levels (Copani et al., 1992). 
In  contrast  to  the  first  family  of  compounds,  the  second  group,  comprising 
levetiracetam (8), brivaracetam (9) and seletracetam (10) (Figure 3), have been 
shown  to  inhibit  neuronal  calcium  ion  channels,  which  can  explain  their 
antiepileptic properties (Lukyanetz et al., 2002).  
 
Figure 3: Piracetam-like anti-epileptic drugs 
Finally, the third group is represented by piracetam derivatives that are mostly 
in the preclinical stage, or those that have entered the clinical stage and their 
mode of action is currently under investigational status such as rolipram (13) or 
those that have been taken into patients and failed to reach clinical endpoints 
such as nefiracetam (11) (Figure 4) (Malykh and Sadaie, 2010). 
 
Figure 4: Piracetam-like compounds with unknown efficacy 
Nootropic drugs are frequently used in the treatment of a very wide spectrum of 
disorders associated with memory and are often used for the treatment of both Blanka Szulc                                                                                               Introduction 
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memory and cognition deficits. The largest of this grouping is that of AD but 
they are also used in the treatment of schizophrenia, stroke, attention deficit 
hyperactivity disorder (ADHD), aging and epilepsy to name but a few (Froestl et 
al., 2012, Giurgea et al., 1983). 
Despite the fact that piracetam (3) (also known as Nootropil) has been used for 
over 40 years its cognitive enhancing effects have remained ethereal in nature. 
It was first approved as a nootropic drug in Europe in the 1970’s, despite a lack 
of knowledge as to its exact mechanism. There have been numerous studies 
carried  out  in  order  to  investigate  its  potential  in  disease  models  that  are 
associated  with  memory  defects.  In  1993  Croisile  and  others  performed  a 
double-blind  placebo-controlled,  parallel-group  study  over  a  one-year  period. 
They used a high dose of piracetam (3) (8g/d per os) and examined its effects 
in 33 patients, who had previously presented with slowly progressive memory 
impairment, which was attributed to probable early onset Alzheimer’s disease. 
The results of their study showed that long-term administration of a high dose of 
piracetam (3) could slow the cognitive deterioration in patients with AD (Croisile 
et al., 1993). 
Further supporting evidence for the nootropic effects of piracetam (3) (Figure 2) 
came from a study where it was demonstrated to be the most effective drug in 
patients with cognitive deterioration or cerebral ischaemia-induced short-term 
memory after heart bypass surgery (Uebelhack et al., 2003). Consistent with 
these  results,  Holinski’s  studies  further  supported  the  demonstrated 
cerebroprotective  properties  of  piracetam  in  patients  who  underwent  heart 
bypass surgery (Holinski et al., 2008). However, follow-up investigations of the 
same patient cohort three years later indicated that administration of piracetam 
prior  to  an  open-heart  surgery  procedure  had  no  demonstrable  preventative 
effect  on  post  surgical  deterioration  of  cognitive  function  in  older  patients 
(Holinski et al., 2011). 
Malykh  and  Sadaie  (Malykh  and  Sadaie,  2010)  carried  out  meta-analysis  of 
nineteen  clinical  double  blind  placebo  controlled  trials  that  were  performed 
against the activity of piracetam (3) (Figure 2), between 1972 and 2001. Most of 
the studies were directed towards memory deficit disorders and the results of Blanka Szulc                                                                                               Introduction 
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the analysis showed that patients treated with piracetam improved by 61% in 
comparison to 33% in the placebo groups. Adverse effects such as headaches 
or drowsiness in patients occurred very rarely and were typically mild in nature, 
clearly  highlighting  the  potential  of  the  racetam  family  of  compounds  and 
piracetam (3) (Figure 2) in particular (Batysheva et al., 2009, Fedi et al., 2001, 
Akhondzadeh et al., 2008). Despite this, piracetam (3) (Figure 2) demonstrated 
no significant improvement in cognitive impairment in patients with Alzheimer’s 
disease, despite its potent neuroprotective and memory enhancing effects on 
those that had undergone heart bypass surgery.  
In piracetam polytherapy with the vasodilator cinnarizine (Fezam), patients with 
multiple sclerosis (MS) showed improvements in activity and/or mood (Gusev et 
al.,  2008).  Fezam  has  also  been  used  in  the  treatment  of  senile  macular 
degeneration and was shown to improve vision significantly (20-80%) in over 
76% of patients. The authors proposed that the effects of piracetam were due to 
improvements in retinal microcirculation (Kiseleva et al., 2005).  
Piracetam  has  also  been  used  in  combination  therapy  in  patients  with  the 
antipsychotic  risperidone.  Results  from  the  study  demonstrated  a  synergistic 
improvement  of  abnormal  behaviour  in  patients  with  autistic  disorders 
(Akhondzadeh et al., 2008). 
Despite the pluripotent effects reported for piracetam (3) (Figure 2), it is known 
to  be  a  weak  positive  modulator  of  AMPA  receptors  (Copani  et  al.,  1992). 
Crystallography  analysis  revealed  that  piracetam  binds  to  the  S1S2  dimer 
interface of GluA2 (Figure 5). Moreover, it was also shown that it could occupy 
three  binding  sites  as  shown  below,  where  the  first  binding  site  (blue)  is 
analogous to the binding site of aniracetam. The second binding site (purple) is 
analogous to the binding site of cyclothiazide and the third binding site (red), 
which appears unique to piracetam (Ahmed and Oswald, 2010).  Blanka Szulc                                                                                               Introduction 
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Figure 5: Piracetam bound to dimeric GluA2 at three binding sites 
 
However, despite the crystallographic evidence of its binding, the mechanism 
by which piracetam exerts its nootropic effects remains a matter of conjecture 
with numerous contrasting studies.  
Marisco  and  others  recently  demonstrated  that  in  the  scopolamine-induced 
cognition loss animal model, piracetam (3) (Figure 2) was shown to decrease 
the discrimination index in the object recognition task (Marisco et al., 2013). The 
data  that  they  reported  was  consistent  with  previous  tests  carried  out  by 
themselves and others, which described the beneficial effects of  piracetam’s 
ability  to  either  prevent  or  reverse  memory  impairments  induced  by 
scopolamine  (Chopin  and  Briley,  1992,  Piercey  et  al.,  1987,  Verloes  et  al., 
1988, Lenegre et al., 1988, Schindler, 1989). The exact mechanism by which 
piracetam  achieves  this  prevention  or  reversal  remains  unknown.  However, 
despite  the  lack  of  a  clear  target,  Marisco  suggested  that  its  effect  can  be 
associated with the purinergic system via a decrease in oxidative stress and a 
corresponding  maintenance  of  adenosine  triphosphate  diphosphohydrolyse 
(NTPDase),  5’-nucleotidase  and  adenosine  deaminase  (ADA)’  levels  in 
synaptosomes in the cerebral cortex and hippocampus (Marisco et al., 2013).  Blanka Szulc                                                                                               Introduction 
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In  support  of  this  proposed  mechanism  is  the  fact  that  oxidative  stress  is 
frequently  observed  in  inflammatory  hyperalgesia  along  with  production  of 
associated inflammatory cytokines (Verri et al., 2012). This also correlates with 
the  recently  reported  analgesic  and  anti-inflammatory  effects  of  piracetam, 
further supporting its mechanism of action (Navarro et al., 2013). Piracetam was 
also shown to reduce the levels of the cytokine tumor necrosis factor (TNF-ʱ), 
in a carrageenin-induced model of inflammation, which further forms interleukin 
1 beta (IL-1β). These two cytokines are known to activate nicotinamide adenine 
dinucleotide  phosphate  (NADPH)  oxidase,  which  is  a  catalyst  for  the 
generation of reactive oxygen species (ROS). As recently observed by Valencia 
(Valencia et al., 2013), the hyperactivity of NADPH oxidase was shown to cause 
a  resultant  and  concomitant  increase  in  oxidative  stress  and  cell  death  in 
Huntington’s disease, which is also characterised by memory loss symptoms. 
1.1.3. AMPA modulators in a clinical setting 
One of the key challenges of converting an active compound into a drug is its 
progression through clinical trials. The area of cognitive enhancers is replete 
with compounds that have failed to demonstrate a significant improvement over 
current  therapy  or  obtention  of  the  desired  clinical  endpoints,  which  are 
frequently difficult to both measure and analyse. Therefore the design of any 
trial has to consider two important elements. The first of these relates to the 
probability of achieving the desired change in the patient’s cognitive function. 
One mechanism  by  which  a  trial  can  achieve  this is by  improvement  of the 
cognitive function of patients by counteracting the 'damage' caused by mental 
decline. However, this positive effect can only be observed when the mental 
decline equates to a mild intellectual deterioration. In cases of severe mental 
deterioration,  the  structural  changes  of  the  brain  are  too  complicated,  so 
obtention of the clinical endpoints with a nootropic drug are very challenging. 
For instance, patients presenting with early signs of dementia are often ‘’good 
experimental subjects,’’ whereas elderly patients with dementia, depression and 
variation in cognition arousal can be improved indirectly - via the improvement 
of  patient’s  mood  and  motivation,  classifying  them  as  ‘’poor  experimental 
subjects.’’  Blanka Szulc                                                                                               Introduction 
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The second concerns the interpretation or achievement of an observed change 
in the requisite cognitive task. The change has to be measured in a ‘’neutral 
environment,’’  meaning  that  factors  that  can  improve  or  reduce  cognitive 
performances have to be excluded. For example, the improvement in cognition 
might be an indirect result of the side effects of a nootropic drug observed in the 
‘’experimental  subject.’’  Hakkarainen  and  Hakamies  (Hakkarainen  and 
Hakamies,  1978)  have  noticed  that  piracetam  caused  anxiety,  irritability  or 
nervousness,  catalysis  of  arousal  and  alertness  that  can  trigger  or  cause 
indirect effects on cognition (Gainotti et al., 1986). 
At present, it is clear that current drug regimens for memory do not effectively 
treat  diseases  associated  with  memory  impairment  such  as  Alzheimer’s 
disease.  As  such,  the  search  for  new  treatments  continues  and  in  order  to 
develop new therapeutics, researchers including us, frequently take inspiration 
from nature. One such potential candidate – clausenamide isolated from the 
Chinese plant Clausena lansium has shown good potential for the treatment of 
neurological  disorders,  but  it  is  not  accessible  in  sufficient  amounts  to  be 
developed into a medicine. The following section describes previous synthetic 
approaches towards this compound and its reported biological activity.  
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1.2. Clausenamide 
Clausenamide 2 is a naturally occurring five-membered heterocycle that exists 
in a racemic form and was first isolated in the early 1980s from the aqueous 
extracts  of  the  dry  leaves  of  the  shrub  Clausena  lansium,  the  enantiomeric 
forms  of  which  are  shown  below  (Figure  6). Clausena  lansium  is  commonly 
known as Wampee and is a plant member of the Rutaceae family, occurring in 
either shrub or tree form with grape-like fruit.  
 
Figure 6: Structures of (-)- and (+)-clausenamide 
Chinese, Taiwanese and Vietnamese herbalists have used Clausena lansium 
as a folk medicine for thousands of years. Its leaves, seeds and fruit have been 
used for the treatment of a variety of disorders such as coughs, asthma, ulcers, 
acute  and  chronic  gastro-intestinal  inflammation,  acute  and  chronic  viral 
hepatitis,  bronchitis  and  malaria.  Additionally,  some  courmarins  and  amides, 
similar to clausenamide were shown to have pharmacological properties, such 
as  anti-lipid  peroxidative  and  cerebral  protective  effects,  as  well  as 
hepatoprotective, hypoglycaemic, anticonvulsant, cardiovascular and antitumor 
activities (Adebajo et al., 2009, Hartwig and Born, 1987). 
This medicinal plant is typically produced in large amounts in the  southwest 
Yunnan province in China. However, only 3.8 grammes of clausenamide are 
isolated from over 10 kilograms of dried leaves (Hartwig and Born, 1987). 
Clausenamide’s structure is based on a pyrrolidine ring, with four contiguous 
chiral centres (C3, C4, C5, C6) leading to 16 possible enantiomers (8 pairs of 
diastereoisomers) as shown below (Figure 7) (Feng et al., 2009). Blanka Szulc                                                                                               Introduction 
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Figure 7: Optically active clausenamide stereoisomers (adapted from (Feng et al., 
2009)). 
1.2.1. Mode of action of clausenamide 
Clausenamide  is  isolated  as  its  racemic  (+/-)  form  and  as  such,  there  are 
several issues associated with this for the development of clausenamide as a 
potential drug. In the drug development process it is essential to isolate a single 
enantiomer  from  the  racemate  of  a  drug,  as  receptors  and  enzymes  have 
specific stereo- selectivity with one enantiomer having positive effects and the 
other having either no effect, or deleterious effects as seen from the problems 
associated with thalidomide use in the 1960s (Kim and Scialli, 2011). In other 
words, production and analysis of each chiral compound is crucial to obtain a 
complete  ADME  (Absorption,  Distribution,  Metabolism,  Elimination)  profile  as 
well as establishing the toxicity of each single enantiomer. As a further example, 
racemic DOPA used for the treatment of Parkinson’s disease has been shown Blanka Szulc                                                                                               Introduction 
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to  possess  many  adverse  effects  such  as  nausea,  vomiting,  anorexia  and 
granulocytopenia  (Hutt  and   alentov ,  2003).  However,  use  of  the  single 
enantiomer clearly demonstrated that L-DOPA not only reduced those effects, 
but also enabled the required dose to be lowered to 50% of that of the racemic 
form. Hence, separation of both enantiomers is crucial in order to ensure that 
any newly developed drug can be safe and reliable in clinical trials. Despite this, 
single enantiomers and racemates can sometimes show similar toxicities and 
pharmacokinetic  profiles,  so  the  overall  effect  of  the  racemic  mixture  can 
sometimes be extrapolated to a single enantiomer (Hutt and  alentov , 2003). 
Clausenamide has been shown to possess nootropic activity in animal tests and 
has also been shown to enhance LTP, which is the long-lasting improvement in 
communication between two neurones, as a result of simultaneous stimulation. 
Liu and Zhang showed that (-)-clausenamide could potentiate  basal synaptic 
transmission  and  high  frequency  stimulation  (HFS)-induced  LTP  on 
anaesthetised or freely moving rats and increased hippocampal and mossy fibre 
sprouting (Liu and Zhang, 1998, Xu et al., 2005, Tang and Zhang, 2002, Liu et 
al., 1999). 
Ning and other researches proposed that the facilitating effect on glutamatergic 
synaptic  transmission  of  (-)-clausenanamide  in  the  CA1  region  is  due  to 
activation of voltage-dependent calcium channels (VDCC) and calcium release 
which then triggers release of intracellular calcium (from endoplasmic reticulum) 
and activates the CaMKIIʱ-CREB singal pathway (Ning et al., 2012b, Ning et 
al., 2012a). 
Moreover, (-)-clausenamide was also shown to be 50-100 times more active 
than the well-known drug piracetam (3) (Figure 8) and 5-10 times more active 
than the racemic form of clausenamide. 
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Inspired  by  this  result,  Feng  and  co-workers  considered  whether 
clausenamide’s nootropic activity might be related to its stereochemistry. They 
investigated  whether  there  is  a  correlation  between  the  configuration  of  the 
stereoisomers  of  clausenamide  and  its  associated  nootropic  activity.  To 
investigate the structure-activity-relationship (SAR), they synthesised all 16 (8 
pairs)  optically  pure  stereoisomers  of  clausenamide  starting  from  the  parent 
compound. They carried out an LTP assay, which indicated that three isomers: 
2e,  2i,  2p  are  more  potent  in  terms  of  increasing  population  spike  (PS) 
amplitude  than  the  purported  most  active  enantiomer,  (-)-clausenamide.  In 
addition, the corresponding enantiomers 2j, 2f, 2o were shown to be less potent 
than (-)-clausenamide (Feng et al., 2009). 
In  order  to  separate  (-)-clausenamide  from  the  naturally  occurring  racemic 
mixture, Wang and others carried out high performance liquid chromatographic 
(HPLC)  separation  using  chiral-ʱ1-acid  glycoprotein  (AGP)  as  the  stationary 
phase. The method used was efficient, universal and enabled ready separation 
of all the enantiomers of racemic clausenamide
 (Wang et al., 2010). 
Recent  data  published  by  Ning  and  other  researchers  confirmed  a  strong 
relationship between chirality and modulation of synaptic transmission, as (+)-
epi-clausenamide (2p) but not (-)-epi-clausenamide (2o) was shown to be more 
potent  than  (-)-clausenamide.  As  suggested,  the  facilitation  of  synaptic 
transmission might be associated with the activation of Synapsin I (Ser 9) (Ning 
et al., 2012a). 
1.2.2. Previous synthetic approaches to clausenamide 
There  have  been  several  reports  directed  towards  the  synthesis  of 
clausenamide, all of which utilise different methods and a number of different 
strategies  to  synthesise  either  the  pyrrolidine  core  or  the  surrounding 
functionality.  
Li  and  co-workers  (Li  et  al.,  2010)  synthesised  clausenamide  2  in  an 
intramolecular cyclisation from an epoxide precursor 21-23 as outlined below 
(Scheme  1).  Use  of  lithium  hydroxide  in  a  water/methanol  mixture  led  to 
intramolecular cyclisation to the pyrrollidine core structure 24-27, but it proved Blanka Szulc                                                                                               Introduction 
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to be a slow and low yielding complicated method. Finally, elaboration of the 
cyclised  product  led  to  clausenamide  2,  via  an  eight  and  six  step  overall 
reaction  sequence  starting  from  β-phenyl-(N-p-methoxylbenzyl)-ethanol  20 
(Scheme  1).  Yang  and  co-workers  and  Wang  and  co-workers  have  also 
reported an analogous approach towards clausenamide, and related isomers 
via ring opening of a chiral epoxide (Yang et al., 2009, Wang and Tian, 1996). 
Scheme 1: Clausenamide cyclisation with LiOH 
Yakura’s  approach  towards  the  total  synthesis  of  clausenamide  involved  an 
oxidative  cleavage-lactamization  of  trans-5-substituted  4-acyl  or  alkyl-
aminocyclohexenes. In this approach, in situ oxidation of cyclohexene 30 using 
ruthenium  chloride  under  Sharpless  conditions  led  to  the  corresponding 
carboxylic acid 31 that was isolated as its methyl ester 32 in 88% yield. The 
corresponding  N-Boc-protected  pyrrolidone  32  was  deprotected  and  N-
methylated  with  lithium  diisopropylamide  and  methyl  iodide  to  give  the  N-
methylpyrrolidone  derivative  33.  By  use  of  the  Barbier-Wieland  degradation 
procedure,  N-methylpyrrolidone  was  subsequently  converted  into  the  key 
intermediate  for  the  synthesis  of  clausenamide  (Scheme  2)
  (Yakura  et  al., 
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Scheme 2: Yakura’s approach to clausenamide 
Zhu  and  others  developed  an  efficient  ylide  cyclisation  for  the  synthesis  of 
isoxazoline N-oxides, which can be used as a precursor in the formal synthesis 
of dehydroclausenamide. As shown below (Scheme 3), treatment of isoxazoline 
with Raney Ni under a H2 atmosphere led to formation of lactam 39, which is 
then methylated and reacted with phenyllithium to give phenylketone 41, which 
according to literature precedent can be transformed to dehydroclausenamide 
in a two step process (Scheme 3) (Zhu et al., 2008). 
 
Scheme 3: Formal synthesis of dehydroclausenamide 
In  the  diastereoselective  total  synthesis  of  clausenamide,  Hartwig  and  Born 
used ethyl cinnamate 43 and diethyl acetamidomalonate 44 to generate 5,5-bis-
(ethoxycarbonyl)-4-phenylbutyrolactam  45  (Hartwig  and  Born,  1987). Blanka Szulc                                                                                               Introduction 
 
17 
 
Methylation  of  pyrrolidinone  45  via  deprotonation  with  sodium  hydride  and 
treatment with methyl iodide gave 46 in an impressive 95% yield. Unfortunately, 
subsequent hydrolysis with barium hydroxide was only partially successful on 
the ester group located in the trans-position to the phenyl group. The resulting 
acid-ester 47 was then heated with collidine according to literature precedent, to 
give  selectively  and  exclusively  the  monocarboxylic  ester  48  with  4,5-cis-
configuration (Abell and Lennon, 1965, Musso, 1968). Under these conditions 
and in contrast to previous reports; both isomers were formed in around a 1:1 
ratio.  Alternatively,  heating  of  the  acid-ester  47  to  140  ºC  without  solvent 
improved the ratio to 2:1 in favour of the cis-isomer. The cis-isomer was then 
separated by crystallisation and reacted with sterically hindered superhydride 
(LiBEt3H) to give exclusively the cis alcohol 49. Swern oxidation of 49 to the 
aldehyde  50  followed  by  Grignard  addition  gave  alcohol  51.  This  was  then 
reoxidised again under Swern conditions, reduced with superhydride and the 
alcohol  moiety  introduced  under  basic  conditions  to  give  clausenamide  2 
(Scheme 4)
 (Hartwig and Born, 1987). 
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Dai  and  Huang  recently  described  a  novel  approach  to  racemic 
neoclausenamide  2i,j  starting  from  N-Boc-pyrrol-2-(5H)-one  54  using  the 
vinylogous Mukaiyama aldol reaction (Scheme 5) (Dai and Huang, 2012). 
  
  
Scheme 5: Dai and Huang synthesis of neoclausenamide  
Reaction of the vinylagous amide 54 with triethylamine and benzaldehyde in the 
presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) gave the addition 
product 55 in excellent yield (93%). Copper catalysed 1-4 Grignard addition of 
phenylmagnesium bromide led to introduction of the 4-phenyl group anti to the 
secondary alcohol moiety in good yield. Incorporation of the alcohol group at C-
2  of  the  pyrrolidine  ring  was  accomplished  via  use  of  the  Davis  Oxaziridine 
reagent, which led to efficient formation of the bis-alcohol 57 with concommitant 
deprotection  of  the  tetramethylsilane  (TMS)  protected  alcohol.  Finally, 
deprotection of the pyrolidinone amide with trifluoroacetic acid (TFA) followed 
by  alkylation  with  methyl  iodide  under  basic  conditions  gave  racemic 
neoclausenamide 2i,j in 94% and 31% overall yield.  
He  and  Bode  recently  reported  a  formal  total  synthesis  of  (±)-clausenamide 
using an N-heterocyclic carbene (NHC) approach (He et al., 2012) as shown 
below (Scheme 6).  Blanka Szulc                                                                                               Introduction 
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Scheme 6: He’s approach to (±)-clausenamide 
Cinnamaldehyde 60 was reacted with N-sulfonylimine 59 in the presence of the 
NHC  catalyst  to  give  the  lactam  61  in  61%  yield  as  an  8:1  mixture  of 
diastereoisomers. Deprotection and alkylation gave the  N-methylated product 
63 in 60% overall yield as a single isomer after purification. Ozonlysis followed 
by Grignard addition led to formation of the secondary alcohol 65 in 63% yield. 
The  final  two  steps  to  (±)-clausenamide  2  had  previously  been  reported  by 
Hartwig and Born as shown in Scheme 4 (Hartwig and Born, 1987).  
Tellitu  and  Dominguez  developed  a  novel  hypervalent  iodine  mediated 
approach  to  the  core  structure  of  clausenamide  via  the  use  of 
[bis(trifluoroacetoxy)iodo]benzene  (PIFA)  as  shown  in  Scheme  7  (Tellitu  and 
Domínguez, 2012). Blanka Szulc                                                                                               Introduction 
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 Scheme 7: Tellitu and Dominguez’s approach to (±)-clausenamide 
Condensation of Meldrum’s acid with benzaldehyde gave adduct 66, which on 
reaction with phenylacetylene gave the conjugate adduct 67. Thermal mediated 
decarboxylation gave acid 68 in 45% yield over two steps, which was reacted 
with methylamine under standard coupling conditions to give amide 69 in 74% 
yield. The key step in the reaction sequence was mediated by PIFA which gave 
efficient conversion to the pyrrolidinone 52 in 67% yield albeit in a disfavourable 
2:1 ratio of trans:cis isomers. This method was a formal total synthesis as the 
subsequent steps had previously been reported by Hartwig and Born (Hartwig 
and Born, 1987).  
One of the earliest syntheses of (+)-clausenamide was reported by Cappi and 
co-workers in their search for the synthetic usefulness of epoxide 71, which was 
obtained  via  Juliá-Colonna  epoxidation  of  the  chalcone  70  (Scheme  8)  (W. 
Cappi  et  al.,  1998).  Reaction  of  the  epoxide  with  meta-chloroperoxybenzoic 
acid (mCPBA) furnished ester 72 in good yield, which was elaborated to the 
cyclisation precursor 74 via treatment with amine 73 and subsequent oxidation. 
Cyclisation was carried out under basic conditions, analogous to the method 
described previously by Li and co-workers (Li et al., 2010). Finally, reduction 
with sodium borohydride gave (+)-clausenamide 2b in 40% overall yield.  Blanka Szulc                                                                                               Introduction 
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Scheme 8: Cappi’s approach to (+)-clausenamide 
Liu and co-workers reported a six-step synthesis of (-)-clausenamide 2a in 2013 
involving a novel Ireland-Claisen rearrangement with an overall yield of 34% 
and >98% enantiomeric excess (ee) (Liu et al., 2013) as shown (Scheme 9).  
   
Scheme 9: Liu and co-workers approach to (-)-clausenamide 
The starting alcohol 76 was prepared from the racemate by kinetic resolution 
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with acetic anhydride. Subsequent Ireland-Claisen rearrangement via treatment 
with excess lithium diisopropylamide (LDA) and trimethylsilyl chloride (TMSCl) 
gave the S-configured 78 in 85% yield. N-Bromosuccinimide (NBS) mediated 
bromolactonisation  led  to  efficient  formation  of  the  lactone  80  in  88%  yield. 
Reaction of 80 with methylamine gave the ring opened product 81, which on 
treatment  with  base  gave  (-)-3-deoxy-clausenamide  85  in  88%  yield.  Finally 
treatment  with  LDA  and  Davis  oxaziridine  gave  (-)-clausenamide  2a  in  80% 
yield.  
As a result of the potent induction of LTP displayed by (+)-epi-clausenamide 2p 
compared  to  (-)-clausenamide  2a,  Zhang and  co-workers developed  a novel 
enantioselective approach starting from protected  L-serine (86) (Scheme 10) 
(Zhang et al., 2012).  
Scheme 10: Zhang’s approach to (+)-epi-clausenamide 
Condensation of the serine derivative 86 with Meldrum’s acid gave the β-keto 
lactam 87, which was converted to its tosylate enolate 88 in 74% yield. Suzuki-
Miyaura coupling led to efficient incorporation of the aryl subunit to give 89, 
which  was  then  reduced  using  catalytic  palladium  on  carbon  at  elevated 
pressure. Deprotection and alkylation with methyl iodide led to introduction of Blanka Szulc                                                                                               Introduction 
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the N-methyl group to give 91 in 82% yield. Finally deprotection of the silylated 
alcohol 91, followed by oxidation, Grignard addition and treatment with Davis 
oxaziridine gave (+)-epi-clausenamide 2p in the first reported enantioselective 
synthesis of this key compound.  
As  outlined  above,  the  various  synthetic  stregies  towards  clausenamide  (2) 
nearly all involve linear methodology with modest to poor yields. The key steps 
in  most  approaches  are  limited  by  their  need  to  synthesise  the  correct 
stereochemistry of the final and intermediate product. As such, they are limited 
in  their  applicability  towards  the  synthesis  of  clausenamide  and  various 
derivatives.  
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1.3. Biological introduction  
At  present,  the  pharmaceutical  market  suffers  from  a  lack  of  provision  of 
available drugs to treat disorders associated with memory impairment such as 
Alzheimer’s  or  Parkinson’s  disease.  The  pyrrolidin-2-one  family  of  cognition-
enhancers, such as piracetam 3 have been studied over a number of decades 
and there  are  several  members of  this  nootropic family  that  are in  use  in a 
number of countries as neuroprotective agents after stroke, to control cognition 
impairment and to cure epilepsy (Malykh and Sadaie, 2010). In order to find 
new  potent  molecules,  robust  neurophysiological  assays  are  required  to 
demonstrate the mechanism of action at a molecular level. 
1.4. Glutamatergic neurotransmission 
Fast communication in the central nervous system (CNS) implies that individual 
neurones  propagate  spikes  down  their  axon  where  synapses  with  other 
neurones  are  formed.  When  such  activity  reaches  the  axon  terminal,  the 
neurotransmitter  packaged  into  the  presynaptic  neurone  is  released;  it  then 
diffuses and binds to receptors localised on the membrane of the postsynaptic 
neurone allowing the passage of information. Such receptors are also present 
on axon terminals in the presynaptic neurone itself, where they modulate both 
the excitability and the capacity to release neurotransmitters. For fast ionotropic 
transmission at most excitatory synapses in the brain,  glutamate is the main 
excitatory neurotransmitter (Storm-Mathisen et al., 1983) and acts on AMPA, 
kainate and NMDA receptors (Bellocchio et al., 2000, Takamori et al., 2000, 
Kullmann,  2007).  AMPA  and  NMDA  receptors  are  mostly  colocalized  in  the 
postsynaptic membrane (Bekkers and Stevens, 1989) (McBain and Dingledine, 
1992) whilst kainate receptors can be distributed both pre- and post-synaptically 
(Huettner,  2003,  Lerma  and  Marques,  2013).  Glutamate  also  activates 
metabotropic  glutamate  receptors  (mGluRs),  which  are  G-protein  coupled 
receptors  that  indirectly  affect  neuronal  excitability  by  modulation  of  other 
conductances, e.g. K
+ channels.  
Several  electrophysiological  techniques  that  have  been  used  to  study  the 
intrinsic electrical properties of peripheral and central neurones as well as the 
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excitatory  and  inhibitory  synapses  and  are  described  below  (Neher  and 
Sakmann, 1992). In the late 1930s Cole and Curtis  (Cole and Curtis, 1939) 
invented the voltage-clamp technique, which enabled an analysis of membrane 
currents  underlying  changes  in  cellular  excitability  by  holding  the  membrane 
potential at a fixed value, e.g. -70 mV. In the late 1970s Neher and Sakmann 
(Neher and Sakmann, 1976, Hamill et al., 1981) introduced the patch-clamp 
technique, which extended the reach of the voltage-clamp technique to be able 
to resolve single channel currents activated by neurotransmitters (ligand-gated 
ion  channels  and  receptors)  or  by  changes  in  membrane  voltage  (voltage-
operated ion channels). This technique first applied to invertebrate preparations 
(Gola  and  Romey,  1970),  required  optimization  when  applied  to  mammalian 
brain slices because in order to obtain a really high electrical resolution, a high 
resistance between the recording electrode and the cell membrane is required 
(defined as giga ohm seal or ‘gigaseal’). Edwards and others (Edwards et al., 
1989) invented a visualization method for neurones in thin brain slices based on 
differential  infrared  videomicroscopy.  This  approach  enables  identification  of 
single  neurones  and  some  of  their  processes  whilst  permitting  simultaneous 
recording from them under visual control. 
The  following  section  provides  a  general  overview  of  the  different  types  of 
ionotropic receptors activated by glutamate.  
1.5. Ionotropic Glutamate Receptors 
Excitatory  synapses  express  AMPA,  NMDA  and  less  commonly  kainate 
receptors, all of which can be activated by the release of glutamate following 
invasion of the terminal by the presynaptic action potential. AMPA and kainate 
receptors  mediate  the  initial  electrophysiological  response  to  glutamate, 
whereas  NMDA  receptors  are  responsible  for  a  slower  and  longer  phase  of 
neurotransmission. Neurotransmission is then terminated by glutamate diffusion 
and clearance mechanisms as well as receptor mechanisms. 
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1.5.1. AMPA receptors  
Fast excitatory postsynaptic currents (EPSCs) are mostly mediated by AMPA 
receptors. AMPARs are heteromers composed of four subunits GluA1-4 forming 
an  ion  channel  permeable  to  Na
+,  K
+  and  for  some,  Ca
2+.  All  subunits  of 
AMPAR  are  expressed  in  the  hippocampus:  GluA1  and  GluA2  mainly  in 
principal cells and  interneurones, whereas GluA3 occurs at lower levels and 
GluA4 occurs only in embryonic and early postnatal principal cells (Keinanen et 
al., 1990). AMPARs have fast kinetics and high opening probability, and their 
activation, deactivation and desensitization occurs within milliseconds. Dynamic 
changes in subunit composition are reflected in the biophysical properties of 
AMPARs.  For  instance,  the  presence  of  the  GluA1  subunit  is  necessary  for 
calcium  permeability  and  as  such,  the  corresponding  synaptic  plasticity.  For 
example,  cerebellar  stellate  cells  exhibit  a  form  of  synaptic  plasticity  that  is 
dependant of incorporation of GluA1 or GluA2 subunits during high frequency 
stimulation (Liu and Cull-Candy, 2002). AMPARs containing GluA2 will have a 
reduced  Ca
2+  permeability  as  well  as  channel  conductance  and  prolonged 
decay  kinetics  of  synaptic  current  (Cull-Candy  et  al.,  2006).  Moreover, 
incorporation  of  the  GluA2  subunit  will  abolish  any  physiologically  occurring 
block  by  endogenous  polyamines  at  GluA1-enriched  AMPARs  (Rozov  and 
Burnashev,  1999,  Savtchouk  and  Liu,  2011).  It  is  therefore  clear  that  the 
sensitivity  of  evoked  EPSCs  to  polyamine  toxins  (e.g.  philantotoxin)  or 
intracellular  polyamines  can  be  used  to  establish  calcium-permeability  of 
AMPARs. Noteworthy is the presence of two pools of AMPARs: functional pools 
and reserve pools. Functional pools of AMPARs are present on the synaptic 
surface, whereas reserve pools exist either intracellularly (driven by endo- and 
exocytosis)  or  at  the  extrasynaptic  surface  membrane  (regulated  by  lateral 
diffusion). Importantly, AMPARs endure an activity-dependent recycling process 
between the two pools mentioned above, thus providing a mechanism for the 
strengthening  of  synaptic  transmission  in  hippocampal  pyramidal  neurones. 
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1.5.2. NMDA receptors 
To date, three families of NMDA receptor subunits have been identified: GluN1, 
GluN2A-D and GluN3A-B. (Paoletti and Neyton, 2007) NMDAR are permeable 
to Ca
2+, Na
+ and K
+ (Ascher and Nowak, 1988). Before the separation into three 
glutamatergic  ionotropic  receptors,  a  division  of  NMDA  and  so  called  ‘non-
NMDA’  receptors  existed.  Indeed,  NMDAR  show  many  distinctive  properties 
amongst other ionotropic glutamate receptors. Firstly, NMDAR mediated signals 
have  characteristic  slow  kinetics  (hundreds  of  milliseconds)  due  to  slow 
glutamate unbinding. Secondly, NMDAR channels are highly permeable to Ca
2+ 
and their opening probability and gating is subunit specific (Gielen et al., 2009). 
Thirdly, their ion channels can be subjected to a voltage-dependant block by 
Mg
2+ (Mayer et al., 1984, Nowak et al., 1984). At the resting membrane potential 
(more negative than -50 mV), NMDARs are blocked by Mg
2+, which is relieved 
by a sufficient membrane depolarisation of the membrane (for example caused 
by strong activation of AMPAR), displaying a characteristic outward rectification 
in the I-V relationship of NMDAR-mediated currents (Ascher and Nowak, 1988). 
Lastly, NMDAR channels require not only glutamate as a co-activator but also 
either a molecule of either glycine or D-serine (Kew et al., 2000). 
NMDARs  contain  many  regulatory  binding  sites  to  which  a  number  of  small 
molecules can bind, either in an agonistic or antagonistic manner. Such diverse 
pharmacology is important, as many neuropsychiatric disorders are linked to 
both the hyperactivation and hypofunction of NMDARs (Paoletti et al., 2013). 
Moreover,  NMDA  receptors  play  an  important  role  in  synaptic  plasticity,  for 
instance  the  induction  of  long-term  potentiation  (LTP)  in  CA1  region  of  the 
hippocampus  and  NMDA  receptor-dependent  metaplasticity  at  mossy  fiber- 
CA3 synapses. 
NMDARs have been proposed to act as ‘coincidence detectors’, implying that 
sufficient depolarization of the postsynaptic membrane removes the Mg
2+ block, 
allowing Ca
2+ fluxes into the cell. This calcium influx triggers various forms of 
synaptic  plasticity,  including  long-term  potentiation,  which  results  from  the 
activation  of  calcium-dependent  signal  transduction  cascades  that  cause 
trafficking  of  AMPA  receptors  into  the  synapse,  thus  strengthening  synaptic Blanka Szulc                                                                                               Introduction 
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signalling (Swanson, 2009, Huganir and Nicoll, 2013). NMDA receptors are the 
switch that triggers LTP, which is expressed and maintained by the presence of 
an  increased  number  of  active  AMPA  receptors  at  the  potentiated  synapse 
(Malenka and Bear, 2004). 
1.5.3. Kainate receptors  
Kainate receptors are built from multimeric assemblies of GluK1-3 and GluK4,5 
subunits (Kumar et al., 2011, Mayer, 2005). GluK1-3 and GluK5 subunits are 
expressed in the CA3 region of the hippocampus, striatum and the inner layer 
of the cortex, whereas GluK4 is distributed exclusively in the hippocampus. A 
large fraction of high-affinity kainate binding sites are localised in the stratum 
lucidum where mossy fibre synapses are formed (Foster et al., 1981). Kainate 
receptors possess similar pharmacology to AMPA receptors and as mentioned 
previously  they  have  been  combined  into  the  ‘non-NMDA  receptors’  family 
(Lerma, 2003). The measurement of native kainate currents in the hippocampus 
became possible with the discovery of the selective AMPA receptor antagonists 
GYKI  52466  and  53655  (Donevan  and  Rogawski,  1993).  Activation  of 
postsynaptic  kainate  receptors  results  in  the  generation  of  small  and  slow 
EPSCs in CA3 pyramidal neurones, whose amplitude represents only 10% of 
the  total  peak  current  generated  by  AMPA  receptor  activation  (Vignes  and 
Collingridge, 1997). However postsynaptic kainate receptors have much slower 
deactivation  kinetics  when  compared  to  AMPAR  (Barberis  et  al.,  2008)  and 
enhance  spike  discharge  probability  via  GluK5-mediated  metabotropic 
mechanisms (Sachidhanandam et al., 2009). 
KAR  also  mediate  presynaptic  effects  at  hippocampal  mossy  fibre  synapses 
where  they  modulate  local  excitability  and  neurotransmitter  release  from 
boutons (Schmitz et al., 2000, Kullmann, 2001). As such, presynaptic kainate 
receptors  are  important  in  short-term  plastic  properties  such  as  frequency-
dependent facilitation of excitatory synaptic transmission (Schmitz et al., 2001) 
and longer forms of plasticity including LTP (Bortolotto et al., 2005). KARs may 
also play a role in the maturation of mossy fibre synapses during development 
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To summarize, pre- and postsynaptic actions of KARs allow coordinated spike 
transmission between presynaptic terminals and postsynaptic neurones. 
The  electrophysiological  study  presented  here  was  conducted  in  acute 
hippocampal  slices  from  young  adult  rats.  Below  are  presented  some 
anatomical  and  physiological  features  of  this  region  of  the  brain  involved  in 
learning, memory and spatial navigation tasks. 
1.6. Anatomy of the hippocampus 
The hippocampus is a structure within the limbic system that displays a highly 
organized laminar distribution. The hippocampus plays a central role in both 
learning and memory and as such, has been widely reported and studied in the 
literature. The rat hippocampus differs markedly from that of the human brain, 
appearing  as  an  elongated  C-shaped  structure  with  its  long  axis  spanning 
rostro-dorsally from the septal nuclei near the midline of the brain through to 
caudo-ventrally behind the thalamus of the temporal lobe (Amaral and Witter, 
1989). The  long  axis is also  known  as  the  septotemporal  axis, whereas  the 
transverse  axis  spans  the  width  of  the  hippocampal  formation  as  shown  in 
Figure 9A.   
 
The term “hippocampal formation” refers to six regions which are functionally 
connected in a uni- or bi-directional fashion: the dentate gyrus, regions of the 
Cornus Amoni (also termed the hippocampus) consisting of CA3, CA2 and CA1, 
the subiculum, the presubiculum, the parasubiculum and the entorhinal cortex 
(EC).  The  classic  tri-synaptic  hippocampal  circuit  is  as  follows:  neurones 
located in the entorhinal cortex give rise to axons that project to the dentate 
gyrus.  This  projection  is  called  the  perforant  pathway  and  it  has  two 
components:  the  medial  and  lateral  perforant  paths  (Steward  and  Scoville, 
1976). Moreover, it is undirectional as the dentate gyrus does not project back 
to the entorhinal cortex. The mossy fibre pathway starts in the principal cells 
pertaining  to  the  dentate  gyrus  or  granule  cells,  which  synapse  onto  CA3 
pyramidal  neurones  via  mossy  fibre  axons.  The  axons  of  CA3  pyramidal 
neurones  or  Schaffer  collaterals  then  project  to  CA1  cells.  The  pattern  of 
connectivity then becomes much more complicated as the CA1 region projects 
both to neurones in the subiculum and the entorhinal cortex. Blanka Szulc                                                                                               Introduction 
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Figure 9: Hippocampal organization of rodent brain and its anatomy A: Anatomy 
of the rodent hippocampus with highlighted location of hippocampal formation (drawing 
adapted from (Amaral and Witter, 1989)). The septotemporal axis extends from the 
septal nuclei (S) towards the thalamus of the temporal lobe (T). B: The connectivity 
within rodent hippocampal formation (diagram adapted from (Andersen P, 2007a)). C: 
Ilustration of the trisynaptic loop (Deng et al., 2010). 
1.6.1. The dentate gyrus 
The dentate gyrus is a highly organised structure, which is comprised of three 
layers, with the closest to the hippocampal fissure being the relatively cell-free 
molecular layer (ML), the second known as the granule cell layer (GCL), also 
referred to as stratum granulosum (SG) and thirdly the polymorph layer, which 
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is also referred to as the hilus, where pyramidal basket cells, mossy cells and 
other interneurones reside (Amaral et al., 2007). The GCL is packed with its 
principal  cells-  granule  cells  (GC)  in  a  characteristic  “U”  or  “ ”  shape  and 
together with the ML is referred to as the fascia dentata.  
1.6.1.1. Dentate granule cells  
There are approximately 1 million compactly packed GCs within the rat dentate 
gyrus (West et al., 1991). GCs have small (10-18 µm) elliptical cell bodies that 
are arranged four to six cells thick in the GCL and a characteristic cone-shaped 
spiny dendritic trees, with all the branches directed superficially toward the ML 
(Claiborne et al., 1990). GCs receive the main neocortical input from layer II 
neurones of the entorhinal cortex (minor input also comes from layer V, VI) via 
the perforant path (Figure 9C). GCs dendrites form characteristic trunks that 
span all the ML, where they receive synaptic connections from various sources 
depending  on  the  location.  As  such,  the  outer  and  medial  part  of  the  ML 
receives  input  from  the  lateral  and  medial  perforant  pathway  respectively; 
whereas the inner part receives its input from commissural/associational fibres. 
GCs  only  project  to  the  CA3  region  of  the  hippocampus.  This  exclusive 
projection is called the mossy fibre pathway (Blackstad et al., 1970, Claiborne et 
al.,  1986).  It  is  highly  enriched  in  ionic  zinc  packaged  with  glutamate  into 
presynaptic vesicles and can be visualised by processing hippocampal tissue 
with Timm’s staining (Figure 10).  
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Figure 10: Timm’s staining reveals high zinc level in hippocampal granule cells 
 
Mossy  fibres  form  giant  synapses  with  a  specialised  spine  or  ‘thorny 
excrescence’ present in proximal dendrites of CA3 pyramidal cells (Figure 11).  
 
Figure 11: The hippocampal mossy fibre bouton. Low power electron microscopic 
images  of  mossy  fibre  boutons  taken  from  an  adult  rat  with  the  contour  of  spiny 
excrescences on the left highlighted in blue (scale bar: 2.5  μm) and magnified on the 
right (scale bar: 1  μm). Images taken from Rollenhagen and Lubke (Rollenhagen and 
Lubke, 2010). 
 
However, their main targets are interneurones in the hilus and CA3 (Acsady et 
al., 1998). For each GC, there is typically one mossy fibre that extends to the 
CA3 region. Mossy fibres innervate their main excitatory targets only sparsely 
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mossy fibres have been shown to branch extensively (Claiborne et al., 1986). 
The axonal plexus of mossy fibres is refined to the hilus, although some fibres 
occasionally  enter  the  GCL  and  terminate  onto  proximal  dendrites  of  BCs. 
Recurrent excitation of GC dendrites by mossy fibre collaterals is observed very 
rarely in rodents compared to GCs in monkeys which extend basal dendrites 
into  the  hilus  and  are  therefore  innervated  by  mossy  fibres  more  frequently 
(Austin and Buckmaster, 2004). Although mossy fibre projections are confined 
to the hilus and the SL in CA3 at their transverse axis, mossy fibres can travel 
up to 400 µm in their septotemporal plane (Acsady et al., 1998).  
Cajal (Cajal, 1909) recognized early in their studies of the mossy fibre system, 
that the terminals of mossy fibres are unique, as these axons possess more 
than one terminal. Electron microscopy studies have shown that mossy fibres 
possess three morphologically different terminals: the large mossy fibre boutons 
(MFBs), filopodial extensions of the mossy fibre terminals and small en passant 
synaptic  varicosities  (Claiborne  et  al.,  1986).  MFBs  terminate  onto  CA3 
pyramidal cells within the SL, but are also present, albeit slightly smaller in size, 
within the hilus where they terminate onto mossy cell dendrites. Interestingly, 
the small varicosities considerably outnumber MFBs (160-200 small varicosities 
versus ~20 MFBs) and synapse onto dendrites of local interneurones within the 
SL or the hilus, showing that the main postsynaptic target of mossy fibres are in 
fact  inhibitory  cells  (Acsady  et  al.,  1998).  Using  electron  microscopy,  the 
authors  showed  that  the  nature  of  the  GABAergic  postsynaptic  targets  was 
diverse, with some postsynaptic cells immunoreactive to parvalbumin, calretinin 
as well as the neuropeptide  substance P. Using MFB  – interneurone paired 
recordings, Szabadics and Soltesz (Szabadics and Soltesz, 2009) showed that 
mossy fibres targeted parvalbumin positive BCs and regular spiking BCs, as 
well as ivy cells and septum projecting spiny SL cells. 
Mossy fibres are also immunoreactive for neuromodulators such as dynorphin 
and,  as  mentioned,  Zn
2+.  Furthermore,  mossy  fibres  show  intense 
immunoreactivity  for  GABA  (Sandler  and  Smith,  1991)  and  have  also  been 
reported  to  contain  the  GABA  synthetic  enzyme  glutamate  decarboxylase 
GAD67 (Schwarzer and Sperk, 1995). The finding that GABA can be released Blanka Szulc                                                                                               Introduction 
 
34 
 
at rat mossy fibre synapses following seizure-like activity raised the possibility 
that GABA release was only associated to a pathological condition (Gutierrez, 
2000).  However,  the  first  electrophysiological  evidence  that  GABA  can  be 
released from a subset of MFBs in normal animals came from studies in guinea-
pig  slices,  and  later  in  rats  (Walker  et  al.,  2001,  Walker  et  al.,  2002, 
Uchigashima et al., 2007). Studies in neonatal rats additionally showed mono-
synaptic  GABAergic  signalling  at  the  mossy  fibre  synapse  in  young  animals 
(Bergersen et al., 2003, Safiulina et al., 2006). The subcellular distribution of 
Zn
2+ and GABA immunogold particles have also been described (Ruiz et al., 
2004). 
1.6.2. Hippocampus proper 
It was De Garengeot’s pioneering research into the structures of the brain who 
first coined the term for this region due to its similarity in shape to a ram’s horn 
(Garengeot,  1742).  He  therefore  named  the  hippocampus  “Cornu  ammonis” 
(“Ammon’s horn”) after the Egyptian god Amun Kneph, whose symbol was a 
ram  (Andersen P, 2007a).  Following  De  Garengeot’s pioneering  studies,  the 
term  -  cornu  ammonis  to  describe  the  hippocampus  is  no  longer  used,  but 
remains the terminology of Lorente de Nó who described the subdivision of the 
hippocampus into three regions: CA1, CA2 and CA3, maintaining the link with 
the original name given by De Garengeot. Within the CA3 region five further 
layers  can  be  distinguished  (Figure  9).  Their  basic  characterization  is 
summarized below (Table 1).  
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Name of layer  Cellular neurophysiology 
Stratum  lacunosum-
moleculare 
  Termination point of EC fibres 
  Contains interneurones 
Stratum radiatum  Suprapyramidal region  
  CA3 to CA3 associational connections; 
  CA3  to  CA1  Schaffer  collateral 
connections; 
  Contains interneurones 
Stratum lucidum    Mossy fibres  
  Acellular 
Stratum pyramidale    pyramidal neurones 
Stratum oriens  Infrapyramidale region 
  CA3 to CA3 associational connections; 
  CA3  to  CA1  Schaffer  collateral 
connections; 
  Contains interneurones. 
Table 1: Layers of the hippocampus 
Each  individual  layer  contains  principal  cells  that  are  glutamatergic  and 
interneurones that release GABA. 
1.6.2.1. Pyramidal cells 
The  principal  cellular  layer  is  known  as  the  pyramidal  cell  layer  or  stratum 
pyramidale and is packed with pyramidal neurones, usually three to six cells 
deep.  PCs  have  shorter  basal  and  longer  apical  dendrites  that  pervade  the 
stratum oriens and hippocampal fissure respectively. The location of PCs within 
the hippocampus determines their size as well as their contribution in numerous 
synaptic pathways. By way of example, CA3 PCs are larger than those found in 
the CA1 region (Andersen P, 2007b). 
1.6.2.2. CA3 pyramidal cells 
The  cellular  body  of  PCs  in  the  CA3  region  varies  greatly  in  size,  with  the 
smallest (20 µm in diameter) occupying the limbs of the DG and the largest (30 Blanka Szulc                                                                                               Introduction 
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µm in diameter), which can be found in the distal region (Ishizuka et al., 1995). 
Similarly to the cell body region pattern, Ishizuka and others (Ishizuka et al., 
1995) found that dendritic length in the rat hippocampus fluctuated between 8-
10 mm to 16-18 mm, depending on the proximity to the dentate gyrus and CA1 
respectively.  The  apical  dendrites  of  CA3  pyramidal  cells  span  the  stratum 
lucidum, stratum radiatum and stratum lacunosum-moleculare, making diverse 
synaptic connections as listed above (Table 1). Depending on the location of 
the soma of PCs, the distribution of their dendritic trees is also shown to vary. 
Basal  and  apical  dendrites  of  CA3  PCs  located  in  the  limb  region  of  CA3 
receive a great number of mossy fibre connections from GCs and very little or 
few connections from the EC. Among pyramidal neurones in the hippocampus, 
only  CA3  pyramidal  neurones  receive  a  mossy  fibre  input,  thus 
electrophysiological  recording  presented  in  this  thesis  will  be  obtained  from 
these. Noteworthy, CA3 pyramidal neurones project to other CA3 cells and this 
projection is called the associational/commissural pathway, depending if it is on 
the same (associational) or opposite (commissural) side of the brain (Ishizuka et 
al., 1990). 
1.6.2.3. CA1 and CA2 pyramidal cells 
The CA1 region displays more anatomical homogeneity than that found in the 
CA3  region.  Cell  bodies  of  CA1  PCs  are  on  average  15  µm  in  diameter, 
whereas their average dendritic length is between 12-13 mm (Ishizuka et al., 
1995). Basal dendrites span the stratum oriens layer whereas apical dendrites 
occupy  the  stratum  radiatum  and  stratum  lacunosum-moleculare  both  in  a 
conical fashion. CA1 pyramidal neurones receive excitatory synaptic inputs from 
axons of CA3 pyramidal neurones (Schaffer collaterals) and NMDA-dependant 
and long term potentiation at these CA3-CA1 synapses has been extensively 
studied (Bliss and Collingridge, 2013). Pyramidal cells, with size-like CA3 PCs 
are found in the CA2 region (Ishizuka et al., 1995). Recently, Kohara and others 
discovered that CA2 pyramidal cells receive monosynaptic inputs from DG cells 
via longitudinal projection (Kohara et al., 2014). Interestingly, CA2  pyramidal 
neurones proved to be more resistant to cell death caused by epilepsy when 
compared with other pyramidal neurones (Corsellis and Bruton, 1983). Blanka Szulc                                                                                               Introduction 
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1.7. Dentate – CA3 neurotransmission 
1.7.1. Receptors and pharmacology 
Dentate  –  CA3  transmission  is  initiated  by  action  potentials  in  granule  cells 
whose discharge at basal rates is less than 0.5 Hz triggering Ca
2+ influx through 
various  types  of  voltage-gated  calcium  channels  (VGCCs)  (Jung  and 
McNaughton,  1993).  Granule  cells  to  CA3  synapses  act  as  ‘conditional 
detonators.’ The term ‘conditional’ relates to the fact that in response to a single 
action potential, postsynaptic targets have a very low discharge probability in 
vivo (Henze et al., 2002). Moreover, another in vivo study in awake rats showed 
that granule cells fire at low frequency and preferentially in bursts. As such, low 
frequency of spiking combined with a high proportion of bursts should lead to 
the maximum facilitation at mossy fibre synapses (Pernia-Andrade and Jonas, 
2014).  Transmission  at  mossy  fibre  synapses  is  regulated  by  several 
neurotransmitters  and  neuromodulators.  In  addition,  mossy  fibre  synaptic 
transmission is regulated by various metabotropic glutamate receptors localized 
both on pre- and postsynaptic mossy fibre bouton membranes (Henze et al., 
2000).  Immunohistochemical  studies  have  also  revealed  groups  II  and  III 
mGluRs in large mossy fibre boutons (Shigemoto et al., 1997) consistent with 
the  effect  of  group  II  mGluR  agonists  such  as  (2S,2'R,3'R)–2–(2',3'–
dicarboxycyclopropyl)glycine (DCG-IV), which block transmission at mossy fibre 
synapses in  both rats and guinea pigs (Kamiya et al., 1996, Yoshino et al., 
1996).  Other  studies  have  shown  that  activation  of  mGluRs  at  mossy  fibre 
synapses  by  endogenous  glutamate  is  followed  by  inhibition  of  glutamate 
release (Vogt and Nicoll, 1999). At mossy fibre synapses onto stratum lucidum 
inhibitory  interneurones,  both  calcium-permeable  (CP)  and  calcium-
impermeable  (CI)  AMPA  receptors  can  be  found  (Toth  and  McBain,  1998), 
whereas  mossy  fibre  synapses  onto  CA3  pyramidal  cell  contain  only  CI-
AMPARs (Toth et al., 2000). Finally, in a recent study (Berg et al., 2013), it was 
shown  that  the  majority  of  subunits  are  found  at  the  postsynaptic  site  with 
GluN1, GluN2B,D and GluN3B exceptionally having a presynaptic locus.  
The relative large size of giant MFBs (~ 4-10 µm) enables direct patch-clamping 
of the terminal and thus the study of presynaptic action potential modulation by Blanka Szulc                                                                                               Introduction 
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voltage-activated  channels  including  presynaptic  Na
+  channels  (Engel  and 
Jonas, 2005) and Ca
2+ channels (Geiger and Jonas, 2000, Bischofberger et al., 
2006).  Mossy  fibre  bouton  recordings  have  also  shed  light  on  the  role  of 
presynaptic ionotropic receptors such as GABAA receptors or glycine receptors 
(Ruiz and Kullmann, 2012). It was shown that P/Q-type and N-type VGCCs are 
mainly expressed at the bouton membrane to ensure the efficient and precisely 
timed Ca
2+ influx at MFBs (Bischofberger et al., 2002, Li et al., 2007, Alle et al., 
2011).  Other  than  Ca
2+  channels,  inactivation  of  a  voltage-gated  K
+ 
conductance  such  as  that  mediated  by  Kv1.1  prolongs  the  action  potential 
duration  by  up  to  3-fold  during  high  frequency  stimulation.  Such  activity-
dependent prolongation of the presynaptic AP waveform causes an increase of 
Ca
2+  influx  in  mossy  fibre  boutons,  which  in  turn  enhances  neurotransmitter 
release (Geiger and Jonas, 2000). 
1.7.2. Plasticity of giant mossy fibre synapses 
Hippocampal mossy fibre synapses onto CA3 pyramidal cells represent a highly 
unique  excitatory  pathway  at  CNS  synapses  with  pronounced  short-term 
facilitation and an NMDA-receptor independent presynaptic mechanism of LTP. 
Mossy  fibre  synapses  also  undergo  a  form  of  long-term  depression  (LTD), 
which is independant of NMDARs, mGluRs or cannabinoid receptors activation 
(Lei et al., 2003). 
1.7.2.1. Short term plasticity 
It has been postulated that mossy fibre synapses act as “conditional detonators” 
(Henze  et  al.,  2002).  Activation  of  mossy  fibre  synapses  in  vivo  can  trigger 
action  potentials  in  postsynaptic  targets  in  response  to  a  brief  train  of 
presynaptic activity (>40 Hz). Mossy fibre synapses express two unique forms 
of  short-term  plasticity  that  facilitate  temporal  signal  integration  in  CA3 
pyramidal  neurones:  paired-pulse  facilitation  and  frequency  dependent 
facilitation.  These  two  forms  of  plasticity  enhance  synaptic  transmission 
enormously and can generate spikes in CA3 cells when modest increases in 
presynaptic frequency firing occur, even at relatively low frequencies. MF-CA3 
synapses  exhibit  very  high  levels  of  paired  pulse  facilitation  (PPF)-  a 
phenomenon in which excitatory postsynaptic potentials (EPSPs) evoked by an Blanka Szulc                                                                                               Introduction 
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impulse are increased when that impulse closely follows a prior impulse (Salin 
1996). In addition, a specific property of mossy fibre-CA3 synapses is the ability 
to undergo frequency-dependant facilitation, meaning that modest increases of 
presynaptic  activity  cause  large  increments  in  the  amplitude  of  postsynaptic 
responses,  thus  leading  to  a  growth  in  synaptic  strength.  The  mechanisms 
responsible for this unusual property of dentate–CA3 transmission are not fully 
elucidated.  Residual Ca
2+  levels  in  the  presynaptic  terminal  as  well  as  Ca
2+ 
released from intracellular calcium stores are reported to play a role (Liang et 
al.,  2002,  Scott  and  Rusakov,  2006,  Lauri  et  al.,  2003).  Other mechanisms, 
dependent  on  Ca
2+/calmodulin  protein  kinase  II  activity,  have  also  been 
reported.  In  contrast,  associational-commissural  synapses  show  little  or  no 
degree  of  facilitation  (Salin  et  al.,  1996).  Finally,  the  partial  occlusion  of 
frequency-dependent facilitation by the induction of LTP suggests a mechanistic 
link between short- and long-term potentiation at mossy fibre synapses.  
1.7.2.2. Long term plasticity 
Hebb’s postulate (Hebb, 1949) describes the basis of strengthening synaptic 
plasticity as a result of presynaptic stimulation of the postsynaptic cell. Such an 
enhancement in signal transmission between two neurones can cause a long 
lasting change in synaptic plasticity called long term potentiation. Repetative 
stimulation induces synaptic plasticity in Schaffer collateral-CA1 and MF-CA3 
synapses. In contrast to LTP at Schaffer collateral-CA1 synapses, LTP at MF-
CA3 synapses has been found to be NMDA-receptor independent (Harris and 
Cotman, 1986). There is evidence for the involment of presynaptic Ca
2+-induced 
Ca
2+ release (Lauri et al., 2003) and that mGluR as well as ionotropic receptors, 
including GABAA and kainate receptors, have a modulatory role on LTP but are 
not essential for its induction (Schmitz et al., 2003, Ruiz et al., 2010). Two forms 
of NMDAR-independent mossy fibre LTP are determined by the nature of the 
stimulus  induction  paradigm.  The  first  one  is  non-Hebbian  in  nature  and 
exclusively dependant on changes in the presynaptic membrane potential and 
presynaptic firing rate. The second implies that mossy fibre LTP induction is 
Hebbian and requires both pre- and postsynaptic activity. Thus, the nature of 
mossy fibre LTP is defined by the type of protocol used for the induction. As 
such, low lasting high frequency stimulation L-HFS (3x100 Hz for 1 s) protocol Blanka Szulc                                                                                               Introduction 
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induces  LTP  despite  postsynaptic  hyperpolarization,  whereas  brief  high 
frequency  stimulation  B-HFS  (8x100  Hz  for  0.1  s)  requires  depolarization  of 
CA3 pyramidal neurones and presynaptic activation of mossy fibres (Henze et 
al.,  2000).  Yeckel  and  others  showed  that  postsynaptic  calcium  elevation 
enables the induction of mossy fibre LTP, despite the protocol used (Yeckel et 
al., 1999). In case of L-HFS induced LTP, it is associated with postsynaptic 
release of calcium from intracellular stores, whilst the B-HFS induced form of 
mossy fibre LTP is concerted via the calcium influx via L-type calcium channels 
by postsynaptic depolarization (Kapur et al., 1998, Yeckel et al., 1999). Other 
studies have shown that (Huang et al., 1994, Yeckel et al., 1999) mossy fibre 
LTP is linked to cAMP-signalling cascades, whereas the presynaptic (L-HFS 
protocol)  or  postsynaptic  (B-HFS  protocol)  Ca
2+  influx  activates  a  cAMP 
cascade  pre-  or  post-synapticaly  respectively  (Henze  et  al.,  2000).  The 
involvement of KAR in the induction of mossy fibre LTP has been investigated 
across pharmacological and mouse knockout studies. Again, their effect has 
been a subject of disagreement, but as summarized by Nicoll and Schmitz KAR 
are  generally  not  essential  for  the  induction  of  mossy  fibre  LTP  (Nicoll  and 
Schmitz, 2005). Contrary to its induction, expression of LTP is more unified and 
dominated by  a presynaptic mechanism  via an increase in the probability of 
neurotransmitter release (Zalutsky and Nicoll, 1990, Nicoll and Malenka, 1995, 
Tong  et  al.,  1996).  Recently,  Wiera  and  co-workers  (Wiera  et  al.,  2013) 
suggested  that  LTP  expression  in  MF-CA3  synapse  could  be  tuned  by  the 
activity of MMP-9, a member of the metalloproteinase family. Interestingly, a 
recent  study  indicates  the  existence  of  NMDAR-dependent  metaplasticity  at 
mossy  fibre  synapses,  in  which  NMDARs  act  as  a  switch  to  generate  LTP, 
which is expressed and maintained by the presence of an increased number of 
active AMPA receptors at potentiated synapses (Rebola et al., 2011). Blanka Szulc                                                                                                                  Project Objectives 
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2.0. Project Objectives 
Diseases associated with memory impairment affect an increasing number of 
patients as a result of the increasing age profile of many societies. As such, 
there is an urgent and pressing need to develop new therapeutics to improve 
and  ultimately  restore  patients’  cognitive  function.  Current  medicines  have 
shown limited therapeutic effect and this research was designed to address this 
deficit. In this project we elected to take inspiration from Nature, where a small 
molecule  natural  product  –  clausenamide  (2),  was  shown  to  have  potent 
neuroprotective and memory enhancing effects. Clausenamide (2) contains four 
contiguous chiral centers and despite the work of Feng and co-workers (Feng et 
al., 2009) into the determination of which enantiomer is most active, the search 
for  synthetically  tractable  analogues  remains  a  viable  challenge  due  to  the 
difficulty  in  obtaining  sufficient  amounts  of  the  parent  compound  and  the 
relatively complicated and generally low yielding syntheses in the literature.  
The  overall  aim  of  this  research  is  therefore  to  develop  novel  synthetic 
methodology to access the core structure of clausenamide and to investigate 
the  effects  of  our  synthetic  analogues  in  neuronal  slices  to  develop  a  small 
molecule that could enhance or restore memory to meet the challenge of our 
ageing society. Clausenamide (2) and its related congener - kainic acid (94) are 
potent small molecules that can regulate synaptic function and as such, have 
key  implications  in  a range  of  CNS  disorders.  Heterocycles  related  to these 
compounds, have therefore frequently been used as synthetic building blocks in 
approaches towards both natural products and related analogues and are of 
significant importance to the pharmaceutical industry. Examples of molecules 
from this class of compound are outlined below (Figure 12).  
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As a result of the synthetic diversity and potent biological activities of these 
molecules, there have been numerous reported approaches towards the core 
structures.
 Despite these, most rely on linear synthetic methodology resulting in 
numerous  steps  rendering  them  unattractive  for  the  generation  of  small 
molecular  libraries.  Tandem  or  domino  synthetic  processes  using  a  modular 
approach are accordingly highly attractive, as they reduce the overall number of 
linear steps and result in the formation of several bonds in one transformation. 
2.1. Synthetic Chemistry  
As stated above, we intend to synthesise the core structure of clausenamide 
(2), but we envisage that any synthetic approach to its synthetic core should be 
flexible enough in order to synthesise  structurally related analogues such as 
kainic acid as part of a longer-term program.  
As  outlined  in  the  introduction  there  have  been  a  number  of  approaches 
towards the formation of clausenamide but most require harsh conditions for 
their  syntheses.  Our  retrosynthetic  approach  towards  formation  of  the  5-
membered pyrrolidine core of clausenamide 2 is outlined below (Scheme 11). 
   
Scheme 11: Retrosynthetic approach towards the pyrrolidine core 
We envisage that the key C3-C4 carbon-carbon bond of the pyrrolidine ring can 
be  formed  via  an  ene-type  intramolecular  Acylal  Cyclisation  reaction  (IAC), 
where the electron-rich enamine part of the molecule reacts with the electron 
deficient  glyoxamide  synthon.  There  are  few  reports  in  the  literature  on Blanka Szulc                                                                                                                  Project Objectives 
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protected  glyoxals,  but  a  recent  report  on  the  synthesis  of 
epidithiodiketopiperazines  outlined  the  utility  of  diacetoxyacetyl  chloride  as  a 
synthon for glyoxylic acid chloride. The aldehyde is protected as its more stable 
form of an acylal. Accordingly we anticipated that reaction of the acylal 98 with a 
Lewis acid should lead to formation of an oxonium ion 99, which will react with 
the enamine already present in the molecule leading to cyclisation to form the 
pyrrolidine ring 100 (Scheme 12).  
 
Scheme 12: Formation of the oxonium ion and cyclisation 
In order to explore the synthetic scope of the reaction, we intend to initially carry 
out a number of cyclisation reactions with the structurally simple alkene 101 
with  a  range  of  Lewis  acids  and  proton  sources  to  determine  the  requisite 
conditions  for  cyclisation.  It  is  anticipated  that  this  precursor  will  potentially 
generate the 6-membered piperidinone ring 106 as the intermediate secondary 
carbocation 105 is more stable than the primary 103 (Scheme 13). 
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Once  we  have  determined  which  Lewis  acid  to  employ  in  the  cyclisation 
reactions, we will extend the cyclisation reaction towards specific formation of 
the pyrrolidinione ring 108 starting from the enamide 107 (Scheme 14)  
 
Scheme 14: Cyclisation reactions with Lewis acids 
The cyclisation precursor enamides can readily be obtained via reaction of the 
enamine  with  diacetoxyacetyl  chloride.  We  anticipate  that  the  enamines 
themselves  will  be  synthesised  via  condensation  of  an  amine  with  the 
corresponding ketone under Dean-Stark water removal conditions. 
Following  the  successful  outcome  of  the  cyclisation  reactions,  we  intend  to 
apply the knowledge that we have gained in an approach towards the synthesis 
of  the  natural  product  clausenamide.  Our  retrosynthetic  approach  to  this  is 
outlined below (Scheme 15). 
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It will be necessary to synthesise the phenylalanine derived dehydroamino acid 
113  in  order  to  synthesise  our  desired  cyclisation  precursor.  However,  this 
should readily be achieved via N-halogenation and elimination as per the work 
by (Lu and Lewin, 1998). Reduction of the double bond in 111, will enable us to 
achieve a formal total synthesis of clausenamide 2 as the subsequent steps 
have previously been reported. 
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2.2. Biological Objectives  
In order to investigate the biological activity of the synthetic compounds that  will 
be synthesised from the first phase of this research program, their effects on 
synaptic transmission and plasticity will be explored using electrophysiology. In 
order  to  achieve  this  goal,  an  investigation  of  their  effects  in  acute  rat 
hippocampal slices as  per previous  endeavours by  other researchers in  this 
field will be conducted, who have investigated a number of AMPA modulators in 
this manner.  
Key to progressing any compound towards further investigation is its activity. 
We intend to look for an enhancement of synaptic transmission and plasticity 
from  our  analogues,  as  (-)-clausenamide  has  been  shown  to  have  such  an 
enhancing effect. However, in order to demonstrate this and to obtain a more 
in-depth  analysis  of  activity  and  elucidation  of  the  hitherto  unqualified 
mechanism of action, we will perform the following sequence of experiments 
with our analogues.  
One of the key weaknesses with the research that has been carried out on 
clausenamide  and  its  enantiomers  has  been  the  lack  of  a  clearly  described 
mechanistic target. In order to try to elucidate this and to provide a more in-
depth  analysis,  we  will  explore  basal  synaptic  transmission  at  a  major 
hippocampal input in the brain to determine whether the enhancing effects of 
compounds  related  to  clausenamide  occur  via  a  pre-  or  post-synaptic 
mechanism. To achieve this, we will focus on mossy fibre to CA3 synapses as 
they  are  one  of  the  major  inputs  into  the  hippocampus  and  can  provide 
information with regard to the mechanism of action of our compounds at the 
synaptic level.  
In the first instance, we intend to explore whether our compounds have any 
activity on mossy fibre to CA3 synapses by investigating evoked postsynaptic 
responses. Once compounds have shown activity, we will compare their effect 
against the well known memory enhancing compound – piracetam, in order to 
have a standard against which to compare. We will focus on piracetam as our 
major  comparator  as  it  has  been  the  mainstay  of  memory  deficit  disorder Blanka Szulc                                                                                                                  Project Objectives 
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treatments for over 50 years and most studies compare the activities of new 
compounds against this key cornerstone of treatment.  
Following demonstration of an enhancing effect, compounds will be investigated 
for their exact mechanism of action at the synaptic level. We will focus on the 
three main receptors – NMDA, AMPA and kainate and via a combination of 
stimulation  and  chemical  blocking  agents,  explore  the  exact  target  of  our 
compounds. We will also focus on whether our molecules work via a pre- or 
postsynaptic mechanism.  
As part of our research focuses on potential chiral analogues of clausenamide, 
we will also explore the activity of each enantiomer if time permits.  
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3.0.  Results and Discussion 
3.1. Initial cyclisations 
As outlined in the objectives, we decided to first investigate the effects of a 
number of acids on the cyclisation of N-allyldiacetoxyglyoxamides to determine 
the requisite conditions for cyclisation. To this end, we decided to synthesise 
precursors 120 and 121 via reaction of commercially available amines 117 and 
118  with  diacetoxyacetyl  chloride  119  under  Schotten-Bauman  conditions 
(Scheme 16). 
 
Scheme 16: Formation of cyclisation precursors 
However  this  necessitated  synthesis  of  the  non-commercially  available  acid 
chloride  119  as  a  key  component  in  our  reactions.  As  such,  we  required 
sufficient  amounts  of  diacetoxyacetyl  chloride  119  in  order  to  allow  us  to 
investigate the proposed cyclisation reactions. The published two-step synthetic 
route to diacetoxyacetyl chloride 119 involved reaction of acetic anhydride 123 
with acetic acid and glyoxylic acid monohydrate 122 at 150 °C (Scheme 17) to 
give intermediate 124.  
 
Scheme 17: Formation of diacetoxyacetic acid  
The second step requires addition of thionyl chloride to the crude compound, 
whereupon the reaction is heated under reflux and the product thus obtained, 
purified by distillation (Scheme 18). Blanka Szulc                                                                                                           Results and Discussion 
 
51 
 
 
Scheme 18: Synthesis of diacetoxyacetyl chloride 
However, in our hands, diacetoxyacetyl chloride 119 could only be obtained in 
low  yield  (<23%)  and  furthermore,  analysis  of  the  crude  material  prior  to 
distillation  showed  that  considerable  amounts  of  intermediate  124  were  still 
present.  
In order to improve the yield and to convert more of the starting material to the 
acid chloride, we added dimethylformamide as a reaction catalyst, which can 
promote the reaction towards completion as shown below (Scheme 19). 
 
Scheme 19: DMF catalysis of diacetoxyacetyl chloride synthesis 
The  reaction  was  monitored  by 
1H  NMR  spectroscopy  to  ensure  complete 
conversion  to  the  acid  chloride  and  once  complete,  distillation  of  the  crude 
mixture led to the required diacetoxyacetyl chloride 119 in a much improved 
yield of 75% (Scheme 19).  
Following  obtention  of  the  acid  chloride  119,  precursors  120  and  121  were 
obtained in 69% and 82% yield respectively follwing reaction of amines 117 and 
118 with diacetoxyacetyl chloride 119 (Scheme 20).  Blanka Szulc                                                                                                           Results and Discussion 
 
52 
 
 
Scheme 20: Formation of cyclisation precursors 120 and 121 
With  both  cyclisation  precursors  120  and  121  in  hand,  we  next  turned  our 
attention towards the intramolecular cyclisation reactions. As the acyal’s were 
stable  even  on  prolonged  heating,  we  decided  to  investigate  the  effects  of 
addition  of  a  range  of  acid  sources  to  these  compounds  to  determine  the 
degree of cyclisation (Scheme 21).  
 
Scheme 21: Proposed cyclisation outcomes 
Initial experiments were carried out with varying amounts of trifluoroacetic acid 
in  dichloromethane  as  a  solvent  both  at  room  temperature  and  at  reflux. 
Surprisingly,  we  observed  that  the  acylal  precursors  proved  to  be  relatively 
stable species and in all cases, starting material was recovered. Indeed, only on 
prolonged heating (>72 hours) could any loss of starting material be observed. 
Accordingly  we  next  investigated  the  effect  of  hydrobromic  acid  and 
hydrochloric acid in a range of solvents such as dichloromethane, water and 
methanol. Such  attempts led to the degradation of the starting material with 
unidentifiable complex product mixtures being observed in all cases. 
As a result of the complex product mixtures observed, it was evident that to gain 
useful insight into the requisite conditions, we required an alternative cyclisation 
precursor  that  would  provide  unambiguous  information. We  then,  turned  our 
attention  towards  the  following  cyclopentenyl  cyclisation  precursor  127.  We 
anticipated  that  cyclisation  of  the  enamine  would  lead  to  formation  of  the 
pyrrolidinone ring 128 (Scheme 22).  Blanka Szulc                                                                                                           Results and Discussion 
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Scheme 22: Cyclisation of the enamine 
In order to synthesise the precursor 127 we decided to first generate the imine/ 
enamine 131 via condensation of benzylamine 129 with cyclopentanone 130 
under Dean-Stark water removal conditions (Scheme 23). Due to the unstable 
nature of the imine/ enamine 131, we decided to react it with diacetoxyacetyl 
chloride 119 without further purification or characterisation.   
 
Scheme 23: Generation of the imine 
Reaction of the intermediate imine 131 with diacetoxyacetyl chloride 119, under 
Schotten-Bauman  conditions  using  a  biphasic  mixture  of  water  and 
dichloromethane  (DCM)  in  the  presence  of  sodium  bicarbonate  gave  the 
cyclisation precursor 132 in a reasonable yield of 46% (Scheme 24).  
 
Scheme 24: General reaction for formation of cyclisation precursors 
This reaction  occurs  via  nucleophilic attack  of  the  amine  on  the  carbonyl of 
diacetoxyacetyl  chloride  119.  The  amine  breaks  the  oxygen  double  bond, 
leading  to  loss  of  chloride  and  reformation  of  the  carbonyl  (Scheme  25). 
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nucleophile and can therefore lead to isolation of the by-product 134. The yield 
of the two products is presumably a reflection of the rate of reaction and relative 
ratio between the imine and enamine intermediate. 
 
Scheme 25: Formation of the cyclisation precursor and by-product 
Following  purification  by  column  chromatography  and  verification  of  the 
structure, we next turned our attention to cyclisation of the substrate 132. Due 
to the implied failure of the preceding use of protic acids, we decided to first 
investigate the use of Lewis acids in the cyclisation. As Lewis acid, we chose 
boron  trifluoride  diethyl  etherate  due  to  its  utility  in  a  plethora  of  reported 
cyclisation reactions and its mild nature (Scheme 26).  
 
Scheme 26: Cyclisation reaction with boron trifluoride dietherate 
Cyclisation  precursor  132  was  reacted  with  boron  trifluoride  dietherate  in 
dichloromethane at reflux for 6 hours. However, on analysis of the crude 
1H 
NMR spectrum following work-up we were surprised to observe that the final 
product wasn’t the acetate that we had predicted, but was instead diene 135, 
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Presumably  on  reformation  of  the  enamine  136  after  intial  cyclisation  and 
further exposure to Lewis acid, the acetate is again activated and eliminated to 
give the intermediate iminium ion 137, which loses a proton to generate the 
observed product 135 (Scheme 27). 
 
Scheme 27: Reformation of the enamine 
As  a  result  of  this  unusual  reaction,  we  decided  to  determine  if  the  same 
reaction would occur with six or seven membered ring precursors. We centered 
our attentions on six membered rings as they are important molecular building 
blocks for more complex molecules. The reactions utilized the same procedure 
as the previous reaction. Therefore to obtain the six membered ring attached to 
the  amine  we  reacted  benzylamine  129  with  cyclohexanone  139  in  order to 
generate the analogous N-cyclohexylidene-1-phenylmethanamine 140 (Scheme 
28).  
 
Scheme 28: Formation of N-cyclohexylidene-1-phenylmethanamine 
Formation  of  the  cyclisation  precursor  2-(benzyl(cyclohexenyl)amino)-2-
oxoethane-1,1-diyl  diacetate  141  proceed  smoothly  under  the  Schotten-
Bauman conditions used previously (Scheme 29).  Blanka Szulc                                                                                                           Results and Discussion 
 
56 
 
 
Scheme 29: Formation of the cyclohexene cyclisation precursor  
Cyclisation  of  141  was  important  as  it  could  correlate  with  the  previous 
cyclisation outcome observed for the pentenyl precursor 132 which had led to 
formation of the conjugated dienone 135 (Scheme 30). Following purification, 
pleasingly  the 
1H  NMR  spectrum  confirmed  the  presence  of  the  desired 
molecule 142 in 38% yield. 
 
Scheme 30: Formation of the fused six-five membered ring system 
The same approach was taken in the formation of the seven membered ring 
building block, with analogous synthetic steps to obtain precursor 142. Due to 
the  ease  of  elimination,  we  conducted  the  final  cyclisation  reaction  at  room 
temperature to try to obtain the intermediate alcohol, but still obtained the diene 
146 in 31% yield (Scheme 31).  Blanka Szulc                                                                                                           Results and Discussion 
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Scheme 31: Pathway to the formation of seven membered ring 
Due  to  the  reactive  nature  of  the  enamines  in  the  above  cyclisations,  we 
decided to synthesise a cyclisation precursor that would not lead to elimination 
of the intermediate acetate.  The planned cyclisation precursor is outlined below 
(Scheme 32).   
 
Scheme 32: Cyclisation with the presence of the intermediate acetate 
Thus on cyclisation we should obtain the exclusive 5-exo cyclised product 147 
with  reduced  possibility  of  elimination  of  the  second  acetate  group.  The 
molecule is reminiscent of our initial precursor, with the one difference being the 
presence of the two methyl groups on the alkene. This will therefore obviate 
formation of the piperidine ring and give exclusive formation of the pyrrolidine 
ring.  
In  order  to  obtain  the  precursor  147,  we  needed  to  synthesise  N-benzyl-3-
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species than the corresponding secondary amine and as such, simple alkylation 
with the corresponding bromide would have led to complex mixtures of alkylated 
amines. 
Thus  it  was  first  necessary  to  protect  benzylamine  126  with  di-tert-butyl 
dicarbonate thereby facilitating facile single alkylation with 1-bromo-3-methyl-2-
butene to reduce the formation of complex mixtures (Scheme 33). 
 
Scheme 33: Reaction to form Boc protected benzylamine  
The reaction is possible solely with triethylamine and di-tert-butyl dicarbonate in 
DCM.  However,  the  reaction  proceeds  slowly.  Therefore  addition  of  the 
nucleophilic  catalyst  4-N,N-dimethylaminopyridine  (DMAP)  results  in  an 
increase of the rate of reaction due to formation of the more reactive acylating 
species. Finally reaction of protected benzylamine 148 with 1-bromo-3-methyl-
2-butene gave 149 in 49% yield (Scheme 34).  
 
Scheme 34: Formation of protected amine with 3-methyl-2-butene substituent 
Efficient deprotection with trifluoroacetic acid in dichloromethane gave amine 
150 as the free base in excellent  yield after basic work-up. Amine 150 was 
acylated  under  Schotten-Bauman  conditions  to  provide  the  diacetoxy  amide 
146  in  62%  yield.  However,  cyclisation  via  addition  of  the  Lewis  acid  boron 
trifluoride diethyl etherate gave an inseparable mixture of diastereoisomers in 
93% yield (Scheme 35) but still provided proof that the original concept was 
successful. Blanka Szulc                                                                                                           Results and Discussion 
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Scheme 35: Pathway to formation of 5 exo-cyclised product Blanka Szulc                                                                                                           Results and Discussion 
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3.2. Synthetic approach towards clausenamide 
Following the successful testing of the intramolecular acyal cyclisations we next 
turned our attention towards the synthesis of the natural product clausenamide. 
To demonstrate the potential of this methodology, we decided to attempt the 
synthesis of clausenamide 2 as it contains the hydroxypyrrolidinone architecture 
that would be ideal to exemplify our methodology (Figure 13).  
 
Figure 13: (±)-Clausenamide 
The first step in our synthetic sequence towards clausenamide as outlined in 
the project objectives, was to introduce a methyl group on the nitrogen atom of 
previously Boc protected phenylalanine as outlined below (Scheme 36). 
 
Scheme 36: N-methylation of N-Boc phenylalanine 
N-Methylation of amino acid derivatives using sodium hydride and methyl iodide 
in DMF has been reported by Benoiton and others (Benoiton et al., 1971). By 
using MeI/NaH with a Leucine derivative in an 8:3:1 molar ratio in the presence 
of DMF at 80 °C they achieved the desired methylated product in 96% yield. 
Following  their  procedure  we  synthesised  the  methylated  phenylalanine 
derivative 115 in 78% by using 3:1:1 MeI/NaH/Boc-Phe molar ratio in DMF at 
room temperature on a 1 gramme scale. Contrary to Benoiton and co-workers 
we  achieved  improved  results  of  nitrogen  alkylation  by  addition  of  sodium 
hydride prior to methyl iodide addition.  
However,  one  key  drawback  was  that  when  scaling  up  the  reaction,  (10 
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of methyl and ethyl ester of N-methylated phenylalanine (Scheme 37). When a 
large  amount  of  sodium  hydride  is  used  in  the  reaction,  our  initial  use  of 
saturated aqueous ammonium chloride as a quenching agent was not ideal. 
After  quenching,  the  mixture  was  not  sufficiently  acidic  and  some  sodium 
hydride  may  have  remained  and  led  to  the  formation  of  aqueous  sodium 
hydroxide  which  in  turn  could  react  with  ethyl  acetate  leading  to  sodium 
ethoxide. This may account for the trans-esterification that we observed in the 
reaction (Scheme 37).  
 
Scheme 37: Mechanism of trans-esterification 
Unfortunately the Rf values of both the methyl and ethyl N-methylated ester of 
phenylalanine  were  equal  and  hence  separation  by  flash  column 
chromatography  was  next  to  impossible.  In  order  to  overcome  this,  we 
attempted  further  trans-esterification  of  our  mixture  by  performing  repeated 
reactions  with  10%  HCl  in  MeOH  in  order  to  produce  the  methyl  ester 
exclusively. 
Due  to  the  problems  with  this,  it  was  clearly  crucial  to  find  an  alternative 
quenching agent, which would neutralize the reaction mixture and avoid the risk 
of ethyl ester formation. In the end, we discovered that use of phosphonate 
buffer appeared optimum, as the quenched reaction mixture was pH neutral 
with  no  ethyl/methyl  ester  mixture  observed.  Pleasingly,  with  the  use  of 
phosphonate buffer at pH 7, the removal of DMF proved to be quicker and less 
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able to improve the yield of the reaction and obtained the desired product in 
81% yield on a larger scale. 
With the methylated product in hand the next step in the synthesis was removal 
of the BOC protecting group to liberate the free amine. To achieve this, we 
treated the BOC protected compound  115 with TFA in dichloromethane and 
after neutralization, obtained the amine 114 in 98% yield (Scheme 38).  
 
Scheme 38: N-Boc deprotection 
In  the  next  step  in  our  synthetic  sequence,  we  needed  to  dehydrate  N-
methylphenylalanine methyl ester 114. To achieve this, we first needed to N-
chlorinate  the  nitrogen  atom  and  eliminate  HCl  via  addition  of  an  organic 
soluble base. We elected to carry this out in a one-pot procedure, where the 
resulting enamine would be acylated with diacetoxyacetyl chloride 119, due to 
the  unstable  nature  of  the  enamine.  As  such,  the  crude  enamine  113  thus 
obtained  was  acylated  under  Schotten-Bauman  conditions  to  provide  the 
diacetoxy amide 112 in poor yield over three transformations (Scheme 39).  We 
now had the desired fully protected cyclisation precursor in good yield as an 
inseparable mixture of E- and Z-isomers.   
 
Scheme 39: Formation of clausenamide cyclisation precursor Blanka Szulc                                                                                                           Results and Discussion 
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However,  one  key  drawback  with  this  method,  was  the  fact  that  the  yields 
obtained were consistently low and only seemed to work on a larger scale. As 
such we decided to investigate this reaction further in order to try to increase 
the yield. 
As shown above (Scheme 39), the deprotected product 114 was first treated 
with  NCS  and  cautiously  monitored  in  the  dark.  As  only  one  proton  was 
available  on  the  nitrogen  atom,  only  monchlorination  was  possible,  which 
allowed us to add the chlorinating agent in a single addition. Chlorination of the 
amine analogue 158 needed to be monitored more carefully and as such, NCS 
was added portionwise over two hours. The resulting light sensitive N-chloro-ʱ-
amino acid ester 159 was then reacted with DABCO to give the dehydroamino 
acid  ester  160  and  HCl  as  a  side  product.  The  enamine  product  of  this 
elimination 161 was sensitive to air, rapidly decolouring and was therefore not 
stable.   
It  is  known  that  enamines  exist  in  equilibrium  with  their  tautomeric  imine 
counterparts and the reaction outcome is clearly dependant on the equilibrium 
between these two key species as shown below (Scheme 40).  
 
Scheme 40: Mechanism of enamine formation 
Enamine-imine tautomerization has been a subject of interest in the literature 
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that influence its equilibrium.  It has been shown that tertiary enamines, with 
regard  to  the  imine,  are  more  stable  than  primary  and  secondary  ones. 
Nevertheless,  it  is  possible  to  gain  extra  stabilization  of  those  less  stable 
systems  via  appropriate  substitution  at  the  β-carbon.  Solvents  have  been 
shown  to  play  an  important  role  as  well.  Polar  solvents  favour  the  enamine 
tautomer form, in other words they favour enamization.  
In the literature there are some examples of enamine/imine tautomerism in ʱ,β-
unsaturated-ʱ-amino acids. A study of dehydropipecolinic acid was conducted 
by Lu and Lewin (Lu and Lewin, 1998), where they showed that this compound 
exists as its enamine form 162 when isolated as a sodium salt and as its imine 
form 163 when extracted as hydrochloride salt (Scheme 41). 
 
Scheme 41: Enamine/ imine tautomerisation 
It was also reported by Lu and Lewin, that dehydropipecolinic acid possesses a 
long  lifetime  when  diluted  in  solution  at  pH=7.  However,  the  nature  of  its 
tautomer was not indicated. Lu and Lewin  also synthesised the sodium and 
lithium carboxylate salts of dehydropipecolinic acid 162, dehydrovaline 164 and 
dehydrophenylalanine 165 by using the same elimination conditions as we used 
during the synthesis of compound 114 (Scheme 42). 
 
Scheme 42: Lu and Lewin’s enamine stability experiments 
As outlined below, both α,β-unsaturated-α-amino acids were converted to the 
corresponding methyl or ethyl ester and subsequently treated with NCS and 
cautiously monitored. The resulting light sensitive N-chloro-ʱ-amino acid ester 
168 was reacted with DABCO or DBU to afford unsaturated ester 169 and HCl 
as by- product. Further hydrolysis of the unsaturated ester with either lithium Blanka Szulc                                                                                                           Results and Discussion 
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hydroxide in aqueous tetrahydrofuran or sodium hydroxide in aqueous dioxane 
led to the lithium or sodium carboxylate salts 171 (Scheme 43). 
                
Scheme 43: Enamine formation 
They  reported  that  the  unstable  product  could  be  stored  intact  at  low 
temperatures (below 20 °C) in the presence of radical scavengers for up to few 
weeks. The proton NMR spectra of both compounds indicated that they exist in 
their enamine forms 171 only. The nuclear Overhauser effect (nOe) on the vinyl 
resonance  (ʴ  6.48  ppm),  resulting  from  an  effect  of  the  ester  methyl  group 
resonance (ʴ 3.86 ppm), defined the Z configuration of the phenyl ring to the 
carboxyl  groups.  In  contrast,  the  cyclic  unsaturated  ester  occurred  as  a  1:1 
mixture of imine and enamine tautomers in CDCl3. When an aqueous solution of 
the sodium salts of 172 and 171 was used, the enamine form was favourable in 
both, but gave rise to an equimolar mixture of Z and E isomers of the imine form 
in  165.  They  also  reported  an  interesting  effect  of  the  solvent,  where  in 
dimethylsulfoxide (DMSO), the sodium salt gave 67% formation of its enamine 
form (in 1:1 Z:E isomers mixture) and 60% of its imine form when D2O was 
used. In summary of their work, they demonstrated that the enamine tautomers 
of α,β-unsaturated-α-amino acids (dehydrophenylalanine) are more stable that 
their  corresponding  imine  form  and  equienergetic  in  the  cyclic 
dehydropipecolinate  ester.  Although,  in  basic  aqueous  media,  the  imine 
tautomers are the ones that are more stable forms, but only in cases where the 
double  bond  is  not  stabilized  by  any  extended  conjugation  (Lu  and  Lewin, 
1998). However, this clearly does not correlate to the low yield (~48%) that we 
observed in our acylation reaction and therfore the key question, is why does Blanka Szulc                                                                                                           Results and Discussion 
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this occur and what is the equilibrium betweeen the two conformers 161 and 
160 as shown below (Scheme 44).  
 
Scheme 44: Enamine/ imine tautomerisation 
When  looking  at  bond  strength, the  imine form  160  is more  stable  than  the 
corresponding enamine 161, because the C=N bond is stronger than the C=C 
bond. In our case when the amine analogue was used as the starting material, 
the  enamine  form  161  should  be  favoured,  due  to  stability  gained  by 
conjugation  via  π  orbital  overlap  from  the  aryl  group  through  to  the  ester 
carbonyl.  In  theory,  we  should  expect  the  same  situation  for  the  N-methyl 
analogue. As stated by Tong and others: “The conjugation of the enamine is 
controlled by changes in the electronic and steric effects of the substituent.” 
(Tong et al., 2012). Therefore, it is possible that the N-methyl-imine is not as 
stable as the enamine due to steric occlusion of the methyl with the aromatic 
ring. This would possibly be an explanation for the  low yields obtained after 
acylation of our crude dehydrogenated product (Figure 14)
 (Erker et al., 1995). 
                      
Figure 14: Enamine - energy 29.3681 kcal/mol vs Imine - energy 12.9678 kcal/mol 
We also decided to look at whether our chlorination step was linked to the low 
yield of the reaction. Initial attempts at chlorination of 114 had focused on the 
use  of  NCS  in  the  presence  of  diethyl  ether.  However,  we  needed  to  filter 
succinimide before addition of DABCO, which therefore exposed the reaction 
mixture to air and increased the risk of hydrolysis. In order to overcome this, we 
decided to use liquid tert-butyl hypochlorite as chlorinating agent. It was the 
cheapest and the safest option for the  chlorination, as tert-butyl hypochlorite Blanka Szulc                                                                                                           Results and Discussion 
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was generated in situ from tert-butanol and commercial hypochlorite. Household 
bleach  could  also  be  used,  but  only  one  that  possessed  low  amounts  of 
detergents  and  surfactants,  as  they  produced  large  amounts  of  soap  in  the 
reaction, making extraction of tert-butyl hypochlorite next to impossible. 
Successful chlorination of the amine 114 could be observed from the 
1H NMR 
spectrum after two hours of stirring the reaction mixture in the dark. As shown 
below (Figure 15), the N-methyl group is clearly shifted from 2.35 ppm to 3.00 
ppm when chlorinated, indicative of attachment of the electronegative chlorine 
atom. 
 
Figure 15: 
1H NMR spectrum of the free amine vs. N-chlorinated product 
Having  established  the  requisite  chlorination  conditions  we  next  turned  our 
attention  to  the  elimination  step.  We  screened  a  number  of  different  non-
nucleophilic bases, as it was crucial to use a strong base, but at the same time 
a poor nucleophile so that no nucleophilic substitution would occur. The ones of 
high basicity such as: potassium tert-butoxide, lithium bis-(trimethylsilyl)-amide 
proved to be harsh, as degradation of the starting material was clearly observed Blanka Szulc                                                                                                           Results and Discussion 
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by  TLC.  Use  of  amine’s  of  moderate  basicity  such  as  triethylamine  or  N,N-
diisopropylethylamine  failed,  as  only  the  non  dehydrogenated  product  was 
attained. We next screened sterically hindered mild bases such as 2,6-lutidine, 
DBU and DABCO. Among these, DABCO (pKa = 8.7) gave the desired product 
in a shorter time and with better yields than 2,6-lutidine, where starting material 
was recovered. DBU proved to be too strong a base, as again, degradation of 
starting material was observed. This correlated with the strength of basicity as 
shown below (Figure 16). 
2,6-lutidine  <   DABCO <  DBU 
pKa= 6.6           pKa= 8.7      pKa=12 
Figure 16: Relative base pKa’s  
As outlined above, Lewis acid mediated cyclisation of a number of enamines 
had led to elimination of the acetate with formation of the corresponding diene. 
As such, we believed that our approach towards clausenamide should obviate 
this problem, as there is no β-hydrogen to facilitate formation of the diene and 
on aqueous work-up we anticipated that we would generate the core structure 
of clausenamide (Scheme 45). 
 
Scheme 45: Clausenamide structure generation 
Having  established  that  intramolecular  cyclisation  occurs  by  use  of  boron 
trifluoride diethyl etherate as a Lewis acid in dichloromethane, we decided to 
carry out the same reaction with our cyclisation precursor 112 (Scheme 46).  Blanka Szulc                                                                                                           Results and Discussion 
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Scheme 46: Cyclisation and formation of BRS-015 
To our delight, we successfully obtained the core structure of clausenamide in 
58% yield. We next turned our attention to the improvement of the yield of this 
reaction.  Due  to  the  relatively  low  boiling  point  of  DCM  we  decided  to  use 
different solvents with higher boiling points as outlined below (Table 2). 
BF3.Et2O 
(equiv.) 
Solvent  Reaction Temp. 
(°C) 
Yield 
 
Time  
(hrs) 
2  DCM  40  58%  12 (reflux) 
2  DCE  60  62%  6 (reflux) 
20  neat  126  70%  3 (reflux) 
20  neat  -  72%  36 (r.t.) 
Table 2: Optimization of cyclisation reaction using boron trifluoride dietherate 
We were pleased to observe that by using neat boron trifluoride diethyl etherate 
we improved the yield and shortened the time of reaction, as the core structure 
of clausenamide could be obtained in 70% yield in just 3 hours at reflux. 
We next carried out the cyclisation with neat boron trifluoride diethyl etherate at 
room temperature for 36 hours and surprisingly produced the desired product in 
72% yield. 
As we observed that Lewis acid-mediated cyclisation leads to the formation of 
the  core  structure  of  clausenamide,  we  decided  to  carry  out  screening  of  a 
number of other Lewis acids to try to improve the yield of the reaction. 
We screened alternative conditions for cyclisation of 112 using different Lewis 
acids.  The  reactions  were  performed  under  reflux  for  2  hours,  using  two 
equivalents  of  each  Lewis  acid.  Using  the  same  conditions,  Lewis  acids 
screening was carried out for 112, giving comparable yields and the results of 
our studies are outlined in the following table (Table 3). 
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 Lewis acid  Yield 
BF3.Et2O  70% 
CF3SO3Si(CH3)3  40% 
AlCl3  21% 
SnCl4  32% 
TiCl4  47% 
FeCl3.6H2O  52% 
FeCl3  43% 
InCl3  60% 
(CF3SO3)2Zn  66% 
Table 3: Effect of a range of Lewis acids on the yield of cyclisation 
3.2.1. Mechanistic investigation of cyclisation  
Whilst  the  IAC  reaction  had  led  to  the  core  structure  of  clausenamide,  the 
formation of the alcohol as the major product was somewhat surprising as we 
had predicted that the acetate 174 would be preferred. It is therefore probable 
that  further  activation  of  the  acetate  174  with  Lewis  acid,  occurs  leading  to 
elimination to give the conjugated enamine 175 that reacts with water on work-
up to give the corresponding alcohol 111 (Scheme 45 and 47). 
 
Scheme 47: Mechanism of cyclisation 
We were also intrigued by the nature of the double bond formation in terms of 
the reaction mechanism. It was hard to determine the double bond location by 
1H  NMR  or 
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structure  was  therefore  determined  by  X-ray  crystallographic  analysis  as 
outlined below (Figure 17).  
 
Figure 17: X-Ray structure of compound 166 
What  is  clear  from  the  X-ray,  is  that  our  predicted  compound  111  has  not 
formed, but instead, it is the compound where the double bond has shifted into 
conjugation 176 (Figure 18). 
 
Figure 18: The two possible double bond configurations 
We  were  surprised  that  compound  111  was  not  generated  as  we  initially 
thought  but  176.  One  possible  explanation  is  that  a  1,3-hydride  shift  of  the 
proton  attached  to  the  carbon  as  hydroxyl  group  occurs  as  shown  below 
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Scheme 48: Proposed hydride shift mechanism 
In order to understand the nature of the molecule and to look at the potential of 
why a 1,3-hydride shift might occur as a possible mechanism, we elected to 
look at the total energy of each conformer as outlined below (Figure 19). We 
envisaged that it must to be due to the stability of both possible products with 
one possessing higher energy than the other. 
On calculating and comparing the energies of both products, we were pleased 
to observe that the total energy of 176 is five times less than the energy of 111, 
clearly indicating that 176 is much more stable and so consequently would be 
favoured.  
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Compound 176                                  Compound 111 
Total energy 8.4760 kcal/mol     Total energy 40.4550 kcal/mol 
Figure 19: Energy confirmations of BRS-015 double bond isomers 
Following the successful obtention of the core structure of clausenamide, we 
were mindful of the need to be able to vary the structure around the central 
core. Compounds based on piracetam (3) that have progressed to the clinic or 
been taken forward to clinical trial have had varying degrees of substitution on 
the  nitrogen  atom.  As  such,  we  elected  to  look  at  the  synthesis  of  the  N-
unsubstitued compound 180 as shown below. We envisaged that alkylation as 
per  previous  researchers,  would  enable  us  to  access  a  wide  array  of  N-
substitued derivatives 181 (Scheme 49).  
 
Scheme 49: Formation of the N-H isomer of clausenamide 
In order to synthesise the N-H precursor 185, we first formed the free base of 
phenylalanine methyl ester and treated it with N-chlorosuccinimide in the dark 
as per our previous synthesis of the core structure of clausenamide. Unlike the 
synthesis of the N-methyl precursor (Scheme 39), we were mindful of the fact 
that  over-chlorination of  the  nitrogen  atom could  occur,  due  to  two  potential 
sites  for  chlorination.  As  such,  we  decided  to  use  NCS  intead  of  tert-
butylhypochlorite in this instance (Scheme 50).  Blanka Szulc                                                                                                           Results and Discussion 
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Scheme 50: Formation of the N-H cyclisation precursor 
As  shown  above,  the  N-chloro  compound  183  was  treated  with  DABCO  to 
promote elimination and tautomerisation to the enamine 184. Surpirisingly, the 
enamine 184 proved remarkably stable and could be isolated and purified by 
column chromatography in 26% yield. Enamine 184 was subsequently alkylated 
with diactoxyacetyl chloride 119 under Schotten-Bauman conditions to give the 
N-H precursor 185 in good yield (74%). As per our investigations with the N-
methyl precursor, we elected to carry out the cyclisation with a range of Lewis 
acids. Surprisingly in this instance, boron trifluoride did not lead to formation of 
the cyclized product, and instead necessiated treatment with a stronger Lewis 
acid  and  higher  temperatures.  As  such,  treatment  of  185  with  titanium 
tetrachloride in 1,2-dichloroethane gave the cyclized product 180 in 52% yield 
as shown below (Scheme 51).  
 
Scheme 51: Cyclisation to give the N-H precursor 
 
The  requirement  for  more  forcing  conditions  was  surprising  as  we  had 
anticipated that the N-H precursor would cyclise in an analogous fashion to its 
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of the N-methyl substituent, which places the diacetate and enamine in close 
proximity for cyclisation as shown below (Scheme 52).  
 
Scheme 52: Potential conformers  
With the obtention of the desired cyclised derivatives, the focus of the project moved 
towards the analysis of their physiological effects.  
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 4.0. Methodology  
4.1. Hippocampal slice preparation and preservation 
All  animal  procedures  strictly  followed  University  College  London  (UCL) 
Research  Ethics  Committee  regulations.  Sprague–Dawley  rats  (Harlan 
Laboratories Ltd, Oxon, UK) aged 21–40 days were killed by an overdose of 
sodium  pentobarbital  injected  intraperitoneally  (100  mg  kg
−1)  and  rapidly 
decapitated  in  accordance  with  the  UK  Animals  (Scientific  Procedures)  Act, 
1986. 
4.1.1. Dissection of the rat brain 
Sprague Dawley rats were killed by decapitation and the skull was exposed by 
a skin incision. Using scissors, the skull was cut along the midline starting from 
the foramen magnum, followed by two cuts in the medio-lateral direction at the 
cerebellum to facilitate the opening of the skull and exposure of the brain. Using 
a spatula, the brain was scooped out of the skull by cutting the cranial nerves 
and quickly submerged into an oxygenated ice-cold sucrose solution.  
The brain was placed on a filter paper inside a Petri dish and via the use of a 
blade; the brain was trimmed in the coronal plane removing the olfactory bulbs 
and the cerebellum. By cutting along the midline, the two hemispheres were 
separated and placed onto the medial side with the lateral side facing up. An 
additional angled cut at approximately 90 ﾺ (“magic cut”) was made along the 
dorsal sides of the hemisphere for mossy fibre recordings. (Bischofberger et al, 
2006). Using the spatula, the hemispheres were glued onto their dorsal sides 
on a stage angled 15-30 º, transferred into a buffer tray and submerged with 
ice-cold  sucrose  solution.  300  µm  thick  transverse  slices  of  the  dorsal 
hippocampus were obtained using a Vibratome (Figure 20) (Leica VT 1200S, 
Leica  Biosystems,  Nussloch  GmbH,  Nussloch,  Germany).  Throughout  the 
cutting process, the hemispheres were constantly oxygenated with 95% O2/5% 
CO2.  
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Figure 20: Preparation of transverse hippocampal slices with special cut. A, B: 
Computer reconstruction of the adult rat brain showing the hippocampal formation (pink 
CA1 and CA3 areas, blue DG) A: Two hemispheres of the brain orientated in the exact 
position, as when removed from the skull; B: One hemisphere of the brain, orientated 
as after the cut along the midline and a 90º turn onto the medial side. Taken from 
(Bischofberger et al., 2006). 
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4.1.2. Slice storage and preservation  
Transverse hippocampal slices thus obtained, were incubated at 35 °C for 30 
min in the sucrose solution and thereafter maintained at room temperature (22 
°C)  until  required.  All  slices  were  stored  in  a  bespoke  submersion  chamber 
(pictured) filled with sucrose solution and perfused with 95% O2/5% CO2 (Figure 
21). 
 
 
Figure 21: Submersion chamber for hippocampal slices maintenance: Picture of 
the custom-made submersion chamber showing the nylon mesh that holds the brain 
slices, filled with sucrose solution and oxygenated with 95% O2/ 5% CO2 through a 
plastic tube to reduce solution turbulence. 
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4.1.3. Solutions 
The composition of the sucrose solution used for dissection and slice storage is 
presented below (Table 4) as well as that used for the artificial cerebrospinal 
fluid (ACSF) for perfusion during electrophysiological recordings shown below 
(Table 5). 
Substance  Concentration (mM) 
Sucrose  75 
D-Glucose  10 
NaCl  87 
NaHCO3  25 
KCl  2.5 
NaH2PO4  1.25 
MgCl2  7 
 CaCl2  0.5 
 
Table 4: The composition of sucrose solution listed 
 
Substance  Concentration (mM) 
D-Glucose  25 
NaCl  125 
NaHCO3  25 
KCl  2.5 
NaH2PO4  1.25 
MgCl2  2 
CaCl2  4 
 
Table 5: The composition of ACSF solution listed 
The osmolarity of both solutions was adjusted to ~ 320 mOsmol/L and the pH to 
7.4 prior to use. 
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5.0. Electrophysiological recordings  
After  one-hour  incubation,  individual  slices  were  transferred  to  a  recording 
chamber that was continuously perfused with oxygenated ACSF and held by 
nylon strings attached to a platinum wire. The gravity-driven perfusion rate was 
set to 2 ml/min. Glass electrodes were pulled from borosilicate capillaries (outer 
diameter of 1.50 mm and inner diameter of 0.86 mm purchased from Harvard 
Apparatus  Ltd.,  Edenbridge,  UK)  with  a  Flaming/Brown  micropipette  puller 
(Model  P-97,  Sutter  Instruments  Co.,  California,  USA).  Heat  settings  were 
adjusted so that pipettes had resistances ranging between from 3 to 6 MΩ.  
Hippocampal  slices  were  visualised  with  an  Olympus  BX  51WI  microscope 
(Olympus Europa Holding GmbH, Hamburg, Germany) which was connected to 
a  KPM-3  Hitachi  infrared  (IR)  video  camera.  Stimulus  electrodes  (bipolar 
tungsten  electrodes  purchased  from  FHC  Inc.  Bowdoin,  Maine,  USA)  were 
positioned  under  a  low  magnification  (10  x)  objective  (Olympus),  while  for 
patch-clamp  experiments,  neurones  were  visualised  under  IR-differential 
interference contrast (DIC) imaging with a water-immersion high-magnification 
(60  x)  objective  (Olympus)  and  a  fourfold  magnification  changer  (Luigs  & 
Neumann  GmbH,  Ratingen,  Germany).  For  local  application,  a  picospritzer 
(Picospritzer  III,  Intracel,  Unit  4,  Shepreth,  Herts,  UK)  was  connected  to  a 
pipette holder designed for pressure application (Figure 22). 
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Figure  22:  Image  showing  stage,  objectives  and  recording  chamber  with 
stimulus electrode, puff pipette and recording electrode positioned in the tissue. 
To study the effects of BRS-015 and its analogues, various electrophysiological 
recordings were performed in acute hippocampal slices. These were divided 
into  extracellular  recordings  or  recordings  of  evoked  field  excitatory 
postsynaptic potentials (f-EPSPs) and patch clamp recordings, where there is 
direct  access  to  the  intracellular  compartment  of  individual  neurones,  hence 
enabling a measurement of the trans-membrane potential as well as the input 
resistance, cell capacitance and firing properties. 
5.1. Extracellular recordings 
The measurement of extracellular recordings is a less challenging method when 
compared with whole-cell recordings because it does not rely on the formation 
of a giga-seal onto individual neurones. As such, this recording configuration 
does  not  enable  the  detection  of  changes  in  the  electrical  properties  of 
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firing properties in response to application of a drug or a modulator of synaptic 
transmission. However, it provides a rapid method with which to explore the 
effects of a drug on a group of neurones. Local f-EPSPs are generated by bulk 
activation of excitatory synapses resulting in the movement of positive charges 
through  glutamate  receptors  in  postsynaptic  neurones.  This  creates  current 
sinks (and sources) that can be detected as negative (downward) deflections 
when  recording  from  the  extracellular  space.  An  intracellular  electrode 
positioned at the soma would on the other hand measure a depolarisation, i.e. a 
positive-going waveform or excitatory postsynaptic potential (EPSP).  
MF f-EPSPs (MF-EPSPs) were evoked every 10 seconds using paired electrical 
stimuli (inter-stimulus interval: 20 ms; constant current, 0.3 – 1.5 µA, 50 µsec) 
and recorded with an ACSF-filled glass pipette (~3 MΩ) placed within the CA3 
stratum lucidum as shown in the schematic below (Figure 23).  
 
 
Figure  23:  Cartoon  representation  of  a  hippocampal  slice  showing  the 
experimental approach for mossy fibre f-EPSP recordings: Stimulus and recording 
electrodes positioned in DG and SL of CA3, respectively. 
Extracellular electrical stimulation in the dentate gyrus can lead to the activation 
of  three  potential  different  pathways  (Henze  et  al.,  2000)  besides  the 
monosynaptic, orthodromic mossy fibre- CA3 input, including: 
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  Antidromic pathway via hilar projecting associational collaterals of CA3 
pyramidal neurones; 
  Polysynaptic pathway, where a strong stimulation causes firing of CA3 
pyramidal  neurones,  thus  synaptic  activation  of  other  CA3  pyramidal 
neurones. 
Therefore, to ensure that DG stimuli activated monosynaptic mossy fibre-CA3 
inputs, three criteria need to be met: 
1.  EPSPs had to have a large degree of paired-pulse facilitation (PPF > 
200%) (Salin et al., 1996); 
2.  EPSPs  needed  to  show  a  large  amplitude  increase  upon  a  modest 
increase in stimulus frequency (e.g. 0.1 Hz to 1 Hz); 
3.  The  application  of  DCG-IV  (1  μM)  at  the  end  of  each  recording 
depressed MF-EPSPs > 70% (Kamiya and Ozawa, 2000, Barnes et al., 
2010). 
To  study  the  effect  of  BRS-015  on  mossy  fibre  LTP,  two  different  stimulus 
paradigms  were  used.  Firstly,  we  designed  a  protocol  where  sub-threshold 
tetanic stimulation (100 Hz for 1 second) in the dentate gyrus only elicited a 
typical post-tetanic potentiation (PTP). Secondly, we used a classic induction 
protocol  of  long-term  potentiation  (3  times  100  Hz  for  1  second,  every  10 
seconds), where sustained LTP (>20 minutes) was formed after initial PTP. A 
second stimulus electrode was placed in the distal stratum radiatum in order to 
activate associational commissural fibres as a control pathway.  
5.2. Intracellular recordings: whole-cell patch-clamp 
Whole-cell recordings were obtained from CA3 pyramidal neurones imaged with 
infra-red videomicroscopy (Figure 24)  
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Figure 24: High magnification IR-DIC image of the PCs of the CA3 region 
5.2.1. Voltage-clamp configuration 
For  voltage-clamp  recordings  in  which  cells  were  held  at  Vholding  =  -70mV, 
electrodes were filled with a cesium chloride based internal solution containing: 
120 mM CsCl, 5 mM QX314 Br, 8 mM NaCl, 0.2 mM MgCl2, 10 mM HEPES, 2 
mM  EGTA,  2  mM  MgATP  and  0.3  mM  Na3GTP.  The  osmolarity  and  pH  of 
intracellular solutions were adjusted to ~310 mOsmol/L and 7.2 respectively. 
A  bipolar  tungstene  electrode  was  positioned  in  the  stratum  granulosum  for 
activation of granule cells and mossy fibres.  Excitatory postsynaptic currents 
evoked by dentate gyrus stimulation (20 µs; 20 – 100 µV) were only analyzed if 
currents were reversibly depressed > 80% by superfusion of DCG–IV (1 µM) at 
the end of each experiment, consistent with the selective sensitivity of mossy 
fibre synapses. The access resistance, monitored throughout the experiments 
by a voltage step was <20 M and results were discarded if it changed by more 
than 20%. The liquid junction potential was not corrected. EPSCs were filtered 
at 2 kHz (internal 4–pole low–pass Bessel filter), and sampled at 10 kHz. Single 
shock electric pulses were delivered every 10 sec (0.1 Hz). GABAA and GABAB 
receptors  were  routinely  blocked  by  picrotoxin  (50  µM)  and  CGP-52432  (10 
µM). To record KAR-EPSCs, the selective AMPARs antagonist GYKI-53655 (50 
M) and the NMDA receptor antagonist D-AP5 (50 µM) were included in the 
20µm 
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recording solution. NMDA-EPSCs were recorded in the presence of NBQX (20 
M) while voltage-clamping pyramidal neurones at +40 mV.  
EPSCs,  evoked  when  holding  CA3  pyramidal  cells  at  -70  mV,  were  fully 
abolished by addition of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 50 µM) 
or  2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione  (NBQX;  20 
µM), confirming that they were mediated by AMPA and kainate receptors. 
For glutamate puffs, glutamate (100 mM in ACSF) was applied at 5-20 psi (10-
50 ms). Puffs were applied every 60 seconds to allow for glutamate clearance. 
The puff electrode was positioned at the border of SL and SR, 100 µm away 
from the soma of the recorded CA3 pyramidal cell and along its apical dendrite. 
 
5.2.2. Current-clamp configuration 
To examine how a drug or compound alters the electrical properties of a given 
neurone, it is necessary to characterize the current – voltage (I–V) relation in 
response to hyperpolarizing and depolarizing current steps and to determine 
the threshold for action potential (AP) generation, as well as the mean firing 
rate. Current-clamp recordings from individual CA3 pyramidal neurones were 
carried-out to examine the effect of BRS-015 on intrinsic membrane properties 
of CA3 pyramidal neurones, including the membrane potential, input resistance 
and the mean firing frequency. The pipette solution for current-clamp recordings 
contained: 135 mM K- gluconate, 5 mM KCl, 1 mM CaCl2, 5 mM EGTA-Na, 10 
mM HEPES, 10 mM glucose, 5 mM MgATP, and 0.4 mM Na3GTP.    Blanka Szulc                                                                                                           Results and Discussion 
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5.3. Data acquisition and analysis 
Recordings  were  obtained  using  an  Axopatch  200B  amplifier  (Axon 
Instruments, Union City, USA) that fed analog data to an A/D converter. The 
resulting  data  were  collected  and  analysed  with  custom-built  routines  in  the 
LabVIEW environment (version 8) using National Instruments drivers and was 
stored on a personal computer (Figure 25).  
 
Figure  25:  Schematic  of  the  recording  configuration  and  signal  flow.  A:  The 
cartoon shows the connection between the headstage, amplifier, A/D converter and the 
personal computer used for data storage and analysis. 
For each recording, EPSC amplitude was normalised to pre-BRS-015 level, and 
the overall change in amplitude for ‘n’ neurones was determined by averaging 
normalised  amplitudes  and  expressed  as  a  percentage.  PSC  traces  of 
representative examples were typically averages of between 3 and 10 individual 
traces.  
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The PPR was determined by dividing the peak amplitude of the second EPSC 
to that of the first EPSC using a paired-stimulus protocol (inter-stimulus interval, 
50 ms) (Figure 26).  
 
Figure 26:  Analysis of exemplified evoked postsynaptic current with specified 
parameters for data analysis  
 
Analysis of the decay kinetics was carried out by fitting trace averages with a 
single exponential using Matlab R2010a (TheMathWorks, version 7.10). 
I-V relationships from CA3 pyramidal neurones were obtained with no constant 
current injection, by applying a series of hyperpolarizing and depolarizing steps 
(-120  pA  to  +100  pA;  500  ms).  For  each  cell,  the  input  resistance  was 
calculated  by  fitting  the  linear  portion  of  the  I-V  relation  at  hyperpolarized 
potentials. The slope of the I-V relation yielded the input resistance. The mean 
firing frequency was calculated by dividing the number of action potentials by 
the duration of a supra-threshold current step of increasing intensity that did not 
inactivate Na
+ channels (20 to 100 pA, 500 ms). The rheobase current was 
defined  as  the  minimum  injected  current  (20  –  60  pA)  that  trigerred  action 
potentials in the recorded neurone. 
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5.4. Statistics  
All  data  are  given  as  mean    standard  error of  the  mean  (SEM).  Statistical 
significance between means was calculated by using paired  Student’s t-test, 
except in Figure 44 where an unpaired t-test was applied. Data were significant 
if P < 0.05. In all figures, error bars indicated  SEM. Averaged traces, used as 
representative examples, include 3-10 individual responses.  
5.5. Drugs 
D-(-)-2-Amino-5-phosphonopentanoic  acid  (D-APV),  a  competitive  NMDA 
receptor antagonist, was obtained from Abcam Biochemicals (Cambridge, UK) 
and diluted to 50 µM. 
Compound BRS-015 was  prepared  in  DMSO  at  a  stock  concentration of 50 
mM. 
3-[[(3,4-Dichlorophenyl)methyl]amino]propyl]  diethoxymethyl)phosphinic  acid 
(CGP-52432),  a  selective  GABAB  antagonist,  was  purchased  from  Tocris 
Bioscience (Bristol, UK) and diluted to a final concentration of 10 µm. 
6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX), a potent AMPA/kainate receptor 
antagonist, was bought from Tocris Bioscience (Bristol, UK) and diluted to a 
final concentration of 50 µM. 
(2S,2'R,3'R)-2-(2',3'-Dicarboxycyclopropyl)glycine (DCG-IV), a selective agonist 
on  presynaptic mGLuR2/3  was  obtained from  Tocris Bioscience,  (Bristol,  UK) 
and prepared at final concentration of 1 µM. 
Picrotoxin, a noncompetitive GABAA receptor antagonist, was purchased from 
Abcam Biochemicals (Cambridge, UK) and prepared in DMSO for use at a final 
concentration of 50 µM.  
Glutamate  was  purchased  from  Abcam  Biochemicals  (Cambridge,  UK)  and 
diluted to 100 mM. 
1-(4-Aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-
5H-2,3-benzodiazepine hydrochloride (GYKI 53655), a non-competative AMPA 
and  kainate  receptor  antagonist,  was  obtained  from  Abcam  Biochemicals Blanka Szulc                                                                                                           Results and Discussion 
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(Cambridge, UK) and prepared in water for use at a final concentration of 50 
µM.  
2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide  (NBQX), 
a potent AMPA receptor antagonist, was bought from Tocris Bioscience (Bristol, 
UK) and diluted to a final concentration of 20 µM. 
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6.0. Electrophysiological profile of BRS-015 
This section describes the neuropharmacological properties of compound BRS-
015 as a modulator of excitatory synaptic transmission at a major hippocampal 
synapse.  Several  electrophysiological  techniques  were  used  to  analyse  the 
profile of compound BRS-015 at a major central synapse, including extracellular 
field potential recordings and whole-cell recordings in different configurations. 
Afferent mossy fibre axons were activated by electrical stimuli delivered in the 
stratum  granulosum  and  postsynaptic  recordings  were  made  from  CA3 
pyramidal neurones. An initial characterisation of the acute effects of BRS-015 
was first undertaken using both extracellular recordings and whole-cell voltage-
clamp  recordings.  This  led  to  the  establishment  of  the  relation  between  the 
concentration  of  BRS-015  in  brain  tissue  and  the  degree  of  modulation  of 
evoked EPSCs in pyramidal neurones. Finally, a pharmacological screen was 
performed  using  selective  antagonists  at  common  receptors found  at  central 
synapses to search for a putative target via which BRS-015 modulated synaptic 
transmission.   
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6.1. Effects of BRS-015 on evoked glutamatergic synaptic 
transmission from the dentate gyrus to CA3 
6.1.2. Field potential recordings  
Extracellular  recordings  were  first  chosen  to  assess  the  acute  effect  of 
compound  BRS-015  on  excitatory  synaptic  transmission  in  a  CA3  neuronal 
population. A bipolar tungsten electrode was positioned in the supra-granular 
blade of the dentate gyrus to activate mossy fibres and a recording pipette filled 
with  ACSF  was  implanted  in  the  stratum  lucidum  in  the  CA3  sub-region  to 
record evoked f-EPSPs. Electrical stimuli were applied every 20 seconds when 
searching  for  typical  mossy  fibre  responses.  In  order  to  identify  mossy  fibre 
inputs, several stringent criteria were applied when maximizing the position of 
stimulus and recording electrodes: 1) a measurable latency (peak 8-10 msec) of 
the response onset that is  compatible with afferent mossy fibre activation at 
room temperature (Derrick et al., 1991), 2) pronounced facilitation of f-EPSP 
amplitude (>150%) upon an increase of stimulus frequency from 0.1 Hz to 1 Hz 
and 3) depression of evoked f-EPSPs > 70% by superfusion of DCG-IV at the 
end of each experiment. The slice was replaced if criteria 1 and 2 were unmet. 
As shown below (Figure 27), superfusion of BRS-015 (100 µM) increased f-
EPSP amplitude by 41.5  10.6% of control (n = 4, P < 0.05, paired t-test). This 
effect was reversible upon wash-out of the compound. Application of the vehicle 
(DMSO) at a similar concentration as that used to solubilise BRS-015 had no 
effect. These results show that BRS-015 had a reversible enhancing effect on 
excitatory synaptic transmission from the dentate gyrus to CA3. Fortuitously, the 
results also indicated that the solvent concentration used for dissolution of BRS-
015 was not responsible for the observed ehancing effect. Blanka Szulc                                                                                                           Results and Discussion 
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Figure 27: BRS-015 enhances excitatory synaptic transmission from the dentate 
gyrus to CA3. A: Plot of f-EPSP amplitude against time showing an increase upon 
superfusion of BRS-015 (100 μM) and no change upon superfusion of DMSO (0.1%). 
Representative example traces (averages of 5 consecutive f-EPSPs) obtained in each 
condition are shown above the plot (data from one slice). B: Summary bar chart from 5 
extracellular recordings showing the enhancing effect of BRS-015.   
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With such a promising result in hand we decided to compare the effect of BRS-
015 with the well-know drug piracetam in order to determine the potential of our 
compound with the most prominent memory enhancing drug. Previous studies 
had  shown  the  onset  of  activity  with  piracetam  in  the  CA1  region  in  the 
hippocampus at a concentration of 1 mM (Olpe and Lynch, 1982).  
We elected to employ the same protocol to measure mossy fibre f-EPSPs as for 
the  initial  screening  of  BRS-015  in  order  to  obtain  a  comparative  result. 
Following this initial study, we observed that piracetam at low concentrations 
(100  µM),  was  essentially  inactive  and  had  no  effect  on  basal 
neurotransmission at mossy fibre synapses. Only superfusion of piracetam at 
much  higher  concentrations  (500  µM)  led  to  a  limited  increase  in  f-EPSP 
amplitude (Figure 28). However, even at this concentration it was essentially 
inactive  as  it  only  increased  f-EPSP  amplitude  by  9.3    3.8%  of  control  as 
shown below (n = 3, P < 0.05, paired t-test). 
 
Figure  28:  Piracetam  enhances  excitatory  synaptic  transmission  from  the 
dentate gyrus to CA3. Plot of EPSP amplitude against time showing an increase upon 
superfusion of piracetam (500 μM) (summary of 3 extracellular recordings). 
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With such an initial promising demonstratation that the comparative activity of 
our compound was better than the current drug used to treat memory disorders, 
we decided to investigate the mechanism of the action of BRS-015 in more 
detail to explore its potential.  
Due to the fact that bath application of BRS-015 will affect many neurones and 
synapses within the slice neuronal network, we elected to selectively apply the 
compound  locally  at  the  border  between  the  stratum  radiatum  and  stratum 
lucidum,  in  close  vicinity  (50-200  micrometers)  to  the  electrode  used  for 
extracellular recordings. As shown in  Figure 29, puff application of BRS-015 
(10-30 psi, 10-20 ms; 100 mM in a patch pipette) increased f-EPSP amplitude 
by 82.3  6.6 % of control (n = 4, P < 0.001, paired t-test, Figure 29). We also 
observed that the effect was quickly reversible and was not accompanied by a 
change in the paired-pulse ratio of evoked synaptic responses (PPR control: 
1.56 ± 0.13, BRS-015: 1.51 ± 0.11, n = 4; P > 0.05, Figure 30). To verify that the 
enhancing effect of BRS-015 was not due to a mechanical artefact, a pipette 
containing  ACSF  was  introduced  in  the  tissue  and  positioned  at  exactly  the 
same location as the BRS-015 containing pipette. We observed that ACSF puffs 
of similar intensities and durations as those used for BRS-015 puffs had no 
effect on f-EPSPs amplitude, arguing against mechanical disturbance induced 
by pressure application. 
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Figure  29:  Local  application  of  BRS-015  in  stratum  lucidum  increases  the 
amplitude of dentate-evoked f-EPSPs recorded from CA3 A: Infrared–DIC image 
showing a puff pipette (top right) used for local pressure application of BRS-015 (100 
μM intrapipette, 10 sec, 20 psi) positioned ~150 µm away from the recording electrode 
(bottom left) located in stratum lucidum. B: In red: plot of EPSP amplitude against time 
showing an increase upon local pressure application of BRS-015; in blue: no change 
occurs following local application of control solution ACSF in the same slice. Data are 
from 4 extracellular recordings.  
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Figure 30: The enhancing effect of BRS-015 is not accompanied by a change in 
paired-pulse ratio of f-EPSP amplitude. A: Summary bar chart showing no change in 
the paired-pulse ratio of f-EPSPs amplitude when BRS-015 was applied locally.  B: 
Similar data expressed against the magnitude of f-EPSP facilitation. Data were pooled 
from 4 extracellular recordings. 
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In summary, although these preliminary experiments were performed from one 
animal,  the  results  clearly  suggested  that  BRS-015  has  a  reversible  and 
powerful enhancing effect on glutamatergic transmission from the dentate gyrus 
to CA3, possibly by acting directly at mossy fibre synapses. The caveat of the 
approach,  however,  is  that  the  concentration  of  BRS-015  that  reaches  the 
synapses is unknown. 
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6.2. Whole-cell patch-clamp recordings 
6.2.1.  Effect  of  BRS-015  on  electrical  properties  of  CA3  pyramidal 
neurones 
Due to the fact that the facilitation of evoked f-EPSPs as shown above could 
result from increased excitability in CA3 pyramidal neurones (e.g. a change in 
Rin), whole-cell recordings were undertaken to examine possible changes in the 
electrical  membrane  properties  and  firing  patterns.  Current-clamp  recordings 
were  performed  in  CA3  pyramidal  cells  using  a  K-gluconate  based  pipette 
solution, whilst obviating DC current injection when applying step protocols in 
current-clamp mode. GABAergic transmission was blocked by adding picrotoxin 
(50 µM) and CGP-52432 (10 µM) in the bath. I-V relations were obtained in 
every  cell  by  delivering  a  series  of  hyperpolarising  and  depolarising  current 
steps (-100 pA – +120 pA) until steady-state firing was reached. Superfusion of 
BRS-015 (100 µM) did not alter the membrane potential (control: -69.8 ± 2.7 
mV, BRS-015: -65.4 ± 3.9 mV, n = 5, P > 0.05) or the Rin of CA3 pyramidal 
neurones (control: 246.4 ± 18.9 MΩ, BRS-015: 212.84 ± 27.6 MΩ, n = 5, P > 
0.05). In addition, BRS-015 had no effect on the mean firing frequency of CA3 
pyramidal neurones (control: 7.4 ± 1.3 Hz, BRS-015: 7.1 ± 1.1 Hz, n = 5; P > 
0.05). Finally, rheobase current was not affected by the application of BRS-015 
(control: 38 pA, BRS-015: 36 pA, n= 5; P > 0.05). A summary of these results is 
presented in Figure 31. 
These findings support the notion that BRS-015 has little effect on the intrinsic 
electrical membrane properties in individual neurones and favor the hypothesis 
that enhancement of synaptic transmission consecutive to BRS-015 application 
might result from an action on synaptic conductances or changes in afferent 
excitability which would then translate into increased glutamate release and/or 
increased number of active synapses. They also emphasise that the increase in 
EPSC  amplitude  is  unlikely  to  result  from  a  network  effect,  where  overall 
excitability would be enhanced. 
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Figure 31: BRS-015 does not alter the basic electrical membrane properties of 
CA3 pyramidal neurones: A: Representative traces showing the effect of BRS-015 
on sub-treshold and supra-treshold voltage responses. The current injected for sub-
treshold  voltage  deflection  is  +40  pA  and  the  rheobase  current  is  +50  pA.  In  the 
background of BRS-015, the rheobase current of +50 pA remains unchanged, eliciting 
the same number of action potentials. B – E: Summary histograms showing no effect 
of the superfusion of BRS-015 (100 μM) on the membrane potential, input resistance, 
rheobase current and mean firing frequency of CA3 pyramidal neurones (data pooled 
from 5 recordings).  Blanka Szulc                                                                                                           Results and Discussion 
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6.2.2. Effect of BRS-015 on dentate-evoked EPSCs 
In this second set of patch clamp recordings we looked at the effects of BRS-
015 on dentate-evoked EPSCs recorded in CA3 pyramidal  neurones held in 
voltage-clamp  mode  at  Vholding  =  -70  mV.  Glutamatergic  responses  were 
recorded  in  the  continuous  presence  of  the  GABAA  receptor  antagonist 
picrotoxin (50 µm) and the GABAB receptor antagonist CGP-52432 (10 µM). 
Dentate stimuli were delivered at a basal frequency of 0.1 Hz and a 50 ms inter-
stimulus interval (20 Hz) was chosen for paired stimuli. As shown in Figure 32, 
superfusion of BRS-015 (100 µM) increased the amplitude of evoked EPSCs by 
77.8  11.3% of control amplitude (n = 5, P < 0.003, paired t-test). The holding 
current measured before and after application of BRS-015 was not significantly 
different (delta ∆Iholding: 10.9 ± 8.3 pA, P > 0.1, paired t-test). Interestingly, the 
potentiating  effect  of  BRS-015  decreased  before  wash-out.  Finally,  bath 
application of the mGluR II agonist DCG-IV (1 µM) depressed dentate evoked 
EPSCs by (70.7  29.3%, n = 4; P < 0.05) implying that they were mediated by 
activation of mossy fibre synapses. 
Figure 32: BRS-015 facilitates evoked mixed AMPA/KA receptor-mediated EPSCs 
in CA3 pyramidal neurones. Left: Plot of normalised EPSC amplitude against time 
showing an increase upon superfusion with BRS-015 (100 µM) and depression by the 
group II metabotropic glutamate receptor agonist DCG-IV (1 µM). (Data are from one 
CA3  pyramidal  neurone).  Right:  Summary  plot  based  on  data from  5  neurones  (5 
slices) (each point represents the mean ± S.E.M).    
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6.2.3. Dose - response relation: EC50. 
Several  experiments  were  performed  based  on  a  similar  design  to  cover  a 
range  of  differing  concentrations  of  BRS-015  (Figure  33).  Again,  a  stimulus 
electrode was implanted in the stratum lucidum and whole-cell voltage-clamp 
recordings were obtained from visually identified CA3 pyramidal neurones held 
in  voltage-clamp.  Bath  application  of  BRS-015  (0.01-0.1  µM,  n  =  2)  had  no 
effect whereas BRS-015 (1 M, n = 4) reversibly enhanced EPSCs by 7.1  
6.7%. When testing higher concentrations, BRS-015 was applied at 10 and 100 
µM and was shown to enhance evoked EPSCs by 39.2  8.4% (n = 4) and 72.9 
 4.7% (n = 5), respectively. Increasing the concentration of BRS-015 up to 1 
mM yielded further facilitation of evoked EPSCs with an initlal saturation of the 
effect  depicted  as  a  plateau  in  the  dose-response  relation  (85.1    4.9% 
amplitude  increase,  n  =  2).  Fitting  the  concentration-facilitation  curve  with  a 
logistic function yielded an EC50 of 12 μM. 
 
Figure 33: The effect of  BRS-015 on dentate-evoked EPSCs in CA3 pyramidal 
neurones is concentration-dependent. Concentration-facilitation curve showing the 
relation between BRS-015 concentration (logarithmic scale) and the enhancement of 
EPSC amplitude in CA3 pyramidal neurones. Doses below 1 µM had no effect whereas 
a  higher  concentration  of  1  mM  enhanced  EPSCs  amplitude  by  ~80%.  Each 
concentration was tested at least in 3 CA3 pyramidal neurones. Fitting the relationship 
with a logistic function yields an EC50 of 12 μM.   
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Although higher concentrations were not tested, these results clearly highlight 
the dose-dependent effects of BRS-015 on synaptic transmission as shown by 
the sigmoid relation between dose and enhancement of EPSC amplitude. The 
compound appeared active at concentrations as low as 1 µM indicating good 
tissue  penetration  and  high  propensity  to  modulate  excitatory  synaptic 
transmission. In summary, BRS-015 has a powerful enhancing and reversible 
action on excitatory synaptic transmission at mossy fibre – CA3 synapses (EC50 
of 12 μm) without altering the intrinsic electrical properties in CA3 pyramidal 
neurones.  
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6.3.  Effect  of  BRS-015  on  the  paired-pulse  ratio  and  decay-time 
constant of evoked EPSCs 
The evidence presented so far indicated that BRS-015 facilitated mossy fibre-
CA3 pyramidal cell transmission and increased the amplitude of mossy fibre 
evoked-EPSCs  by  >80%  (Figure  34).  A  possible  explanation  for  such  an 
increase could be that compound BRS-015 increases glutamate release from 
presynaptic  sites.  Alternatively,  increased  glutamate  binding  to  postsynaptic 
receptors might occur in the presence of BRS-015. Therefore our next step was 
to analyse changes in the paired-pulse ratio of the amplitude of evoked synaptic 
responses and to examine differences in the  decay-time constant of evoked 
EPSCs  following  BRS-015  application.  These  two  measurements  were 
performed to gain insight into changes affecting the release probability and the 
biophysical properties of postsynaptic receptors respectively.  
The ratio of amplitude of two consecutive EPSCs elicited with a 50 ms interval 
(20 Hz) was compared before and after application of BRS-015 (100 µM). The 
PPR  of  EPSC amplitude  was  not  significantly  affected  by  BRS-015  (control: 
1.86 ± 0.34, BRS-015: 1.52 ± 0.14, n = 5; P > 0.05). This result could suggests 
that BRS-015 does not influence glutamate release probability at large mossy 
fibre – CA3 synapses.  
 
Figure 34: Lack of effect of BRS-015 on paired-pulse ratio of mossy fibre-evoked 
EPSCs. Summary histogram showing a non-significant reduction of the paired-pulse 
ratio of EPSCs amplitude in the presence of BRS-015 (100 µM). Data are presented 
from 5 CA3 pyramidal neurones; P > 0.05, paired t-test. 
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Compound BRS-015 could also act on glutamate receptors in the postsynaptic 
membrane, by a mechanism that enhances glutamate receptor affinity and thus 
glutamate binding. Indeed,  glutamate  binding  to postsynaptic  receptors for  a 
longer time could lead to larger EPSCs in pyramidal neurones. Differences in 
the EPSC decay-time constant could indicate such an increase in affinity. To 
analyse EPSCs kinetics, consecutive traces were averaged and scaled to their 
maximum peak amplitude in control conditions and in the presence of BRS-015 
(100 µM). As shown in Figure 35, EPSCs decays were then fitted with a single 
exponential function to extract the decay-time constant, m.  
 
Figure 35: BRS-015 has no effect on dentate-evoked EPSCs decay-time constant 
in CA3 pyramidal neurones: A: Superimposed peak-scaled EPSCs (averages on 5 
consecutive trials) taken from 1 CA3 pyramidal cell in control condition (black trace) 
and under superfusion of BRS-015 (100 µm) (red trace). B: Summary bar plot showing 
no significant difference in EPSC decay-time constant between control and BRS-015 
groups (Data presented are from 5 neurones (5 slices) P > 0.05, paired t-test). 
Comparing  m  before  and  after  superfusion  of  BRS-015  did  not  yield  a 
significant difference (mcontrol 40.8 ± 7.8 ms, n = 5; P < 0.05, mBRS-015: 
37.9 ± 4.3 ms, n = 5; P < 0.05). Thus it is unlikely that the enhancement of 
EPSC amplude induced by BRS-015 resulted from changes in EPSC kinetics, 
as those observed when glutamate spills over from neighboring synapses or 
when receptor affinity has increased.   
Control BRS-015
0
25
50

E
P
S
C
 
(
m
s
)
Peak-scaled
A BBlanka Szulc                                                                                                           Results and Discussion 
 
107 
 
6.4. Effect of BRS-15 on pharmacologically isolated EPSCs 
Electrical  stimulation  in  the  dentate  gyrus  evokes  EPSCs  in  CA3  pyramidal 
neurones whose components may be pharmacologically distinguished by using 
appropriate specific glutamate receptor antagonists. Hence,  we analysed the 
effect  of  BRS-015  on  firstly  NMDA  receptor-mediated  EPSCs  and  secondly, 
kainate receptor mediated EPSCs and compared the results to those obtained 
when recording mixed AMPA/kainate EPSCs as shown in the results above.  
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6.4.1. Effect on NMDA receptor–mediated EPSCs 
In order to record NMDA-mediated EPSCs, CA3 pyramidal cells were held in 
voltage-clamp  mode  at  Vholding  =  +40  mV  while  GABAA,  GABAB,  AMPA  and 
kainate receptors were blocked by bath application of picrotoxin (50 µm), CGP 
52432 (5 µm) and NBQX (20 µm), respectively. As shown below in Figure 36 
NMDA–EPSCs had the tendency to run-down. However, superfusion of BRS-
015 (100 µM) had no major effect on their amplitude (decreased by 4.0  13.5% 
of  control,  n  =  6;  P  >  0.05,  paired  t-test).  NMDAR-mediated  EPSCs  were 
completely abolished with addition of D-APV (50 µm) in the perfusion solution 
showing that they were mediated by NMDA receptors. These results show that 
NMDA receptor-mediated EPSCs are not affected by compound BRS-015.  
 
Figure  36:  BRS-015  does  not  affect  NMDA  receptor-mediated  EPSCs  in  CA3 
pyramidal neurones. Plot of normalised NMDA receptor-mediated EPSC amplitude 
against  time  showing  no  effect  of  BRS-015  (100  μM)  when  AMPA  and  kainate 
receptors were blocked with NBQX (20 µM). Representative NMDA receptor-mediated 
currents (NMDAR-EPSC, averages of 5 consecutive trials) are shown on top. (Data 
from  6  CA3  pyramidal  neurones.)  There  was  a  slight  run-down  of  NMDA  receptor 
mediated EPSC that developed with time. 
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6.5. Effect on kainate receptor-mediated EPSCs 
Kainate  receptor-mediated  EPSCs  form  a  minor  component  of  the  evoked 
response  implying  that  kainate  receptors  could  potentially  be  modulated  by 
BRS-015.  In  order  to  isolate  kainate  receptor-mediated  EPSCs,  AMPA 
receptors  were  blocked  by  addition  of  GYKI-53655  (50  µM)  in  the  perfusion 
solution together with all other antagonists. Again, cells were held in voltage-
clamp  at  -60  mV  using  a  CsCl-containing  micropipette.  After  obtention  of  a 
stable baseline, BRS-015 was then added to the bath and the effect on kainate 
receptor mediated transmission analysed. BRS-015 (100 µM) did not affect the 
amplitude of kainate receptor-mediated EPSCs (decrease of 2.2  1.4%, n = 5, 
P > 0.05, paired t-test, Figure 37). The holding current measured before and 
after application of BRS-015 was not significantly different either (delta ∆Iholding: 
10.9 ± 8.3 pA, P > 0.1, paired t-test).  
 
 
Figure  37:  No  effect  of  BRS-015  on  kainate  receptor-mediated  EPSCs  in  CA3 
pyramidal neurones. Plot of normalised EPSC amplitude against time showing no 
effect of BRS-015 (100 μM) when NMDA receptors were blocked with D-AP5 (50 µm) 
and AMPA receptors blocked with GYKI 53655 (50 μM) (Data from 5 CA3 pyramidal 
neurones). Representative kainate receptor mediated currents (KAR-EPSC, averages 
of 5 consecutive trials) are shown on top. 
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The final application of  NBQX (20 µM) completely abolished evoked EPSCs 
demonstrating that they were mediated by kainate receptors (not shown). Thus, 
neither NMDA receptors nor kainate receptors seemed to be directly modulated 
by compound BRS-015 prompting the possibility that it could act as an AMPA 
receptor modulator. 
6.6. Summary of pharmacological manipulations 
So far, the cumulative pharmacology experiments seemed to indicate that BRS-
015 facilitates glutamatergic neurotransmission by enhancing AMPA receptor 
function. Using selective glutamate receptor antagonists,  we determined that 
BRS-015 enhanced mixed AMPA/kainate receptor-mediated EPSCs but had no 
effect  on  NMDA  or kainate  receptor-mediated  EPSCs  studied  in  isolation.  A 
histrogram  summarising  the  results  obtained  from  different  pharmacological 
manipulations is shown below in Figure 38.  
 
Figure 38: Bar chart summarising the effect of BRS-015 on pharmacologically 
isolated EPSCs in CA3 pyramidal neurones. BRS-015 selectively potentiated mixed 
AMPA and kainate receptor-mediated EPSCs but had no effect on NMDA or kainate 
receptor-mediated EPSCs (**, P < 0.01; unpaired t-test).  
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Introduction  
 
Current drug regimens used to alleviate the symptoms of cognitive decline (nootropic drugs  
or cognitive enhancers) do not effectively treat memory impairments in the demented brain. 
In  order  to  develop  new  therapeutics,  we  have  taken  inspiration  from  nature  where  a  
molecule (clausenamide 1) isolated from the Chinese plant Clausena Lansium has shown  
neuroprotective properties that are interesting for the treatment of degenerative disorders,  
but it is not accessible in sufficient amounts to be developed into a medicine.  
 
 
 
 
.  
 
 
We obtained the core structure of  
clausenamide 1 via Intramolecular  
Acylal  Cylisation ( IAC) f rom a  
simple  cylisation p recursor  6  
available from an amino acid 2 in  
multi-gram  amounts.  In  our  
synthesis,  DHP-001  7 w as a n  
advanced  intermediate  in  the  
approach towards clausenamide 1.  
  
DHP-001 facilitates synaptic transmission to CA3 pyramidal neurons  
  
A) Extracellular recordings 
A: Plot of normalised EPSC amplitude against time showing an increase upon superfusion of DHP-001 (100 µM) and depression  
by the group II metabotropic glutamate receptor agonist DCG-IV (1 µM). Representative examples for each condition are shown  
on top. (Data from one CA3 pyramidal neuron.)  B: Summary plot from 5 neurons (each point represent the mean ± s.e.m). 
Methods  
We present here the pharmacological properties of our novel compound 7 DHP-001 in native  
hippocampal slices. 
 
Patch-clamp recordings were obtained from granule cells and CA3 pyramidal neurons at  
post-natal day 21 – 40. All recordings were made at room temperature. 
 
CA3 pyramidal neuron  Transverse hippocampal slice  Infrared video-microscopy  Dentate granule cell 
Conclusions  
 
We discovered a new modulator of AMPA receptor mediated synaptic transmission that has  
powerful  effects  at  mossy  fibre  synapses.  It  potentiated  evoked  excitatory  synaptic  
transmission in CA3 pyramidal neurons by ~70%. It also facilitated the induction of NMDA-
receptor independent mossy fibre LTP. It has therefore good potential for treating memory  
related disorders 
Aims 
 
The aim of our research is to develop a novel synthetic approach to the core structure of  
clausenamide and related analogues to evaluate their effects on synaptic transmission. 
 
Synthesis of DHP-001  
  
 DHP-001 modulates AMPA receptors 
  DHP-001 facilitates the induction of mossy fibre LTP    
Left: Plot of field-EPSP amplitude against time showing that a sub-threshold high-frequency stimulus train (HFS1: 100 Hz for 1  
second, repeated 3 times with an interval of 10 seconds) does not induce LTP in contrast to a second sub-threshold stimulus train  
(HFS2) delivered 20 minutes following DHP 001 (100 µM) superfusion, leading to sustained LTP. Summary plot from 5 slices  
(each point represents the mean ± s.e.m). Right: No effect of DHP-001 during sustained LTP induced by HFS (3 times 100 Hz for  
1 sec, every 10 sec) and depression by DCG-IV (1 µM).  
Left: Plot of normalised EPSC amplitude against time showing no effect of DHP-001 (100 µM) in the presence of the AMPA  
receptor  blocker  GYKI  53655  (50  µM).  Representative  kainate  receptor  mediated  currents  (KAR-EPSC,  averages  of  5  
consecutive trials) are shown on top. (Data from 5 CA3 pyramidal neurons.) Right: NMDA receptor-mediated EPSCs are not  
affected by DHP-001 (V holding = +40 mV, data from 6 pyramidal neurons). 
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with a logistic function yields an EC50 of 12 µM. 
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examples for each condition are shown on top. (Data from one CA3 pyramidal  
neuron.) Right: Summary plot from 5 neurons (each point represent the mean ±  
s.e.m). 
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Whether this selective action on mixed AMPA/KA receptor-mediated EPSCs is 
a consequence of direct modulation of AMPA receptors by BRS-015 remains to 
be demonstrated in studies performed in expression systems and in binding 
studies.  Other  potential  candidate  mechanisms  would  involve  direct  AMPA 
receptor  subunit  phosphorylation  and  increased  cell  surface  expression  of 
AMPA receptors. 
6.7.  Effect  of  BRS-015  on  glutamate-evoked  currents  in  CA3 
pyramidal neurones. 
One potential mechanism by which BRS-015 could modulate AMPA receptor-
mediated  neurotransmission  is  by  direct  binding  to  AMPA  receptors  in  the 
postsynaptic membrane. If this was the case, then BRS-015 should enhance 
glutamate-evoked currents recorded from CA3 pyramidal neurones. To test this 
hypothesis,  L-glutamate  was  puff-applied  with  a  Picospritzer  (100  mM 
intrapipette, puff pressure 5 – 20 psi, puff duration 10 -50 ms; every 60 sec) 
approximately 50-150 m away from a patched CA3 pyramidal neuronee held 
with a Cs-Cl electrode at Vholding=-70 mV. GABA receptors were blocked with 
picrotoxin (50 µm) and CGP 52432 (5 µm), and NMDA receptors with D-APV 
(50 µm). As shown in Figure 39, when pressure-applying glutamate onto the 
recorded neurone, inward currents were recorded as a reversible increase in 
Iholding  that  lasted  0.8  –  1.2  seconds.  Repetitive  glutamate  application  every 
minute in control conditions elicited inward currents that did not show signs of 
desensitisation. Superfusion of BRS-015 (100 µM) increased the amplitude of 
glutamate-evoked  currents  by  51.3    14.7%  (n  =  5;  P  <  0.05,  paired  t-test, 
Figure 39). This effect was reversible and decreased before wash-out, similar to 
the effects on electrically-evoked EPSCs. Application of CNQX (50 M) at the 
end of the experiments almost abolished glutamate-evoked currents confirming 
that they were largely mediated by AMPA and KA receptors.  
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Figure  39:  BRS-015  enhances  glutamate-evoked  currents  in  CA3  pyramidal 
neurones: Amplitude of puff-evoked glutamate currents plotted against time showing a 
reversible increase upon superfusion of BRS-015 (100 µM). Application of CNQX (50 
µM)  at  the  end  of  the  experiment  demonstrated  that  glutamate  responses  were 
mediated by AMPA and kainate receptors, but also involved other receptors as judged 
by the residual current. Data presented are from 3 different slices. Traces on top show 
glutamate currents recorded in the different pharmacological conditions (single traces). 
These experiments showed that a postsynaptic cationic conductance mediated 
by direct activation of AMPA and kainate receptors with exogenous glutamate 
induced inward currents that were substantially enhanced, thus mimicked the 
effect of BRS-015 on stimulus-evoked EPSCs in CA3 neurones. Interestingly, 
the level of facilitation of glutamate-evoked mixed AMPA/KA currents was of the 
same order of magnitude as that of evoked EPSCs.  
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6.8. Effect of BRS-015 on mossy fibre LTP 
In addition to the acute enhancing action of BRS-015 on baseline excitatory 
synaptic transmission at mossy fibre synapses, we tested the hypothesis that 
BRS-015  could  modulate  LTP  induction.  LTP  is  a  long  lasting  change  in 
synaptic strength that is expressed when presynaptic afferences are stimulated 
repetitively at high frequency (e.g. 100 Hz). The classic Hebbian LTP is present 
at  Schaffer  collateral  synapses  in  the  CA1  region  and  it  is  dependent  on 
NMDAR  (Harris  and  Cotman,  1986).  Unlike  LTP  in  the  CA1  region,  the 
induction of mossy fibre LTP is independent of NMDAR activation. However, 
recent  studies  by  Rebola  indicated  an  existence  of  NMDAR-dependant 
metaplasticity at MF synapses, in which NMDARs act as a switch to generate 
LTP,  which  is  expressed  and  maintained  by  the  presence  of  an  increased 
number of active AMPA receptors at the potentiated synapse (Rebola et al., 
2011). 
In a first set of experiments,  we examined the effect of BRS-015 on NMDA 
receptor-independent  mossy  fibre  LTP  (MF-LTP)  in  slices  superfused  with 
picrotoxin (50 μM), CGP-52432 (10 M) and D-AP5 (50 μM). A bipolar stimulus 
electrode was placed in the stratum granulosum in the dentate gyrus to activate 
granule cells and their mossy fibre inputs and a second electrode positioned in 
the distal part of stratum radiatum, to activate associational-commisural fibres 
(A/C) acting as a control pathway (Figure 40). 
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Figure  40:  Drawing  of  the  experimental  design.  A  stimulus  electrode  (SE1)  was 
positioned in the hilus at the start of area CA3 stimulating mossy fibre (red) exiting a 
granule cell in the dentate gyrus (DG) and the recording electrode (RE) in stratum 
lucidum next to synapses on pyramidal cell dendrites (blue). Second stimulus electrode 
(SE2) was positioned in the distal part of stratum radiatum, to activate associational-
commisural fibres (A/C) acting as a control pathway. 
Electrical  stimulation  was  delivered  every  10  seconds  at  one  or  the  other 
pathways and tetanic stimulation was delivered to the mossy fibre input only. As 
shown  in  Figure  41,  a  subtreshold  stimulus  burst  HFS1  (100  Hz  for  1  sec) 
delivered  in  the  stratum  granulosum  caused  postsynaptic  potentiation  of  f-
EPSPs (74.5 ± 30.6%, n = 4, P > 0.05) but their amplitude returned to baseline 
after  5-7  minutes.  This  stimulus  protocol  did  not  affect  f-EPSPs  evoked  by 
stimulation  of  A/C  fibres  (Figure  42)  indicating  little  cross-contamination 
between  the  two  pathways.  Consecutive  application  of  BRS-015  (100  µm) 
increased stratum granulosum-evoked f-EPSPs by 81.4 ± 43.8% (n = 4, P > 
0.05) but had no significant effect on A/C evoked responses (increase of 8.9 ± 
14.7%, n = 5, P > 0.05). In the continous presence of BRS-015, the strength of 
the stratum granulosum stimulus was then reset to match the amplitude of f-
EPSPs before HFS1. After a period of recording of baseline activity, a second 
stimulus (HFS2) of the same strength as HFS1 was then applied. The amplitude 
of f-EPSPs measured 20 minutes after HFS2 was increased by 47.8 ± 10.6% (n 
=  4,  P  <  0.05,  paired  t-test).  Final  application  of  DCG-IV  (1  µM)  depressed 
stratum-granulosum evoked f-EPSPs by 82.8 ± 3.8 % (n = 4, P < 0.01, paired t-
test) confirming that they were mediated by mossy fibre synapses (not shown). Blanka Szulc                                                                                                           Results and Discussion 
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Figure  41:  BRS-015  lowers  the  threshold  for  induction  of  mossy  fibre  LTP. 
Normalised f-EPSP amplitude plotted against time showing that a sub-threshold high-
frequency stimulus train (HFS1: 100 Hz for 1 second) does not induce LTP in contrast 
to a second sub-threshold stimulus (HFS2) delivered 20 minutes following  BRS-015 
(100 µM) superfusion, leading to sustained LTP. A stimulus reset was performed when 
the enhancing effect of BRS-015 on f-EPSP amplitude had reached a maximum. The 
stimulus  strength  was  then  lowered  to  match  the  size  of  f-EPSPs  before  HFS1. 
Representative  paired  f-EPSPs  (inter-stimulus  interval  20  ms)  are  shown  on  top 
(averages  of  5  consecutive  trials).  Data  are  plotted  as  mean  ±  S.E.M  and  are 
presented from recordings obtained in  4 slices from 4 animals.  Picrotoxin (50  M), 
CGP-52432 (10 M) and D-AP5 (50 M) were included in the perfusion solution. 
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Figure 42: BRS-015 does not alter basal synaptic transmission at A/C fibre – CA3 
synapses. Data are represented as mean ± S.E.M and are from the same experiments 
as those shown in Figure 41. 
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It has been shown that NMDA receptors contribute to a form of LTP that is 
expressed  postsynaptically  at  mossy  fibre  –  CA3  synapses  (Rebola  et  al., 
2011).  This  form  of  LTP  differs  from  the  NMDA  receptor  independent  LTP 
examined above, the locus of which is presynaptic. Thus, in a second set of 
experiments, we explored whether the effect of BRS-015 on the induction of 
MF-LTP differed when NMDARs were left intact and were not blocked. In this 
case,  D-AP5  was  omitted  from  the  perfusion  medium  but  the  same  LTP 
induction paradigm was used. As shown in Figure 43, a subthreshold stimulus 
burst  HFS1  (100  Hz  for  1  sec)  delivered  in  the  stratum  granulosum  again 
caused postsynaptic potentiation of f-EPSPs (55.4 ± 17.9%, n = 10, P > 0.05) 
but their amplitude returned to baseline. Consecutive application of BRS-015 
(100 µM) increased stratum granulosum-evoked f-EPSPs by 24.9 ± 9.1% (n = 
7, P > 0.05). The amplitude of f-EPSPs measured 20 minutes after HFS2 was 
also enhanced by 79.6 ± 16.9% (n = 7, P < 0.05, paired t-test). Final application 
of DCG-IV (1 µM) depressed f-EPSPs to 56 ± 15.4% (n = 5, P < 0.01, paired t-
test) confirming that they were mediated by mossy fibre synapses. 
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Figure  43:  Effect  of  BRS-015  on  mossy  fibre  LTP  in  the  absence  of  NMDA 
receptor blockade. Normalised f-EPSP amplitude plotted against time showing that a 
sub-threshold  high-frequency  stimulus  train  (HFS1:  100  Hz  for  1  second)  does  not 
induce LTP in contrast to a second sub-threshold stimulus (HFS2) delivered 20 minutes 
following BRS-015 (100 µM) superfusion, leading to sustained LTP. The pronounced 
depression of evoked responses consecutive to DCG-IV application confirms that they 
were mediated by mossy fibre synapses. A stimulus reset was performed when the 
enhancing  effect  of  BRS-015  on  f-EPSP  amplitude  had  reached  a  maximum.  The 
stimulus  strength  was  then  lowered  to  match  the  size  of  f-EPSPs  before  HFS1. 
Representative  paired  f-EPSPs  (inter-stimulus  interval  20  ms)  are  shown  on  top 
(averages  of  5  consecutive  trials).  Data  are  plotted  as  mean  ±  S.E.M  and  are 
presented from recordings obtained in 4 slices. Picrotoxin (50 M) and CGP-52432 (10 
M) were included in the perfusion solution. 
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Comparing the magnitude of LTP measured 15 minutes after when BRS-015 
(100  µM)  was  applied  in  the  presence  or  absence  of  an  NMDA  receptor 
antagonist  yielded  a  non-significant  increase  of  22  ±  16.5%  when  NMDA 
receptors where left unblocked (Figure 44, LTP-D-AP5: 44.6 ± 16.5%, n = 4; 
LTP- no D-AP5, 66.6 ± 21.7% n = 8; P > 0.05, Wilcoxon Rank Sum test for 
unpaired data). 
 
Figure 44: Comparing the effect of BRS-015 on mossy fibre LTP in the presence 
or  absence  of  the  NMDA  receptor  antagonist  D-AP5.  All  experiments  were 
performed  in  the  presence  of  GABAA  and  GABAB  receptor  blockers  added  to  the 
perfusion solution. 
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In  a  third  set  of  experiments,  the  effect  of  BRS-015  was  analysed  when 
synapses  had  already  been  potentiated  using  a  standard  high-frequency 
stimulation  induction  protocol  made  of  3  bursts  of  100  stimuli  at  100  Hz 
separated by 10 seconds. A shown in Figure 45, this protocol induced a large 
post-tetanic potentiation of f-EPSPs followed by decay and a period of mossy 
fibre LTP. When BRS-015 (100 µM) was applied during this period of sustained 
plasticity no effect on f-EPSPs amplitude was observed (0.5  15 % decrease, n 
= 4; P > 0.05). 
 
 
Figure  45:  BRS-015  does  not  affect  synaptic  transmission  at  synapses  that 
undergo mossy fibre LTP. No effect of BRS-015 during sustained LTP induced by 
HFS (3 times 100 Hz for 1 sec, every 10 sec) and depression by DCG-I  (1 μM). 
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Taken  together,  these  experiments  demonstrated  that  BRS-015  lowers  the 
threshold for induction of MF-LTP without altering the shorter form of plasticity 
known  as  PTP.  They  also  suggested  that  A/C  synapses  have  a  different 
sensititvity to BRS-015 compared to mossy fibre synapses. Furthermore, they 
illustrated  that  the  magnitude  of  plasticity  attained  when  bath-applying  the 
compound had little dependence upon NMDA receptors being available, in line 
with  a  mechanism  driven  by  AMPA  receptor  modulation.  Lastly,  compound 
BRS-015 had  no  effect  when  applied after  mossy fibre  synapses  underwent 
LTP. Most likely, saturation of LTP might have prevented further enhancement 
of f-EPSPs by the compound (ceiling effect).  
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6.9.  Effect  of  single  enantiomers  of  BRS-015  on  evoked 
glutamatergic synaptic transmission from the dentate gyrus to CA3 
From  our  results,  we  have  shown  that  BRS-015  is  a  highly  potent  small 
molecule,  which  causes  a  large  increase  in  synaptic  transmission  and 
potentiation and as such, has good potential for further development. However, 
despite its activity, a key question remains which relates to its structure. BRS-
015 is obtained as a racemate following the intramolecular acylal cyclisation 
and as such, both the (+)- and (-)-enantiomers were present in our assays. The 
initial focus of this thesis was directed towards identification of the molecular 
target and we were therefore unable to separate each enantiomer due to a lack 
of time, but if BRS-015 or related congeners are to progress towards pre-clinical 
development, there is a need to determine whether it is the racemate or a single 
enantiomer that is active and accounts for its enhancing activity.  
The  literature  is  replete  with  drugs  that  have  been  supplied  to  patients  as 
racemic mixtures, only for the deleterious effects of one of the enantiomers to 
emerge. The most prominent of these is thalidomide, which caused such tragic 
consequences  in  unborn  infants  the  1970’s.  It  was  supplied  as  a  single 
enantiomer for the treatment of morning sickness, but underwent racemisation 
under physiological conditions, where its supposedly inactive enantiomer led to 
its notorious effects on limb growth. As such, regulatory agencies have since 
pushed  for  single  enantiomers  as  treatments  and  if  BRS-015  or  a  related 
compound is to progress towards development as a drug, we therefore need to 
address  this  key  question  and  investigate  the  activity  and  toxicity  of  both 
enantiomers.  
There are a number of methods that are available whereby enantiomers can be 
separated, but due to time restraints, BRS-015 was separated by chiral HPLC 
of the racemate by Reach Separations who were able to separate ~ 50 mg of 
each enantiomer from 200 mg of the racemate. With each enantiomer in hand, 
we looked at the effect of (-)- and (+)-BRS-015 on mossy fibre f-EPSPs at a 
concentration of 100 µM. As can be seen below, superfusion of (-)-BRS-015 
(100 µM) caused an increase in f-EPSP amplitude by 73.5  15.1% of control 
(Figure 46; n = 5, P < 0.05), paired t-test). However, under the same conditions, Blanka Szulc                                                                                                           Results and Discussion 
 
123 
 
superfusion  of  (+)-BRS-015  (100  µM)  had  no  effect  on  f-EPSP  amplitude 
(Figure 47; increase of 0.2  3.2% of control n = 5, P > 0.05, paired t-test). Final 
application of DCG-IV (1 µM) depressed stratum-granulosum evoked f-EPSPs > 
70%, confirming that they were mediated by mossy fibre synapses. 
 
 
 
 
 
Figure 46: The effect of (-)-BRS-015 on basal synaptic transmission. A: Plot of 
EPSP amplitude against time showing an increase upon superfusion of (-)-BRS-015 
(100  μM)  and  depression  upon  superfusion  by  DCG-IV  (1  µM)  (data  from  5 
extracellular recordings). Representative example traces (averages of 5 consecutive f-
EPSPs) obtained in each condition are shown above the plot. 
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Figure 47: The effect of (+)-BRS-015 on basal synaptic transmission. A: Plot of 
EPSP amplitude against time showing no change upon superfusion of (+)-BRS-015 
(100  μM)  and  depression  upon  superfusion  by  DCG-IV  (1  µM)  (data  from  5 
extracellular recordings). Representative example traces (averages of 5 consecutive f-
EPSPs) obtained in each condition are shown above the plot. 
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7.0. Toxicity of BRS-015 
 
As  a  result  of  the  fact  that  BRS-015  had  displayed  significant  potential  and 
enhanced EPSPs and fEPSCs to such a great extent, we elected to look at the 
toxicity profile of the racemate as all studies to date, had been performed on 
this mixture. The compound was first examined for its effects against CrFK cells 
(a feline liver cell line), which in our research group had proven useful for the 
determination of toxic compounds and was carried out at Vetsuisse in Zurich by 
Mr Christopher Asquith in the Hilton group.  
The  method  used  for  the  assay  was  the  MTT  assay,  where  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT)  was  used  to 
determine the compounds’ toxicity and viability of cells by MTT dye reduction. 
First  10,000  CRFK  cells  were  eluted  with  Roswell  Park  Memorial  Institute 
(RPMI) 1640 medium supplemented with 10% fetal bovine serum 100 M/mL 
Glutamine and 1% v/v antibiotic antimycotic (Ab/Am) (total volume 200 μL) onto 
96-well plates and incubated for 24 hours (37 ºC, 5% CO2). The medium was 
then removed by vacuum and replaced with the specific dilution (1 nM-1 mM) to 
test the toxicity (3 x 200 μL). BRS-015 was then suspended in 2% DMSO and 
RPMI  1640  medium  supplemented  with  10%  fetal  bovine  serum  100  M/mL 
Glutamine  (Gibco)  and  1%  v/v  antibiotic/  antimycotic  (Ab/Am)  (Gibco)  and 
diluted to the desired concentrations. After 24 hours, the wells were observed 
and the medium removed. The cells were then suspended in RPMI 1640 phenol 
red-free medium (180 μL) and MTT (3 mg/mL) (20 μL) and incubated 4 hours at 
(37 ºC, 5% CO2). The medium was then removed by vacuum and the cells were 
lysed with methanol (200 μL) to reveal a bright purple formazan product. The 
methanol-formazan absorbance was then determined at 570 nm using a BioTek 
Synergy  HT  plate  reader  with  KC4  software.  Data  was  expressed  as  the 
percentage  of  viability  (normalised  to  cells  with  no  exposure)  of  compound-
treated wells compared to that of untreated control wells. 
 
The 24-hour assay was designed to rule out any major toxicity issues, which 
was important as cytotoxic compounds removed at an early stage can prevent 
false positives and later development of toxic core structures. The MTT assay 
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can  be  used  for  measuring  the  viability  of  living  cells.  The  mitochondrial 
reductase enzymes reduce the tetrazolium salt, by cleavage of the central core 
to  produce  an  insoluble  formazan,  which  gives  a  purple  colour.  The  assay 
measures  the  cellular  metabolic  activity  via  NADPH-dependent  cellular 
oxidoreductase  enzymes  and  the  amount  of  formazan  dye  is  directly 
proportional to the amount of viable cells (ratio between number of live versus 
dead cells).  
 
BRS-015  performed  well  with  a  high  concentration  CC50  of  847.0  μM.  This 
leaves  a  wide  range  potential  for  dosing  and  avoids  any  short-term  toxicity 
issues (Table 6).  
 
 
Table  6:  Results  of  BRS-015  toxicity  screening. 
a  Geometric  mean,  each 
concentration tested in triplicate after 24 hours, as a difference of the untreated cells. 
 
To  further  develop  BRS-015  and  direct  it  towards  lead  development,  further 
toxicity  analysis  was  carried  out  using  HepG2  cells,  which  are  a  human 
hepatocellular carcinoma cell line, whose cells are epithelial in morphology, as 
well  as  the  3T6  murine  cell  line,  which  was  derived  from  a  primary  mouse 
embryonic fibroblast cells. Using this assay, cells (3T6 murine fibroblast) were 
grown to ~80% confluency in a 10-cm dish, before splitting to 96-well plates, 
10% of the 10-cm dish per 96-well plate, 50 µl per well. One column of 8 wells 
was left empty (to be a reagent blank in the assay). The cells were then allowed 
to  grow  overnight  before  drug  was  added  to  four  wells  at  the  starting 
concentration (typically 200 µM) and in subsequent wells down a 1 in 2 dilution Blanka Szulc                                                                                                           Results and Discussion 
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series with the final four wells of cells where no drug was present. This allowed 
two drugs to be tested per 96-well plate. The cells were left in the presence of 
drug for 48 hrs. The medium was removed and the cells washed with PBS.  The 
cell number was determined using a CytoTox 96
® Non-Radioactive Cytotoxicity 
Assay (Promega) which is used to measure lactate dehydrogenase (LDH) that 
is released from lysed cells. LDH is a stable cytosolic enzyme that is measured 
with  an  enzymatic  assay.  The  addition  of  the  reaction  buffer  results  in  a 
conversion  of  a  tetrazolium  salt  into  a  red  formazan  product  that  can  be 
measured  with  a  96-well  plate  reader.  The  amount  of  colour  formed  is 
proportional to the number of cells lysed.  
Cells were lysed with 50 µl/well of single-strength lysis buffer for 45-60 minutes.  
This was followed by 50 µl/well of LDH assay reagent for 30 minutes before 
terminating  the  reaction  by  the  addition  of  50  µl/well  stop  buffer.  The 
absorbance was read at 490 nm and the absorbance relative to untreated wells 
(untreated cells = 1.0) was plotted against drug concentration. The LD50 was 
determined graphically from the concentration at which the absorbance falls to 
50% of the control value. 
From this assay, it was shown that BRS-015 was essentially non-toxic  (2 mM 
max  tested,  n=6)  using  the  3T6  cell  line.  In  the  HepG2  cell  line,  BRS-015 
presented with an LD50 of 914 µM, showing that HepG2 cells are marginally 
sensitive,  with  an  LD50  of  0.9  mM,  which  is  a  concentration  that  can  be 
considered to be high.  
From  these  combined  assays,  we  clearly  demonstrated  that  BRS-015  is 
surprisingly non-toxic to two different species derived cell lines and that due to 
its activity, it is a highly non-toxic compound that warrants further investigation.  
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8.0. Discussion and Conclusions 
 
The research described in this thesis was based on the synthesis and activity of 
the novel compound BRS-015, which was discovered during the total synthesis 
of  the  natural  product  clausenamide.  Following  its  synthesis,  analysis  of  its 
electrophysiological profile in acute hippocampal slices was carried out in order 
to try to determine its pertinent biological activity and mode of action.  
Despite extensive studies into the effects and biological activities of nootropic 
drugs in the CA1 region of the hippocampus, the literature is surprisingly silent 
about  their  effects  in the  CA3  region  (Kaneko  et al.,  1997,  Moriguchi et al., 
2013). Mossy fibre – CA3 pyramidal cell synapses provide a major excitatory 
input to the hippocampus and as such, are an ideal model with which to study 
the effects of nootropic drugs. In particular, mossy fibre synapses present a 
form of LTP whose induction is independent of NMDA receptors, thus narrowing 
our investigations into the mechanisms by which nootropic drugs might affect 
the threshold for synaptic plasticity. In addition, the large size of mossy fibre 
terminals  allows  direct  patch-clamp  measurements  to  be  undertaken  which 
enable investigations into presynaptic mechanisms, e.g. an effect of nootropic 
drugs on presynaptic ion channels or receptors. We therefore used this model 
as a means to determine the effect of compounds that were discovered during 
the  total  synthesis  of  clausenamide.  Finally,  we  limited  our  investigations 
towards glutamatergic transmission to CA3 pyramidal neurones.  
8.1. The effect of BRS-015 on dentate – CA3 neurotransmission 
Our  results  clearly  demonstrate  that  our  novel  compound  has  a  reversible 
enhancing effect on excitatory synaptic transmission mediated by hippocampal 
mossy fibre synapses. We analysed the effect of BRS-015 on basal synaptic 
transmission from the dentate gyrus to CA3 (Figures 27–38) and found that 
superfusion of BRS-015 had a powerful enhancing effect when compared with 
piracetam with annual sales of over $2 billion (Figure 28), on responses elicited 
by activation of mossy fibre synapses. This effect was reversible and was not 
due to the effect of the solvent DMSO, as shown by the separate application of 
DMSO, which clearly had no effect on basal synaptic transmission (Figure 27).  Blanka Szulc                                                                                                           Results and Discussion 
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In addition to bath-application, we also used local puff application of BRS-015 in 
order to deliver the compound near to active synapses made onto the recorded 
neurones and found that it increased synaptic transmission without altering the 
ratio of amplitude of paired f-EPSPs (Figures 29, 30). 
These findings were validated in single cell experiments where we analysed the 
effects of BRS-015 on the electrical properties of CA3 pyramidal neurones as 
well as evoked EPSCs. Whilst it had no effect on the membrane potential, input 
resistance or firing rate in CA3 pyramidal neurones, superfusion of BRS-015 
(100 µM) reversibly enhanced the amplitude of evoked EPSCs by around 75%. 
Furthermore,  the  effect  of  BRS-015  on  dentate-evoked  EPSCs  was 
concentration-dependent with an EC50 of 12 μM (Figure 33). 
We examined the effect of BRS-015 on synaptic transmission in the continuous 
presence of AMPA, AMPA/kainate and NMDA receptor antagonists in order to 
shed light on putative receptor targets (Figure 38). When AMPA receptors were 
blocked  by  GYKI-53655,  superfusion  of  BRS-015  had  no  effect  on  kainate 
receptor  mediated  EPSCs.  Similarly,  NMDA  receptor  mediated  EPSCs 
recorded  in  the  presence  of  the  AMPA/kainate  antagonist  NBQX  were  not 
affected by BRS-015. These results strongly suggested that BRS-015 may act 
as  a  positive  modulator  of  AMPA  receptors,  thus  enhancing  synaptic 
transmission.  
8.2. Mechanistic insights into the mode of action of BRS-015 
We  demonstrated  that  BRS-015  does  not  change  the  intrinsic  electrical 
membrane properties of CA3 pyramidal cells, namely the membrane potential, 
the  input  resistance, or the  mean firing  rate.  These  results  suggest  that  the 
enhancing effect of BRS-015 on evoked EPSCs in CA3 pyramidal neurones is 
unlikely  to  result  from  changes  in  network  excitability  and  emphasizes  the 
potential of this compound to modulate an excitatory synaptic conductance in 
pyramidal neurones.  
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8.3. Pre- or postsynaptic mechanism of BRS-015? 
Changes  in  the  ratio  of  amplitudes  of  two  consecutive  synaptic  responses 
evoked by a paired-pulse stimulus paradigm (e.g. 50 ms inter-stimulus interval) 
provide  indirect  information  about  whether  a  drug  or  compound  affects 
transmitter  release  via  a  presynaptic  mode  of  action  (Zucker,  1989).  The 
present results show that application of BRS-015 (100 µM) had no effect on the 
paired-pulse  ratio  of  evoked  EPSCs  suggesting  that  it  does  not  modulate 
receptors or channels that regulate glutamate release probability (Figure 34). 
Again,  this  analysis  emphasizes  that  the  enhancing  effect  of  BRS-015  on 
excitatory  synaptic  transmission  is  likely  to  originate  from  postsynaptic  sites 
rather  than  via  presynaptic  modulation  of  glutamate  release  at  mossy  fibre 
synapses. 
Further supporting evidence for direct AMPAR modulation by BRS-015 came 
from  our  results  on  the  enhancing  effect  of  BRS-015  on  glutamate-induced 
currents  in  CA3  pyramidal  neurones.  Indeed,  with  NMDA  receptors blocked, 
superfusion  of  BRS-015  (100  µM)  reversibly  increased  the  amplitude  of 
glutamate-induced currents by around 50% (Figure 39), in line with postsynaptic 
modulation of membrane conductance. 
Overall, the data presented here are in line with previous studies in which  a 
structural  relative  of  BRS-015  –  aniracetam  –  was  found  to  facilitate 
glutamatergic  transmission  in  the  hippocampus.  Aniracetam  increased  the 
amplitude of f-EPSPs evoked by stimulation of Schaffer collaterals (Staubli et 
al.,  1990;  Xiao  et  al.,  1991)  and  had  no  effect  on  the  paired-pulse  ratio. 
Aniracetam was also shown to increase the size of glutamate-induced inward 
currents (Isaacson and Nicoll, 1991) and, similar to BRS-015, the effect was 
almost instantaneous and reversible. Piracetam, in contrast, had no effect on 
glutamate-evoked responses, indicating that not every member of the nootropic 
drug family possesses a similar enhancing effect on  f-EPSPs (Isaacson and 
Nicoll,  1991,  Heise,  1987).  In  our  hands,  only  superfusion  of  a  very  high 
concentration of piracetam (500 µM) gave a slight increase of f-EPSP amplitude 
of 9.3  3.8% (Figure 29; n = 3, P < 0.03), paired t-test) (Olpe and Lynch, 1982). Blanka Szulc                                                                                                           Results and Discussion 
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As  shown  by  Arai  and  Suzuki  (Arai  et  al.,  2004)  nootropic  drugs  can  also 
regulate  the  kinetics  of  AMPA  receptors.  Aniracetam  was  shown  to  reduce 
glutamate receptor desensitisation and slow the decay-time constant of evoked 
EPSCs  (Isaacson  and  Nicoll,  1991,  Ito  et  al.,  1990).  Analysis  of  the 
corresponding EPSCs decay-time in our experiments revealed that BRS-015 
has no effect. However, a more detailed investigation as to whether BRS-015 
might  alter  AMPA  receptor  desensetization  and  kinetics  would  require 
experiments performed with  outside-out patches from pyramidal cells. It was 
presented by Partin and co-workers that aniracetam can slow AMPARs channel 
closing machinery and as a consequence, the onset of their desensetization 
(Partin et al., 1996). Interestingly, the enhancing effect of BRS-015 started to 
decrease before the wash-out period which could suggest modulatory action on 
AMPARs and associated desensetization. 
8.4. Effect of BRS-015 on synaptic plasticity 
Positive  AMPA  receptor modulators have frequently  been  shown  to promote 
long-term potentiation, in addition to their known enhancing effects on various 
forms of memory in animals and humans via several different mechanisms (Arai 
et al., 2004, Staubli et al., 1990, Staubli et al., 1994, Ingvar et al., 1997). 
We examined the  effects  of  BRS-015  on mossy fibre  synaptic plasticity  and 
found  that  i)  it  had no  effect  on  the  large post-tetanic potentiation  typical  of 
mossy fibre synapses, ii) it lowered the threshold for LTP induced with a sub-
threshold paradigm and iii) BRS-015 had no effect when it was delivered 20 
minutes after LTP induction, i.e. when mossy fibre synapses had already been 
potentiated. 
The use of a sub-threshold stimulus paradigm by itself was clearly insufficient to 
achieve  sustained  potentiation  of  postsynaptic  responses.  Such  a  limited 
stimulus therefore served as a sub-threshold LTP induction protocol to study the 
effect of BRS-015 on mossy fibre LTP. As previously noted by several groups 
(Arai et al., 2004, Arai and Lynch, 1992), the possibility of generating LTP in the 
CA1  region  under  such  condition  is  increased  in  the  presence  of  an  AMPA 
receptor modulator. In line with these studies, the sub-threshold high-frequency 
stimulation protocol used in our experiments elicited LTP only when BRS-015 Blanka Szulc                                                                                                           Results and Discussion 
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(100 µM) was present in the perfusion medium (Figures 41, 43). These results 
demonstrate that BRS-015 facilitated mossy fibre LTP by lowering its threshold 
of  induction.  However,  whether  this  was  a  consequence  of  presynaptic 
modulation, or the result of enhanced AMPA receptor function still remains to be 
fully elucidated.  
Interestingly, in the absence of an NMDA receptor antagonist, the amplitude of 
f-EPSPs  measured  20  minutes  after  HFS2  increased  to  179.6  ±  16.6%  of 
baseline  (Figure  44)  compared  to  132%  when  D-AP5  was  included  in  the 
perfusion solution. Although circumstantial, this observation is in line with the 
recent  idea  that  (Rebola  et  al.,  2011)  NMDA  receptors  might  drive  a 
‘metaplastic  switch’  “making  mossy  fibre  synapses  competent  for  generating 
NMDAR-dependent LTP of AMPA EPSCs”. Thus, during LTP induction, BRS-
015 could act as a catalyst and ‘awake’ silent NMDARs at mossy fibre synapses 
via modulation of AMPA receptor activity. Conversely, functional AMPA receptor 
expression could be induced by NMDAR activation at initially silent synapses 
(Liao et al., 1995, Durand et al., 1996). This phenomenon might be relevant to 
LTP induction in the CA1 region where it can trigger the conversion from silent 
AMPA receptors to functional ones (Nicoll and Malenka, 1995). The facilitatory 
effect  of  BRS-015  on  mossy  fibre  LTP  could  thus  result  from  the  interplay 
between direct AMPA receptor modulation and indirect recruitment of NMDA 
receptors consecutive to depolarisation and relief of the Mg
2+ block.  
The  magnitude  of LTP  that  is frequently  achieved  in  CA1  when  superfusing 
compounds  of  the  racetam  family  is  typically between  30-60%, (Malykh  and 
Sadaie,  2010)  similar  to  the  effect  of  BRS-015  (100  M).  Interestingly, 
application of CX546 has been shown to result in an increase in LTP of almost 
100% via AMPA receptor-mediated depolarisation, which in turn can enhance 
NMDA  receptor  activation.  Noteworthy  is  the  fact  that  CX546;  analogous  to 
BRS-015, showed no effect on NMDA receptor-mediated currents (Arai et al., 
2004). Moreover, aniracetam had no effect on NMDA-receptor mediated EPSCs 
in  CA1  pyramidal  neurones  but  increased  the  magnitude  of  post-tetanic 
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In summary, a secondary consequence of the positive modulation of AMPAR 
via  BRS-015  can  be  linked  with  the  recruitment  of  voltage-sensitive  NMDA 
receptor activity, providing evidence for an additional mechanism for increasing 
synaptic strength. 
A downstream mechanism of AMPA receptor modulation by BRS-015 would 
lead to increased calcium levels in the postsynaptic neurone and thus further 
LTP  (Arai  et  al.,  2004).  At  hippocampal  synapses,  the  strength  of  synaptic 
plasticity is determined by the amount of calcium influx during the LTP induction 
process. Therefore, BRS-015 could modulate the strength of synaptic plasticity 
by  regulating  the  activity  of  Ca
2+  dependent  protein  kinases  such  as 
calcium/calmodulin-dependent protein kinase II (CaMKII) (Lisman et al., 2002).   
Finally, when applying BRS-015 following the classic LTP induction protocol (3 
x 100 Hz during 1 second, every 10 seconds) no further potentiation of evoked 
f-EPSPs  was  observed  (Figure  45).  This  result  supports  the  idea  that  once 
synapses have been potentiated to their maximum level, no further effect on 
LTP can be seen. Previous studies have shown that aniracetam interferes with 
the expression of LTP  (Staubli et al., 1990, Staubli et al., 1992, Xiao et al., 
1991) and has also been shown to modulate the induction of LTP, dependent 
on the induction protocol. As such, an approximate 22% increase of control was 
observed with the application of 5 theta bursts and no effect when 10 theta 
burst stimuli was used on the induction of LTP (Arai and Lynch, 1992). Such a 
result indicates that the drug affects the induction of LTP per burst but does not 
change the ceiling of the maximum degree of LTP that is normally present.  
Pleasingly one of the key results regarding the future potential of BRS-015 in 
the cytotoxicity assays revealed that BRS-015 is essentially non-toxic and so 
warrants further development to explore its potential.  Blanka Szulc                                                                                                                             Conclusions  
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9.0. Conclusions  
 
In  summary,  the  present  study  has  clearly  shown  the  intramolecular  acylal 
cyclisation  reaction  that  we  have  developed  has  led  to  the  synthesis  of 
compounds  realted  to  clausenamide  as  shown  below  (Scheme  53).  In 
particular, the mechanistic insights observed in the synthesis of related bicyclic 
derivatives (Scheme 27) demonstrate that this chemical approach is feasible for 
a number of related analogues and warrants further investigation.  
 
Scheme 53: Synthesis of BRS-015 
In  addition,  the  chemistry that  we  have  developed  has  led  to  the  filing  of a 
patent to protect a novel compound - BRS-015, which we have shown to have a 
strong and reversible enhancing effect on excitatory synaptic transmission in 
the CA3 region by a mechanism involving the modulation of AMPA receptor 
mediated  currents.  It  also  facilitated  the  induction  of  a  long-lasting  form  of 
synaptic  plasticity  in  CA3  cells.  However,  the  exact  mechanistic pathway  by 
which  it  has  led  to  such  an  enhanced  transmission  remains  still  to  be  fully 
elucidated if BRS-015 or a closely related analogue were to progress towards 
further  development  as  a  memory  enhancing  compound,  its  plausible 
mechanism is presented in Figure 48. 
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Figure 48: Schematic diagram showing the possible mechanism by which BRS-
015 induces long-lasting enhancement in excitatory synaptic transmission. 
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10.0. Future Work  
The results have clarly shown that the effects of (-)-BRS-015 on mossy fibre f-
EPSPs is clearly promising and warrants further investigation as it indicates the 
selective  nature  of  this  small  molecule  and  suggests  that  the  (-)-enantiomer 
accounts for all of the observed activity. Future work should therefore focus on 
the (-)-enantiomer and should explore its effects on LTP.  
However, despite this result, it clearly does not exclude the possibility that the 
drug cannot be developed as a racemic mixture, only that we should investigate 
the potential effects of each enantiomer. One of the challenges associated with 
the structure of BRS-015 is its vinylogous double bond. The single chiral centre 
may  undergo  epimerisation  under  physiological  conditions  as  shown  below 
(Scheme 54).  
 
Scheme 54: Potential Racemisation of BRS-015 
Protonation of the carbonyl oxygen can lead to formation of the intermediate 
pyrrole 188. However, re-protonation of this intermediate can occur from either 
face and therefore may lead to racemisation under physiological conditions. We 
therefore  need  to  examine  this  under  simulated  physiological  conditions  to 
determine whether this is indeed the case.  Blanka Szulc                                                                                                                             Future Work  
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In addition to the question of chirality is the need to investigate the activity of 
related molecules in order to develop a compound that can progress towards 
further development.  Clearly  the  methyl ester is a  sensible  starting  point for 
functional  group  interconversion,  but  we  should  also  look  at  the  effects  on 
activity of modification of the phenyl ring and the group on the amidic nitrogen. 
Examples of compounds that we intend to investigate in the future are shown 
below (Figure 49). 
 
Figure 49: Potential analogues development of BRS-015 
We also anticipate that the amide and OH groups are crucial for binding and 
resultant biological activity. Simple methylation of the alcohol will enable us to 
demonstrate this as shown below (Figure 50).  
 
Figure 50: Alcohol analogues of BRS-015 
In order to guide our future synthetic developments relating to BRS-015, we 
also need to investigate the insilico binding of BRS-015. Therefore future work 
should  also  focus  on  the  effects  of  BRS-015  on  various  AMPA  receptor 
subunits. Using the published crystal structure of piracetam bound to GluA2, we 
will carry out docking studies to examine where the molecule binds in the three 
possible  binding  pockets  as  shown  by  Ahmed  and  co-workers  (Ahmed  and 
Oswald, 2010). Moreover, only AMPA receptors that lack GluA2 are permeable 
to calcium, which makes the GluA2 subunit a preferred target.  
At the cellular level, future mainstream lines of research need to be developed 
to  elucidate  the  mechanisms  of  action  of  BRS-015  and  to  grasp  a  better 
understanding of the biological spectrum of activity of apparented compounds. Blanka Szulc                                                                                                                             Future Work  
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The following processes need to be investigated, all of which can potentiate 
synaptic strength via candidate postsynaptic mechanisms: 
i)  Direct binding to AMPA receptors: in this scenario, BRS-015 would bind 
to  a  specific  AMPA  receptor  subunit  as  shown  for  previous  allosteric 
modulators, e.g. phillantotoxine on GluA2 (Poulsen et al., 2014); 
ii)  Indirect  modulation  via  protein  kinase  activation  and  downstream 
phosphorylation of AMPA receptor subunits; 
iii)  Indirect modulation via inhibition of phosphodiesterases: in this model, 
AMPA  receptors  would  normally  function  under  constitutive 
phosphorylation and de-phosphorylation activity; 
iv) All of the above, leading to insertion of new AMPA receptors at synapses 
either by lateral diffusion of via intracellular recycling pathways. 
 Despite the amount of in vitro studies required to progress BRS-015 or related 
congeners  towards  preclinical  development,  it  is  clear  that  it  already  has  a 
significant effect. It therefore has good potential for the treatment of memory 
disorders, implying that future efforts should also be explored in vivo. Therefore, 
future  work  should  focus  on  classic  memory  impairment  tests  such  as  the 
Morris water maze, or passive avoidance, novel object recognition tests and 
paired learning and memory tests, ideally in aged animals (Savonenko et al., 
2012). Currently, BRS-015 is under evaluation and further studies by Eli Lilly will 
be  reported  in  due  course.  These  studies  were  intiated  after  the  research 
described in this thesis and will be reported elsewhere. 
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11.0. Experimental 
11.1. General Methods for Synthesis 
All  reactions  requiring  the  use  of  dry  conditions  were  carried  out  under  an 
atmosphere of nitrogen and all glassware was pre-dried in an oven (110 C) 
and  cooled  under  nitrogen  prior  to  use.  Stirring  was  by  internal  magnetic 
follower  unless  otherwise  stated.  All  reactions  were  followed  by  TLC  and 
organic phases extracted were dried with anhydrous magnesium sulfate. Diethyl 
ether,  tetrahydrofuran,  dichloromethane,  toluene,  methanol,  acetonitrile  and 
triethylamine  were  purchased  as  anhydrous  solvents  from  Sigma-Aldrich 
chemical  company.  Purification  was  carried  out  by  column  chromatography 
using the flash column chromatography technique reported by Still and others 
(Still et al, 1978) or by Biotage automatic purification.  The silica gel used was 
Merck 60 (230-400 mesh). Thin layer chromatographic analysis was carried out 
using  Merck  aluminium-backed  plates  coated  with  silica  gel  60  F254. 
Components were visualised using combinations of ultraviolet light and iodine 
stain. 
Infrared  spectra  were  recorded  on  a  Perkin  Elmer  1605  FT-IR 
spectrophotometer. Melting points were determined using open glass capillaries 
on a Stuart Scientific SMP3 apparatus and are uncorrected. 
1H NMR and 
13C 
NMR  spectra  were  recorded  on  a  Bruker  AV400,  operating  at  400  MHz  for 
proton and 101 MHz for carbon, or a Bruker AV500 spectrometer operating at 
500 MHz for proton and 126 MHz for carbon.  
Chemical shifts (H and C) are quoted as parts per million downfield from 0.  
The  multiplicity  of  a 
1H  NMR  signal  is  designated  by  one  of  the  following 
abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sept 
= septet, br = broad and m = multiplet.  Coupling constants (J) are expressed in 
Hertz. 
High resolution mass spectra were carried out at School of Pharmacy. Mass 
spectra  were  carried  out  using  either  an  Agilent  Micromass  Q-TOF  premier 
Tandem Mass Spectrometer from Micromass utilising electrospray. All samples Blanka Szulc                                                                                             Experimental 
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were run under electrospray ionization mode using 50% acetonitrile in water 
and 0.1% formic acid as solvent.   Blanka Szulc                                                                                             Experimental 
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Diacetoxyacetyl chloride 119 
 
A  solution  of  glyoxylic  acid  monohydrate  122  (16.0  g,  174  mmol)  in  acetic 
anhydride  (49.2  mL,  521  mmol)  and  acetic  acid  (30.0  mL,  521  mmol)  was 
heated  at  150  C for  3  hours  and  then  allowed  to  cool  to  RT  over  1  hour. 
Excess reactants were removed under azeotropic distillation (toluene 2 x 100 
mL) under reduced  pressure. The  residue was  taken  up  in  dichloromethane 
(200  mL)  followed  by  sequential  addition  of  thionyl  chloride  (25.4  mL,  348 
mmol) and dimethylformamide (0.03 mL, 0.35 mmol). The mixture was heated 
under reflux conditions (50 °C) until formation of diacetoxyacetyl chloride and 
loss of diacetoxyactic acid was confirmed by 
1H NMR spectroscopy. Solvent 
and  excess  thionyl  chloride  were  removed  under  reduced  pressure  and  the 
crude  product  purified  by  distillation  under  reduced  pressure  (64-65  C/  1.0 
mmHg) to  give  diacetoxyacetyl chloride  119  (15.0  g,  77.1 mmol,  45%) as a 
colourless oil; υmax/ cm
-1 1763 (C=O), 1376 (CH3), 1200 (C-C(O)-C), 718 (C-Cl); 
 H (500 MHz; CDCl3) 6.79 (1 H, s, CH), 2.09 (6 H, s, CH(OC(O)CH3)2),;  C 
(126 MHz; CDCl3) 168.21 (CO), 167.67 (CO), 88.03 (CH(OAc)2), 20.48 (CH3); 
m/z 195 (100%, [M+H]
+): Found [M+H]
+ 195.5805, C6H8ClO5 requires 195.5801. 
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2-(Allyl(methyl)amino)-2-oxoethane-1,1-diyl diacetate 120 
 
A  solution  of  diacetoxyacetyl  chloride  119  (1.24  g,  6.38  mmol)  in 
dichloromethane (5 mL) was added to a rapidly stirred biphasic solution of N-
allylmethylamine 117 (0.45 g, 6.38 mmol) and sodium bicarbonate (0.54 g, 6.38 
mmol) in water (50 mL) and the resulting mixture stirred rapidly for 3 hours. The 
mixture was separated and the aqueous layer extracted with dichloromethane 
(50  mL).  The  combined  organic  extracts  were  dried  (MgSO4),  filtered  and 
solvent  removed under reduced  pressure. The  residue  was  purified  by  flash 
column chromatography (1:1 EtOAc-petroleum ether (40-60 °C), Rf = 0.46) to 
give amide 120 (1.02 g, 4.43 mmol, 69%) as a pale pink oil as a 1:1 mixture of 
amide  rotamers;  υmax/  cm
-1  (CH2Cl2)  2595  (NCH3),  1717  (C=O),
  1646 
(N(CH3)C=O); 
1H NMR (400 MHz, CDCl3) ʴ 7.14 (0.5 H, s, C(O)CH), 7.10 (0.5 
H,  s,  C(O)CH),  5.72  (1  H,  m,  CH2=CH-CH2-N(CH3)),  5.32  -  5.01  (2  H,  m, 
CH2=CH-CH2-N(CH3)), 3.97 (1 H, d,  J=5.8 Hz, CH2=CH-CH2-N(CH3)), 3.94 - 
3.78  (1  H,  m,  CH2=CH-CH2-N(CH3)),  2.94  (1.5  H,  s,  NCH3),  2.93  (1.5  H,  s, 
NCH3), 2.14 (3 H, s, OC(O)CH3), 2.11 (3 H, s, OC(O)CH3); 
13C NMR (101 MHz, 
CDCl3) ʴ 168.95 (OC(O)CH3), 168.85 (OC(O)CH3), 164.20 (C(O)CH), 163.79 
(C(O)CH),  132.01  (CH2=CH-CH2-N(CH3)),  131.83  (CH2=CH-CH2-N(CH3)), 
118.16  (CH2=CH-CH2-N(CH3)),  117.85  (CH2=CH-CH2-N(CH3)),  84.07 
(C(O)CH), 83.90 (C(O)CH), 51.56 (CH2=CH-CH2-N(CH3)), 50.94 (CH2=CH-CH2-
N(CH3)), 34.27 (NCH3), 34.05 (NCH3), 20.73 (OC(O)CH3), 20.70 (OC(O)CH3); 
m/z 230 (43%, [M+H]
+); Found [M+H]
+ 230.1027, C10H16NO5 requires 230.1028.  Blanka Szulc                                                                                             Experimental 
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2-(Diallylamino)-2-oxoethane-1,1-diyl diacetate 121 
 
A  solution  of  diacetoxyacetyl  chloride  119  (1.58  g,  8.13  mmol)  in 
dichloromethane  (10  mL)  was  added  to  a  rapidly  stirred  biphasic  mixture  of 
diallylamine 118 (0.79 g, 8.13 mmol) in dichloromethane (100 mL) and sodium 
bicarbonate  (0.68  g,  8.13  mmol)  in  water  (50  mL) and  the  resulting  mixture 
stirred for 3 hours. The mixture was separated, and the aqueous layer extracted 
with  dichloromethane  (50  mL).  The  combined  organic  extracts  were  dried 
(MgSO4), filtered and solvent removed under reduced pressure. The residue 
was purified by flash column chromatography (1:3 EtOAc- petroleum ether (40-
60 °C), Rf = 0.31) to give 2-(diallylamino)-2-oxoethane-1,1-diyl diacetate 121 
(1.69 g, 6.63 mmol, 82%) as a pale pink oil; υmax/ cm
-1 (CH2Cl2) 1718 (C=O),
 
1657 N(CH3)C=O); 
1H NMR (400 MHz, CDCl3) ʴ 7.08 (1 H, s, C(O)CH), 5.84 - 
5.64 (2 H, m, CH2=CH-CH2-N, N-CH2-CH=CH2), 5.24 - 5.09 (4 H, m, CH2=CH-
CH2-N, N-CH2-CH=CH2), 3.97 (2 H, d, J = 5.8 Hz, N-CH2-CH=CH2), 3.88 (2 H, 
dt, J = 4.9, 1.6 Hz, N-CH2-CH=CH2), 2.11 (6 H, s, (OC(O)CH3))2; 
13C NMR (101 
MHz,  CDCl3)  ʴ  168.73  (OC(O)CH3),  164.01  (OC(O)CH3),  132.15  (CH2=CH-
CH2-N), 131.86 (N-CH2-CH=CH2), 118.04 (CH2=CH-CH2-N), 117.62 (CH2=CH-
CH2-N),  83.83  (C(O)CH),  48.54  (CH2=CH-CH2-N),  48.52  (N-CH2-CH=CH2), 
20.56  (OC(O)CH3);  m/z  278  (42%,  [M+Na]
+);  Found  [M+Na]
+  278.0999, 
C12H17NNaO5 requires 278.1004. Blanka Szulc                                                                                             Experimental 
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Cycloheptanone imine 144 
 
A mixture of cycloheptanone 143 (0.72 mL, 6.07 mmol) and benzylamine 129 
(0.66 mL, 6.07 mmol) in toluene was heated at reflux in the presence of a Dean 
Stark trap for 3 hours. Solvent was removed under reduced pressure to give the 
imine  144  as  a  colourless  oil  that  was  used  immediately  without  further 
purification. 
 Blanka Szulc                                                                                             Experimental 
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2-(Benzyl(cycloheptenyl)amino)-2-oxoethane-1,1-diyl diacetate 145 
 
A  solution  of  diacetoxyacetyl  chloride  119  (1.28  g,  6.56  mmol)  in 
dichloromethane  (10  mL)  was  added  to  a  rapidly  stirred  biphasic  mixture  of 
cycloheptanone imine 144 (1.20 g, 5.96 mmol) and sodium bicarbonate (1.00 g, 
11.9 mmol) in dichloromethane (100 mL) and water (20 mL) and the resulting 
mixture stirred for 3 hours. The mixture was separated, and the aqueous layer 
extracted with dichloromethane (50 mL). The combined organic extracts were 
dried  (MgSO4),  filtered  and  solvent  removed  under  reduced  pressure.  The 
residue  was  purified  by  flash  column  chromatography  (1:2  EtOAc-petroleum 
ether  (40-60  °C),  Rf  =  0.38)  to  give  2-(benzyl(cycloheptenyl)amino)-2-
oxoethane-1,1-diyl diacetate 145 (0.86 g, 2.38 mmol, 44%) as a colourless oil; 
υmax/ cm
-1 (CH2Cl2) 2932 (C-H), 1772 (C=O), 1677 (C=C); 
1H NMR (400 MHz, 
CDCl3) ʴ 7.30 (5 H, m, CH-Ar), 7.16 (1 H, s, CH-O), 5.53 (1 H, t, J 5.5, CH-C), 
5.01 (1H, brs, CH2-Ar), 4.26 (1 H, brs, CH2-Ar), 2.32 (2 H, brs, CH2-C), 2.16 (6 
H, s, 2x(CH3)), 2.01 (2 H, q, J 6.6, CH2-CH), 1.61 (6 H, brm, 3x(CH2-CH2)); 
13C 
NMR (101 MHz, CDCl3) ʴ 163.1 (C=O), 140.7 (Cq), 136.6 (Cq), 134.6 (CH-C), 
129.0 (CH-Ar), 128.3 (CH-Ar), 127.5 (CH-Ar), 84.2 (CH-O), 49.9 (CH2-Ar), 33.1 
(CH2-C), 30.9 (CH2-CH), 26.8 (CH2-CH2), 26.0 (CH2-CH2), 25.8 (CH2-CH2), 20.6 
(2x(CH3)); m/z 360 (26%, [M+H]
+); Found [M+H]
+ 360.1802, C20H26NO5 requires 
360.1811.
 Blanka Szulc                                                                                             Experimental 
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1-Benzyl-4,5,6,7-tetrahydrocyclohepta-(β)-pyrrol-2(1H)-one 146 
 
Boron trifluoride diethyl etherate (0.07 mL, 0.56 mmol)was added to the solution 
of 2-(benzyl(cycloheptenyl)amino)-2-oxoethane-1,1-diyl diacetate 145 (0.100 g, 
0.28 mmol) in DCM (10 mL) at 0 °C and the resulting mixture stirred at this 
temperature  for  30  minutes  and  then  at  room  temperature  overnight.  The 
mixture was poured into water (40-50 mL), and extracted with dichloromethane 
(3 x 30 mL). The combined organic extracts were washed with water (2 x 50 
mL), dried (MgSO4), filtered and solvent removed under reduced pressure. The 
residue  was  purified  by  flash  column  chromatography  (1:2  EtOAc-petroleum 
ether (40-60 °C), Rf = 0.43) to give 1-benzyl-4,5,6,7-tetrahydrocyclohepta-(β)-
pyrrol-2(1H)-one 146 (0.02 g, 0.09 mmol, 31%) as a colourless oil; υmax/ cm
-1 
(CH2Cl2) 1682 (C=O);
 1H NMR (400 MHz, CDCl3) ʴ 7.33 - 7.06 (5 H, m, ArH), 
5.85 (1 H, s, C(O)CH), 5.49 (1 H, dd, J = 8.0, 3.4 Hz, CH), 4.70 (2 H, s, N-CH2-
Ph), 2.74 - 2.61 (2 H, m, CH2), 2.29 (2 H, m, CH2), 1.67 (4 H, m, CH2); 
13C NMR 
(101 MHz, CDCl3) ʴ 169.62 (C=O), 151.71 (C=C(H)C=O), 140.27 (quaternary 
C), 137.75 (ArCH), 128.55 (ArCH) , 127.04 (ArCH) , 120.28 (C(O)CH), 116.87 
(CH), 42.45 (N-CH2-Ph), 29.90 (CH2), 28.17 (CH2), 27.53 (CH2), 24.64 (CH2); 
m/z 240 (34%, [M+H]
+); Found [M+H]
+ 240.1396, C16H18NO requires 240.1388.  
 Blanka Szulc                                                                                             Experimental 
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N-Cyclopentylidene-1-phenylmethanamine 131 
 
A mixture of cyclopentanone 130 (0.54 mL, 6.07 mmol) and benzylamine 129 
(0.66 mL, 6.07 mmol) in toluene (15 mL) was heated at reflux under Dean and 
Stark  water  removal  conditions  for  3  hours.  Solvent  was  removed  under 
reduced pressure to give N-cyclopentylidene-1-phenylmethanamine 131 (1.05 
g,  6.07  mmol,  100%)  as  a  colourless  oil  that  was  used  immediately  without 
further purification. Blanka Szulc                                                                                             Experimental 
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2-(Benzyl(cyclopentenyl)amino)-2-oxoethane-1,1-diyl diacetate 132 
 
A  solution  of  diacetoxyacetyl  chloride  119  (1.18  g,  6.07  mmol)  in 
dichloromethane (10 mL) was added to a rapidly stirred biphasic mixture of N-
cyclopentylidene-1-phenylmethanamine  131  (1.05  g,  6.07  mmol)  and  sodium 
bicarbonate  (0.51  g,  6.07  mmol)  in  DCM  (100  mL)  and  water  (50  mL)  the 
resulting  mixture  stirred  for  48  hours.  The  mixture  was  separated,  and  the 
aqueous  layer  extracted  with  dichloromethane  (50  mL)  and  the  combined 
extracts dried (MgSO4), filtered and solvent removed under reduced pressure. 
Purification by flash column chromatography (1:4, EtOAc-petroleum ether (40-
60  °C),  Rf  =  0.38)  gave  2-(benzyl(cyclopentenyl)amino)-2-oxoethane-1,1-diyl 
diacetate 132 (0.92 g, 2.77 mmol, 46%) as a colourless oil; 
1H NMR (400 MHz, 
CDCl3) ʴ 7.29 - 7.12 (5 H, m, Ar CH), 7.09 (1 H, s, C(O)CH), 5.39 (1 H, s, 
C(H)=C), 4.59 (2 H, s, NCH2), 2.37 - 2.14 (4 H, m, CH2, CH2), 2.07 (6 H, s, 
OC(O)CH3), 1.83 (2 H, dd, J = 15.1, 7.7 Hz, CH2); 
13C NMR (101 MHz, CDCl3) ʴ 
168.52  (C=O),  163.43  (NC=O),  136.42  (C(H)=C),  140.36  (C(H)=C),  129.97 
(quaternary C), 128.29(ArCH), 128.00 (ArCH), 127.30 (ArCH), 83.93 (C(O)CH), 
49.52 (NCH2), 32.07(CH2), 30.04 (CH2), 21.99, (CH2), 20.38 (OC(O)CH3); m/z 
331 (100%, [M]
+); Found [M+H]
+ 332.1489, C18H22NO5 requires 332.1498.  
 Blanka Szulc                                                                                             Experimental 
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1-Benzyl-4,5-dihydrocyclopenta[b]pyrrol-2(1H)-one 135 
 
Boron trifluoride diethyl etherate (0.52 mL, 4.22 mmol) was added to a solution 
of  2-(benzyl(cyclopentenyl)amino)-2-oxoethane-1,1-diyl diacetate  132  (0.28  g, 
0.85 mmol) in DCM (3.5 mL) and the resulting solution stirred for 10 minutes 
and heated at reflux for 6 hours. The mixture was poured into water (40-50 mL), 
and extracted with DCM (3 x 30 mL) and the combined organic extracts washed 
with  water  (2  x  50  mL),  dried  (MgSO4),  filtered  and  solvent  removed  under 
reduced pressure. The residue was purified by flash column chromatography 
(1:2,  EtOAc-petroleum  ether  (40-60  °C),  Rf  =  0.47)  to  give  1-benzyl-4,5-
dihydrocyclopenta-(β)-pyrrol-2(1H)-one  135  (0.12  g,  0.56  mmol,  67%)  as  a 
colourless oil; υmax/ cm
-1(CH2Cl2)
 1692 (C=O); 
1H NMR (400 MHz, CDCl3) ʴ 7.34 
- 7.10 (5 H, m, ArCH), 5.76 - 5.57 (1 H, m, C(H)-C=O), 5.33 (1 H, m, C(H)=C), 
4.72 (2 H, s, NCH2), 2.80 - 2.68 (2 H, m, CH2), 2.68 - 2.59 (2 H, m, CH2); 
13C 
NMR  (101  MHz,  CDCl3)  ʴ  161.87  (C=O),  146.39  (C=C(H)C=O),  137.28 
(quaternary  C),  128.60  (ArCH),  127.68  (ArCH),  127.44  (ArCH),  113.36 
(C=C(H)C=O),  109.31  (HC=C),  44.34  (N-CH2-Ph),  35.07  (CH2), 23.89  (CH2); 
m/z 349 (15%, [M+H]
+); Found [M+H]
+ 212.1071, C14H14NO requires 212.1075. 
 Blanka Szulc                                                                                             Experimental 
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N-Cyclohexylidene-1-phenylmethanamine 140 
 
A solution of cyclohexanone 139 (0.63 mL, 6.07 mmol) and benzylamine 129 
(0.66 mL, 6.07 mmol) in toluene (15 mL) was heated at reflux under Dean and 
Stark water removal conditions for 3 hours and solvent removed under reduced 
pressure  to  give  N-cyclohexylidene-1-phenylmethanamine  140  (1.14  g,  6.07 
mmol,  100%)  as  a  colourless  oil  that  was  used  immediately  without  further 
purification. 
 
 Blanka Szulc                                                                                             Experimental 
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2-(Benzyl(cyclohexenyl)amino)-2-oxoethane-1,1-diyl diacetate 141 
 
A  solution  of  diacetoxyacetyl  chloride  119  (1.18  g,  6.07  mmol)  in 
dichloromethane (10 mL) was added to a rapidly stirred biphasic mixture of N-
cyclohexylidene-1-phenylmethanamine  140  (1.14  g,  6.07  mmol)  and  sodium 
bicarbonate (0.51 g, 6.07 mmol) in dichloromethane (100 mL) and water (100 
mL) and the resulting mixture stirred for 48 hours. The mixture was separated, 
and the aqueous layer extracted with dichloromethane (50 mL). The combined 
organic  extracts  were  dried  (MgSO4),  filtered  and  solvent  removed  under 
reduced pressure. The residue was purified by flash column chromatography 
(1:3,  EtOAc-petroleum  ether  (40-60  °C),  Rf  =  0.34)  to  give  2-
(benzyl(cyclohexenyl)amino)-2-oxoethane-1,1-diyl  diacetate  141  (0.37  g,  1.07 
mmol, 18%) as a colourless oil; υmax/ cm
-1 (CH2Cl2) 1748 (OAc), 1682 (C=O); 
1H 
NMR (400 MHz, CDCl3) ʴ 7.27 - 7.13 (5 H, m, ArCH), 7.04 (1 H, s, C(O)CH), 
5.38 (1 H, t, J = 1.6 Hz, C=CH), 4.56 (2 H, s, NCH2), 2.07 (6 H, s, OC(O)CH3), 
2.05 - 1.99 (2 H, m, CH2), 1.94 - 1.84 (2 H, m, CH2), 1.64 - 1.51 (2 H, m, CH2), 
1.50 - 1.37 (2 H, m, CH2); 
13C NMR (101 MHz, CDCl3) ʴ 168.76 (C=O), 163.51 
(NC=O),  136.78  (C(H)=C),  136.36  (quaternary  C)  130.14  (ArCH),  128.63 
(ArCH), 128.37 (ArCH), 127.44 (C=CH), 84.19 (C(O)CH), 49.78 (NCH2), 27.70 
(CH2), 24.78 (CH2), 22.45 (CH2), 21.20 (CH2), 20.58 (OC(O)CH3). m/z 368 (100 
%, [M+Na]
+); Found [M+H]
+ 346.1646, C19H24NO5 requires 346.1654. 
 Blanka Szulc                                                                                             Experimental 
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1-Benzyl-5,6-dihydro-(1H)-indol-2(4H)-one 142 
 
Boron trifluoride diethyl etherate (0.18 mL, 1.46 mmol) was added to a solution 
of  2-(benzyl(cyclohexenyl)amino)-2-oxoethane-1,1-diyl  diacetate  141  (0.10  g, 
0.29 mmol) in DCM (3.5 mL) and the resulting mixture stirred for 10 minutes 
and heated at reflux for 3 hours. The mixture was poured into water (40-50 mL) 
and extracted with dichloromethane (3 x 30 mL). The combined organic extracts 
were  washed  with  water  (2  x  50  mL),  dried  (MgSO4),  filtered  and  solvent 
removed under reduced pressure. The residue was purified by flash column 
chromatography (1:3, EtOAc-petroleum ether (40-60 °C), Rf = 0.28) to give 1-
benzyl-5,6-dihydro-1H-indol-2(4H)-one  142  (0.03  g,  0.11  mmol,  38%)  as  a 
colourless oil; υmax/ cm
-1 (CH2Cl2) 1678 (NC=O);
 1H NMR (400 MHz, CDCl3) ʴ 
7.32 - 7.25 (2 H, m, Ar-CH), 7.23 - 7.17 (3 H, m, Ar-CH), 5.80 (1 H, d, J = 1.6 
Hz, C=CH), 5.50 (1 H, td, J = 4.7, 1.7 Hz, HC=C), 4.74 (2 H, s, N-CH2-Ph), 2.69 
- 2.55 (2 H, m, CH2), 2.24 (2 H, m, CH2), 1.78 (2 H, m, CH2); 
13C NMR (101 
MHz,  CDCl3)  ʴ  166.4  (C=O),  147.60  (C=C(H)C=O),  128.55  (ArCH),  127.17 
(ArCH),  127.10  (ArCH),  115.55  (C=CH),  110.89  (HC=C),  42.60  (N-CH2-Ph), 
24.36 (CH2), 24.23 (CH2), 23.44 (CH2) missing 2 x quaternary C; m/z 248 (38%, 
[M+Na]
+), Found [M+H]
+ 226.1237, C15H16NO requires 226.1232. 
 Blanka Szulc                                                                                             Experimental 
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Methyl 2-(tert-Butoxycarbonylamino)-3-phenylpropanoate 116 
 
Di-tert-butyl dicarbonate (19.4 mL, 83.0 mmol) was added to a solution of  L-
phenylalanine  methyl  ester  hydrochloride  182  (15.0  g,  69.5  mmol)  and 
triethylamine  (19.6  mL,  139  mmol)  in  dichloromethane  (200  mL)  and  the 
resulting  solution  stirred  at  room  temperature  for  48  hours.  Solvent  was 
removed  under  reduced  pressure  and  the  residue  partitioned  between  DCM 
(100 mL) and a saturated aqueous solution of sodium bicarbonate (50 mL). The 
combined  organic  layers  were  washed  with  aqueous  solution  of  sodium 
bicarbonate (50 mL) and dried (MgSO4). The residue was purified via Biotage 
(1:2, EtOAc-petroleum ether (40-60 °C), snap 50 g column, Rf = 0.73) to give 
methyl  2-(tert-butoxycarbonylamino)-3-phenylpropanoate  116  (19.4  g,  69.6 
mmol, 100%) as a colourless oil as a mixture of amide rotamers; υmax/ cm
-1 
(CH2Cl2) 3373 (NH), 2977 (Ar(CH)), 1744 (CO2CH3), 1667 (NCO2
tBu); 
1H NMR 
(400 MHz, CDCl3) ʴ 7.27 (5H, m, ArCH), 7.08 (1H, br s, -NH-), 4.94 (0.6H, s, 
NHCH),  4.53  (0.4H,  s,  NHCH),  3.62  (3H,  s,  COOCH3),  3.04  (2H,  m, 
ArCH2COOCH3), 1.38 (9H, s, HN-COOC(CH3)3); 
13C NMR (101 MHz, CDCl3) ʴ 
172.55  (COOCH3),  155.40  (NC(O)OC(CH3)3),  136.44  (quaternary  C),  129.44 
(ArCH),  128.69  (ArCH),  127.27  (ArCH),  76.85  (C(CH3)3),  54.63 
(CH2CHC(O)OCH3), 51.68 (OCH3), 38.46 (CH2), 27.18 (C(CH3)3); m/z: 302.1 
(100%, [M+Na]
+); Found [M+Na]
+ 302.1364, C15H21NNaO4 requires 302.1368. 
 Blanka Szulc                                                                                             Experimental 
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Methyl 2-(tert-Butoxycarbonyl(methyl)amino)-3-phenylpropanoate 115 
 
A suspension of sodium hydride (0.17 g of a 60% in mineral oil, 4.32 mmol) was 
added to a solution of methyl 2-(tert-butoxycarbonylamino)-3-phenylpropanoate 
116 (1.09 g, 3.92 mmol) in DMF (15 mL) and the resulting mixture stirred for 4 
hours. Iodomethane (0.45 mL, 7.20 mmol) was added to the resulting solution 
and the mixture stirred for 24 hours at room temperature. The final mixture was 
quenched by addition of a solution of saturated aqueous ammonium chloride 
(15  mL)  and  solvent  removed  under  reduced  pressure.  The  residue  was 
partitioned between water (50 mL) and ethyl acetate (50 mL) and the combined 
organic  extracts  washed  with  brine  (100  mL),  dried  (MgSO4),  filtered  and 
solvent removed under reduced pressure. The residue was purified via Biotage 
(1:6, EtOAc-petroleum ether (40-60 °C), snap 50 g column, Rf = 0.50) to give N-
Boc-N-methyl phenylalanine methyl ester 115 (0.82 g, 2.80 mmol, 78%) as a 
light  oil  as  a  0.6  :  0.4  mixture  of  amide  rotamers;  υmax/  cm
-1  (CH2Cl2)  2975 
(Ar(CH)), 1744 (CO2CH3), 1669 (NCO2
tBu); 
1H NMR (400 MHz, CDCl3) ʴ 7.12-
7.26  (5  H, m,  Ar-H),  4.90  (0.6  H,  s,  CH),  4.53  (0.4  H,s,  CH),  3.70  (3  H,  s, 
COOCH3), 3.22 (1 H, m, CH2), 2.94 (1 H, m, CH2), 2.67 (3 H, s, NCH3), 1.30 (9 
H,  s,  C(CH3)3); 
13C  NMR  (101  MHz,  CDCl3)  ʴ  172.11  (COOCH3),  171.82 
(COOCH3), 156.01 (NCOOC(CH3)3), 155.16 (NCOOC(CH3)3), 137.92 (ArCH), 
137.61(ArCH), 129.24 (ArCH), 129.15 (ArCH), 128.74 (ArCH), 128.58 (ArCH), 
126.84(ArCH),  126.78  (ArCH),  80.46  (C(CH3)3),  80.18  (C(CH3)3),  61.86 
(CH2CHC(O)OCH3),  59.73  (CH2CHC(O)OCH3),  52.35  (OCH3),  35.75  (CH2), 
35.26 (CH2), 32.75 (CH3N), 32.12 (CH3N), 28.43 (C(CH3)3), 28.39 (C(CH3)3); 
m/z:  293  (26%,  M
+);  Found  [M+Na]
+  316.1523,  C16H23NNaO4  requires 
316.1525. Blanka Szulc                                                                                             Experimental 
 
159 
 
N-Methyl phenylalanine methyl ester 114 
 
Trifluoroacetic acid (1.2 mL, 15.58 mmol) was added to a solution of N-Boc-N-
methyl phenylalanine methyl ester 115 (0.82 g, 2.80 mmol) in DCM (10 mL) at 
room temperature and the resulting solution stirred for 6 hours. The resulting 
mixture  was  quenched  with  saturated  aqueous  sodium  hydrogen  carbonate 
solution (30 mL). Solvent and excess trifluoroacetic acid were removed under 
reduced pressure. The residue was partitioned between dichloromethane (50 
mL) and saturated aqueous sodium hydrogen carbonate solution (50 mL). The 
combined  organic  layers  were  dried  (MgSO4),  filtered  and  solvent  removed 
under  reduced  pressure  to  give  methyl-2-(methylamino)-3-phenylpropanoate 
114 (0.53 g, 2.76 mmol, 99%) as a pale yellow oil; (1:2, EtOAc-petroleum ether 
(40-60°C), Rf = 0.08); υmax/ cm
-1 (CH2Cl2) 2975 (Ar(CH)), 1744 (CO2CH3); 
1H 
NMR (400 MHz, CDCl3) ʴ 7.15 - 7.29 (5 H, m, Ar-H), 3.64 (3 H, s, COOCH3), 
3.44 (1 H, t, J = 6.7 Hz, CH), 2.94 (2 H, d, J = 6.7 Hz, CH2), 2.35 (3 H, s, NCH3), 
1.60 (1 H, s, NH); 
13C NMR (101 MHz, CDCl3) ʴ 174.64 (COOCH3), 137.07 
(quaternary C), 129.0(ArCH), 128.37 (ArCH), 126.65 (ArCH), 64.69 (CH), 51.66 
(OCH3), 39.51 (CH2), 34.62 (CH3N); m/z 194.1 (100%, [M+H]
+); Found [M+H]
+ 
194.1183, C11H16NO2 requires 194.1181. 
 Blanka Szulc                                                                                             Experimental 
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(Z)-2-((3-Methoxy-3-oxo-1-phenylprop-1-en-2-yl)(methyl)amino)-2-
oxoethane-1,1-diyl diacetate 112 
 
tert-Butyl hypochlorite (1.78 g, 16.4 mmol) was added in one portion to a stirred 
solution  of  N-methyl  phenylalanine  methyl  ester  114  (3.01  g,  15.6  mmol)  in 
diethyl  ether  (60  mL)  in  the  dark  (foil  wrapped)  and  stirred  for  two  hours. 
DABCO  (2.75  g,  24.5  mmol)  was  added  to  the  resulting  mixture  and  the 
resulting  mixture  stirred  in  the  absence  of  light  for  12  hours.  The  reaction 
mixture  was  filtered  and  the  solids  washed  with  a  little  dry  ether  (15  mL). 
Solvent  was  removed  under  reduced  pressure  to  give  the  crude 
dehydrogenated product 113. The crude product thus obtained, was taken up in 
dichloromethane (100 mL) and a solution of sodium hydrogen carbonate (2.62 
g,  31.2  mmol)  in  water (50  mL) was  added,  followed  by  rapid  addition  of  a 
solution of diacetoxyacetyl chloride 119 (1.59 g, 8.19 mmol) in dichloromethane 
(20 mL). The resulting biphasic mixture was stirred rapidly for 24 hours. The 
layers were separated and the aqueous phase extracted with dichloromethane 
(2 x 50 mL). The combined extracts were dried (MgSO4), filtered and solvent 
removed  under  reduced  pressure.  Purification  by  Biotage  (1:2,  EtOAc-
petroleum  ether  (40-60  °C),  snap  50  g  column,  Rf  =  0.31)  gave  the  title 
compound 112 (3.82 g, 10.9 mmol, 70%) as a yellow oil; υmax/ cm
-1 (CH2Cl2) 
3058,  3028,  2952,  1755,  1742  (CO2CH3),
  1693  (C=O); 
1H  NMR  (400  MHz, 
CDCl3) ʴ 7.20-7.40 (5 H, m, Ar-H), 3.89 (1 H, s, HC=COOCH3), 3.71 (3 H, s, 
COOCH3), 3.19 (3 H, s, NCH3), 2.11 (6 H, s, (CH(OC(O)CH3)2); 
13C NMR (101 
MHz,  CDCl3)  ʴ  170.29  (COOCH3),  164.94  (NCO(C(O)COCH3)2),  142.15 
(quaternary C), 132.56 (HC=C), 131.39 (Ar-CH), 130.86 (Ar-CH), 129.70 (Ar-
CH), 100.21 (HC=C), 83.48 (C(O)CH(OAc)2), 52.30 (COOCH3), 36.23 (NCH3), 
20.41  (CH(OC(O)CH3)2);  m/z  349  (31%,  M
+),  218  (36),  191  (100),  131  (51); 
Found [M
+] 349.11615, C17H19NO7 requires 349.11686. Blanka Szulc                                                                                             Experimental 
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Methyl  4-hydroxy-1-methyl-5-oxo-3-phenyl-4,  5-dihydro-1H-pyrrole-2-
carboxylate 176 
 
Boron trifluoride diethyl etherate (8.00 mL, 63.1 mmol) was added to amide 112 
(1.64 g, 4.69 mmol) at room temperature and the resulting mixture stirred for 36 
hours.  The  mixture  was  poured  into  water  (40-50  mL)  and  extracted  with 
dichloromethane (3 x 30 mL). The combined organic extracts were washed with 
water (2 x 50 mL), dried (MgSO4), filtered and solvent removed under reduced 
pressure. The residue was purified by Biotage (1:2, EtOAc-petroleum ether (40-
60 °C), snap 25 g column, Rf = 0.21) and further purified by recrystallisation 
(methanol)  to  give  methyl  4-hydroxy-1-methyl-5-oxo-3-phenyl-2,5-dihydro-1H-
pyrrole-2-carboxylate 176 (0.856 g, 3.94 mmol, 72%) as a white solid; mp. 219-
221°C;  υmax/  cm
-1  (CH2Cl2)  3133  (OH),  1741  (COOCH3),  1687  (C=O),  1206 
(NCH3); 
1H NMR (400 MHz, CDCl3) ʴ 7.72 - 7.66 (2 H, m, Ar-H), 7.27 - 7.36 (2 
H,  m,  Ar-H),  7.17-  7.24  (1  H,  m,  Ar-H),  6.42  (1  H,  s,  OH),  4.92(1  H,  s, 
CHCO2CH3), 3.63 (3 H, s, CO2CH3), 3.01 (3 H, s, NCH3); 
13C NMR (101 MHz, 
CDCl3)  ʴ  168.93  (CO2CH3),  167.75  (NCO),  143.45  (C(OH)=C(Ph)),  130.78 
(quaternary  C),  128.59  (Ar-CH),  127.90  (Ar-CH),  126.85  (Ar-CH),  116.98 
(C(OH)=C(Ph)), 63.28 (CH(COOCH3), 53.01 (OCH3), 28.61 (NCH3);  m/z 246 
(100%,  M-H
+),  217.9  (43%);  Found  [M+H
+]  248.0931,  C13H14NO4  requires 
248.0923. 
BF3.Et2O(eq.)  Solvent  Boiling point[°C]  Yield  Time [hrs] 
2  DCM  40 °C  58%  12 (reflux) 
2  DCE  60 °C  62%  6 (reflux) 
20  neat  126 °C  70%  3 (reflux) 
20  neat  -  72%  36 (r. t.) Blanka Szulc                                                                                             Experimental 
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(Z)-Methyl 2-amino-3-phenylacrylate 184 
 
N-Chlorosuccinimide  (8.06  g,  60.4  mmol)  was  added  portionwise  over  two 
hours  to  a  stirred  solution  of  phenylalanine  methyl  ester  193  (10.8  g,  60.4 
mmol). The resulting mixture was stirred for 2 hours in the dark (foil wrapped). 
Solvent was removed in the dark and the residue taken up in petroleum spirit 
(150 mL), filtered and solvent removed under reduced pressure. The residue 
was taken up in diethyl ether (150 mL) and DABCO (8.13 g, 72.4 mmol) added 
and  the  resulting  mixture  stirred  in  the  absence  of  light  for  12  hours.  The 
mixture was filtered and solvent removed under reduced pressure. The residue 
was purified by flash column chromatography (1:5, EtOAc -petroleum spirit 40-
60 ºC, Rf = 0.53) to give the amine 184 as a yellow semi-solid (2.80 g, 15.80 
mmol, 26%); υmax/ cm
-1 (CH2Cl2) 3367 (NH2), 2951 (C=CH), 1710 (CO2CH3); 
1H 
NMR (400 MHz, CDCl3) ʴ 7.12 - 7.26 (5 H, m, Ar-H), 6.43 (1 H, s, CH=C), 4.18 
(2 H, s, NH2), 3.81 (3 H, s, COOCH3); 
13C NMR (101 MHz, CDCl3) ʴ 166.38 
(C=O), 136.71 (quaternary C), 132.35 (CH=C), 129.10 (ArCH), 128.15 (ArCH), 
127.24 (ArCH), 109.67 (CH=C), 52.87 (OCH3). Due to the unstable nature of 
this compound further data was not obtained.  
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(Z)-2-((3-Methoxy-3-oxo-1-phenylprop-1-en-2-yl)amino)-2-oxoethane-1,1-
diyl diacetate 185 
 
A solution of sodium hydrogen carbonate (2.44 g, 29.0 mmol) in water (100 mL) 
was  added  to  a  solution  of  amine  (5.14  g,  29.0  mmol)  in  DCM  (150  mL), 
followed by addition of a solution of diactoxyacetyl chloride 119 (5.64 g, 29.0 
mmol) in DCM (50 mL). The resulting biphasic mixture was stirred for 12 hours. 
The  layers  were  separated  and  the  aqueous  phase  extracted  with 
dichloromethane  (2  x  50  mL).  The  combined  extracts  were  dried  (MgSO4), 
filtered  and  solvent  removed  under  reduced  pressure.  Purification  by  flash 
column  chromatography  (1:2,  EtOAc  -petroleum  spirit  (40-60  ºC),  Rf  =  0.22) 
gave the title compound 185 as a colourless oil (7.21 g, 21.5 mmol, 74%); υmax/ 
cm
-1 (CH2Cl2) 3446 (NH), 1746.6 (CO2CH3),
 1693, 1434, 1224; 
1H NMR (400 
MHz,  CDCl3)  ʴ  8.08  (1  H,  s,  NH),  7.42-7.45  (2  H,  m,  Ar-H),  7.38  (1  H,  s, 
CH(OAc)2), 7.30-7.34 (3 H, m, Ar-H), 6.91 (1 H, s, HC=C), 3.74 (3 H, s, OCH3), 
2.11  (6  H,  s,  (CH(OC(O)CH3)2); 
13C  NMR  (101  MHz,  CDCl3)  ʴ  168.48 
(COOCH3),  165.11  (CH3NCO(COCOCH3)2),  133.92  (quaternary  C),  133.04 
(HC=C),  131.39  (Ar-CH),  129.78  (Ar-CH),  128.44  (Ar-CH),  122.81  (HC=C), 
85.10 (C(O)CH(OAc)2), 53.03 (COOCH3), 20.51 (CH(OC(O)CH3)2); m/z 358.1 
(100%, [M+Na]
+); Found [M+Na
+] 358.0914, C16H17NNaO7 requires 358.0903. 
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Methyl  4-hydroxy-5-oxo-3-phenyl-2,5-dihydro-1H-pyrrole-2-  carboxylate 
180 
 
Titanium tetrachloride (3.29 µL, 0.03 mmol) was added to a solution of amide 
185  (0.01  g,  0.03  mmol)  in  1,2-dichloroethane  (0.15  mL)  and  the  resulting 
mixture  heated  at  reflux  for  2  hours.  The  resulting  brown  solution  was 
concentrated under reduced pressure and the residue taken up in DCM (10 mL) 
poured into water (40-50 mL) and extracted with dichloromethane (3 x 30 mL). 
The  combined  organic  extracts  were  washed  with  water  (2  x  50  mL),  dried 
(MgSO4),  filtered  and  solvent  was  removed  under  reduced  pressure.  The 
product was purified by recrystallisation (ethyl acetate/ petroleum spirit) to give 
methyl  4-hydroxy-5-oxo-3-phenyl-2,5-dihydro-1H-pyrrole-2-carboxylate  180 
(3.60 mg, 0.02 mmol, 52%) as a pale yellow solid; υmax/ cm
-1 (CH2Cl2) 3133.4 
(OH), 1741.34 (COOCH3), 1687.5 (C=O); 
1H NMR (400 MHz,  CDCl3) 7.73 - 
7.77 (2 H, s, Ar-H), 7.39-7.45 (2 H, s, Ar-H), 7.30-7.35 (1 H, s, Ar-H), 6.60 (1 H, 
s, OH), 6.34 (1 H, br. s, NH), 5.17 (1 H, d, J 1.0, CH(CO2CH3)), 3.70 (3 H, s, 
OCH3); 
13C NMR (101 MHz, CDCl3) ʴ 168.37 (C=O), 165.07 (CH(COOCH3)), 
140.82 (C(OH)=C(Ph)), 130.01 (quaternary C), 129.87 (Ar-CH), 128.92 (Ar-CH), 
128.76 (Ar-CH), 116.48 (C(OH)=C(Ph)), 61.66 (CH(COOCH3), 53.62 (OCH3); 
Found [M+Na]
+ 256.0595, C12H11NO4Na requires 256.0586. 
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